

Tight blood pressure control and risk of macrovascular
in type 2 diabetes: UKPDS 38. UK Prospective Diabetes S

BMJ: British Medical Journal

317, 703-13

Citation Report

#	ARTICLE	IF	CITATIONS
1	Analysis of therapeutic effect and safety of target-dose metoprolol in the treatment of patients with diabetes mellitus plus chronic heart failure. Pakistan Journal of Medical Sciences, 1969, 30, 7-11.	0.6	4
2	Diabetes: a time for excitement—and concern. BMJ: British Medical Journal, 1998, 317, 691-692.	2.3	19
3	Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. BMJ: British Medical Journal, 1998, 317, 693-694.	2.3	72
4	BMJ introduces a fast track system for papers. BMJ: British Medical Journal, 1999, 318, 620-620.	2.3	12
5	The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British Journal of Clinical Pharmacology, 1999, 48, 643-648.	2.4	436
6	Treatment of diabetic patients with hypertension. Current Hypertension Reports, 1999, 1, 225-231.	3.5	10
7	Does social medicine still matter in an era of molecular medicine?. Journal of Urban Health, 1999, 76, 164-175.	3.6	23
8	Controversies surrounding the treatment of the hypertensive patient with diabetes. Current Hypertension Reports, 1999, 1, 512-520.	3.5	9
9	Hypertensive cardiovascular disease in African Americans. Current Hypertension Reports, 1999, 1, 521-528.	3.5	28
10	Obesity, hypertension, and vascular disease. Current Hypertension Reports, 1999, 1, 140-144.	3.5	8
11	Antihypertensive drugs and diabetic nephropathy. Current Hypertension Reports, 1999, 1, 170-177.	3.5	0
12	Current Trials. Current Hypertension Reports, 1999, 1, 201-203.	3.5	0
13	Recent outcome trials of newer antihypertensives. Current Hypertension Reports, 1999, 1, 238-240.	3.5	0
14	Intensive antihypertensive treatment to the new lower blood pressure targets. Current Hypertension Reports, 1999, 1, 313-319.	3.5	2
15	Recent clinical trials: A critical appraisal. Current Hypertension Reports, 1999, 1, 333-336.	3.5	4
16	The world health organization's International society of hypertension blood pressure lowering treatment trialists' collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. Current Hypertension Reports, 1999, 1, 346-356.	3.5	19
17	Three recently published trials in hypertension. Current Hypertension Reports, 1999, 1, 377-378.	3.5	0
18	Good news for the older patient with diabetes: added cardiovascular risk reduction. Current Hypertension Reports, 1999, 1, 379-380.	3.5	1

#	ARTICLE	IF	CITATIONS
19	Optimal blood pressure on antihypertensive medication. Current Hypertension Reports, 1999, 1, 381-386.	3.5	1
20	Hypertension: Goal systolic and diastolic blood pressure. Current Hypertension Reports, 1999, 1, 411-413.	3.5	0
21	Is normotension good enough for the patient with type 2 diabetes?. Current Hypertension Reports, 1999, 1, 414-416.	3.5	0
22	Antihypertensive therapy and progression of chronic renal disease. Current Hypertension Reports, 1999, 1, 417-422.	3.5	1
23	Importance of blood pressure reduction for prevention of progression of renal disease. Current Hypertension Reports, 1999, 1, 423-430.	3.5	1
24	Calcium-channel blockers and the progression of renal disease. Current Hypertension Reports, 1999, 1, 436-445.	3.5	16
25	The case for combining angiotensinconverting enzyme inhibitors and calcium-channel blockers. Current Hypertension Reports, 1999, 1, 446-453.	3.5	13
26	Clinical Efficacy of Metformin against Insulin Resistance Parameters. Drugs, 1999, 58, 21-28.	10.9	19
27	Concluding Remarks. Clinical Pharmacokinetics, 1999, 37, 33-38.	3.5	4
28	Benefits and Risks of Transfer from Oral Agents to Insulin in Type 2 Diabetes Mellitus. Drug Safety, 1999, 21, 7-22.	3.2	27
29	Renal Protection and Antihypertensive Drugs. Drugs, 1999, 57, 665-693.	10.9	46
30	Antihypertensive Therapy in the Prevention of Stroke. Drugs, 1999, 58, 663-674.	10.9	26
31	British Hypertension Society guidelines for hypertension management 1999: summary. BMJ: British Medical Journal, 1999, 319, 630-635.	2.3	324
32	Perceived access problems among patients with diabetes in two public systems of care. Journal of General Internal Medicine, 2000, 15, 797-804.	2.6	19
33	Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes. Journal of General Internal Medicine, 2000, 15, 220-228.	2.6	55
34	Michigan Diabetes Outreach Networks: a public health approach to strengthening diabetes care. , 2000, 25, 495-511.		6
35	Joint national committee VI: Individualized versus indiscriminate therapy for hypertension. Current Hypertension Reports, 2000, 2, 243-246.	3.5	3
36	Treatment of hypertension in diabetes mellitus. Current Hypertension Reports, 2000, 2, 335-342.	3.5	8

#	ARTICLE	IF	CITATIONS
37	Protection from vascular risk in diabetic hypertension. <i>Current Hypertension Reports</i> , 2000, 2, 154-159.	3.5	25
38	Excess Costs of Diabetes in the Aboriginal Population of Manitoba, Canada. <i>Canadian Journal of Public Health</i> , 2000, 91, 298-301.	2.3	16
39	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. <i>BMJ: British Medical Journal</i> , 2000, 321, 412-419.	2.3	1,737
40	Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. <i>BMJ: British Medical Journal</i> , 2000, 321, 405-412.	2.3	7,060
41	Beneficial and Detrimental Effects of Intensive Glycaemic Control, with Emphasis on Type 2 Diabetes Mellitus. <i>Drugs and Aging</i> , 2000, 17, 463-476.	2.7	12
42	Optimising Therapy for Insulin-Treated Type 2 Diabetes Mellitus. <i>Drugs and Aging</i> , 2000, 17, 283-294.	2.7	8
43	Implications of the UK Prospective Diabetes Study. <i>Drugs and Aging</i> , 2000, 16, 159-164.	2.7	18
45	Is it possible to predict diabetic kidney disease?. <i>Journal of Endocrinological Investigation</i> , 2000, 23, 44-53.	3.3	1
47	Irbesartan. <i>Drugs</i> , 2000, 59, 1187-1206.	10.9	39
48	Eprosartan. <i>Drugs</i> , 2000, 60, 177-201.	10.9	26
49	??-Blockers in the Management of Hypertension in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2001, 61, 429-435.	10.9	7
50	Hypertension in Diabetes Mellitus. <i>Drugs</i> , 2001, 61, 1531-1533.	10.9	4
51	Role of ACE Inhibitors in Patients with Diabetes Mellitus. <i>Drugs</i> , 2001, 61, 1883-1892.	10.9	19
54	Management of Type 2 Diabetes Mellitus in the Elderly. <i>Drugs and Aging</i> , 2001, 18, 31-44.	2.7	88
55	The ? Blockers: Are They as Protective in Hypertension as in other Cardiovascular Conditions?. <i>Journal of Clinical Hypertension</i> , 2001, 3, 236-243.	2.0	8
56	Diuretics Revisited?Again. <i>Journal of Clinical Hypertension</i> , 2001, 3, 136-138.	2.0	7
57	Management of High-Risk Hypertensive Patients with Diabetes: Potential Role of Angiotensin II Receptor Antagonists. <i>Journal of Clinical Hypertension</i> , 2001, 3, 225-235.	2.0	3
58	Randomised controlled trial of structured personal care of type 2 diabetes mellitus. <i>BMJ: British Medical Journal</i> , 2001, 323, 970-970.	2.3	252

#	ARTICLE	IF	CITATIONS
65	Management of Diabetic Nephropathy. Journal of the Royal Society of Medicine, 2001, 94, 210-217.	2.0	21
66	"Normal" blood glucose and coronary risk. BMJ: British Medical Journal, 2001, 322, 5-6.	2.3	28
67	Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ: British Medical Journal, 2001, 322, 986-988.	2.3	120
68	Diabetes: Statins, fibrates, or both?. Current Atherosclerosis Reports, 2001, 3, 19-28.	4.8	19
69	Prevention of strokes. Current Atherosclerosis Reports, 2001, 3, 321-327.	4.8	5
70	Type 2 diabetes in children. Current Diabetes Reports, 2001, 1, 19-27.	4.2	43
71	Drugs for cardiovascular risk reduction in the diabetic patient. Current Diabetes Reports, 2001, 1, 133-139.	4.2	5
72	Combating diabetic nephropathy with drug therapy. Current Diabetes Reports, 2001, 1, 148-156.	4.2	12
73	Treatment of hypertension in diabetic patients with nephropathy. Current Diabetes Reports, 2001, 1, 251-260.	4.2	6
74	Angiotensin receptor blockers in diabetic nephropathy. Current Diabetes Reports, 2001, 1, 267-274.	4.2	2
75	Choices and goals in the treatment of the diabetic hypertensive patient. Current Hypertension Reports, 2001, 3, 387-391.	3.5	2
76	What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?. Current Hypertension Reports, 2001, 3, 422-428.	3.5	11
77	Systolic hypertension and cardiovascular risk reduction: A clinical review. Current Hypertension Reports, 2001, 3, S11-S15.	3.5	4
78	Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low". Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 8.	1.5	6
79	Hypertension and combinations of cardiovascular risk factors. An epidemiologic case-control study in an adult population in Guadeloupe (FWI). European Journal of Epidemiology, 2001, 17, 1089-1095.	5.7	14
80	Diagnosis and treatment of type 2 diabetes in three Belgian regions. Registration via a network of sentinel general practices. European Journal of Epidemiology, 2001, 17, 743-750.	5.7	15
81	Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ: British Medical Journal, 2001, 322, 15-15.	2.3	832
82	Evidence based management of hypertension: What to do when blood pressure is difficult to control. BMJ: British Medical Journal, 2001, 322, 1229-1232.	2.3	31

#	ARTICLE	IF	CITATIONS
83	Retinal microvascular abnormalities and blood pressure in older people: the Cardiovascular Health Study. <i>British Journal of Ophthalmology</i> , 2002, 86, 1007-1013.	3.9	235
84	Chronic renal disease. <i>BMJ: British Medical Journal</i> , 2002, 325, 85-90.	2.3	88
85	Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. <i>BMJ: British Medical Journal</i> , 2002, 324, 459-464.	2.3	58
86	Blood pressure control and diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2002, 86, 365-367.	3.9	51
87	The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study. <i>British Journal of Ophthalmology</i> , 2002, 86, 84-90.	3.9	117
88	Atherosclerotic cardiovascular disease and diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2002, 86, 3-4.	3.9	4
89	Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). <i>BMJ: British Medical Journal</i> , 2002, 325, 860-860.	2.3	72
90	Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: Rationale and Design. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2002, 9, 49-62.	4.4	162
91	Should β Blockers Be Used in the Treatment of Hypertension in the Elderly?. <i>Journal of Clinical Hypertension</i> , 2002, 4, 286-294.	2.0	7
92	Update on the Management of Hypertension: Do Recent Clinical Trial Results Indicate a Change in National Recommendations for Therapy?. <i>Journal of Clinical Hypertension</i> , 2002, 4, 20-31.	2.0	8
93	Update on the Management of Diabetes and Hypertension. <i>Journal of Clinical Hypertension</i> , 2002, 4, 3-10.	2.0	9
94	A Benefit-Risk Assessment of Agents Used in the Secondary Prevention of Stroke. <i>Drug Safety</i> , 2002, 25, 943-963.	3.2	8
95	Treatment of Heart Failure in Patients with Diabetes Mellitus. <i>Drugs</i> , 2002, 62, 285-307.	10.9	7
96	Quinapril. <i>Drugs</i> , 2002, 62, 339-385.	10.9	15
97	Rationale for Fixed-Dose Combinations in the Treatment of Hypertension. <i>Drugs</i> , 2002, 62, 443-462.	10.9	263
98	The Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in the Management of Diabetic Complications. <i>Drugs</i> , 2002, 62, 2007-2012.	10.9	13
99	Fixed Combination Trandolapril/Verapamil Sustained-Release. <i>Drugs</i> , 2002, 62, 2541-2569.	10.9	11
101	Effects of Combined Treatment with Simvastatin and L-Carnitine on Triglyceride Levels in Diabetic Patients with Hyperlipidaemia. <i>Clinical Drug Investigation</i> , 2002, 22, 23-28.	2.2	12

#	ARTICLE	IF	CITATIONS
102	Increasing Incidence of Type 2 Diabetes in Children and Adolescents. Paediatric Drugs, 2002, 4, 209-221.	3.1	55
104	Effective diabetes care: a need for realistic targets. BMJ: British Medical Journal, 2002, 324, 1577-1580.	2.3	84
105	Prevention of heart failure. Current Cardiology Reports, 2002, 4, 194-199.	2.9	7
106	Patient-centered diabetes self-management education. Current Diabetes Reports, 2002, 2, 145-152.	4.2	23
107	Is hepatic glucose production increased in type 2 diabetes mellitus?. Current Diabetes Reports, 2002, 2, 231-236.	4.2	32
108	Role of ACE Inhibitors in treating hypertensive diabetic patients. Current Diabetes Reports, 2002, 2, 251-257.	4.2	9
109	Cardiovascular risk factors in diabetic patients with hypertension. Current Diabetes Reports, 2002, 2, 263-266.	4.2	2
110	The choice of antihypertensive drugs in patients with diabetes: Angiotensin II and beyond. Current Diabetes Reports, 2002, 2, 423-430.	4.2	0
111	Blood pressure controlâ€™Effects on diabetic nephropathy progression: How low does blood pressure have to be?. Current Diabetes Reports, 2002, 2, 530-538.	4.2	5
112	Appropriate drug therapy for improving outcomes in diabetic nephropathy. Current Diabetes Reports, 2002, 2, 545-552.	4.2	3
113	Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?. Current Hypertension Reports, 2002, 4, 290-297.	3.5	1
114	Screening for diabetes in an outpatient clinic population. Journal of General Internal Medicine, 2002, 17, 23-28.	2.6	38
115	The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management. Journal of General Internal Medicine, 2002, 17, 243-252.	2.6	564
116	What should we measure in the diabetic patient and how does this respond to therapy?. British Journal of Clinical Pharmacology, 2002, 54, 81-86.	2.4	0
117	Reducing global risk for cardiovascular disease: Using lifestyle changes and pharmacotherapy. Clinical Cardiology, 2002, 25, 205-212.	1.8	23
118	The Cost of Diabetes Type II in Europe The CODE-2 Study. Diabetologia, 2002, 45, S1-S4.	6.3	97
119	Trends in hypertension management in Type I diabetes across Europe, 1989/1990 ? 1997/1999. Diabetologia, 2002, 45, 1362-1371.	6.3	33
120	Unexpected yes- and no-answering behaviour in the discrete choice approach to elicit willingness to pay: a methodological comparison with payment cards. International Journal of Health Care Finance and Economics, 2003, 3, 147-166.	1.2	6

#	ARTICLE	IF	CITATIONS
121	Angiotensin II blockade: A therapeutic strategy with wide applications. <i>Clinical Cardiology</i> , 2003, 26, 500-502.	1.8	4
122	Getting to goal in complex patients. <i>Clinical Cardiology</i> , 2003, 26, 3-6.	1.8	1
123	Evolution of calcium antagonists: Past, present, and future. <i>Clinical Cardiology</i> , 2003, 26, 12-16.	1.8	24
124	Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. <i>Diabetologia</i> , 2003, 46, 843-851.	6.3	87
125	Variations in process and outcomes of diabetes care by socio-economic status in Salford, UK. <i>Diabetologia</i> , 2003, 46, 750-759.	6.3	27
126	Target blood pressure for patients with type 2 diabetes is difficult to achieve in the setting of a busy diabetes clinic. <i>Irish Journal of Medical Science</i> , 2003, 172, 168-170.	1.5	4
127	Clinical trials report. <i>Current Atherosclerosis Reports</i> , 2003, 5, 339-340.	4.8	1
128	Microalbuminuria and diabetic cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2003, 5, 350-357.	4.8	9
129	Heart disease in diabetic patients. <i>Current Diabetes Reports</i> , 2003, 3, 223-229.	4.2	71
130	Prevention of type 2 diabetes. <i>Current Diabetes Reports</i> , 2003, 3, 235-241.	4.2	32
131	Are low target blood pressure goals justified in persons with diabetes mellitus?. <i>Current Hypertension Reports</i> , 2003, 5, 231-238.	3.5	3
132	Management of diabetic and hypertensive cardiovascular disease. <i>Current Hypertension Reports</i> , 2003, 5, 309-315.	3.5	3
133	Lessons from trials in hypertensive type 2 diabetic patients. <i>Current Hypertension Reports</i> , 2003, 5, 322-328.	3.5	1
136	Spatial visual filtering in diabetes mellitus. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2003, 241, 489-496.	1.9	1
137	Influence of diabetes mellitus on heart failure risk and outcome. <i>Cardiovascular Diabetology</i> , 2003, 2, 1.	6.8	163
140	Current Management Strategies for Coexisting Diabetes Mellitus and Obesity. <i>Drugs</i> , 2003, 63, 1165-1184.	10.9	76
141	Current Treatment of Patients with Hypertension. <i>Drugs</i> , 2003, 63, 1435-1444.	10.9	7
142	Dual ACE and Neutral Endopeptidase Inhibitors. <i>Drugs</i> , 2003, 63, 2185-2202.	10.9	29

#	ARTICLE	IF	CITATIONS
143	The Renin-Angiotensin System Influences Ocular Endothelial Cell Proliferation in Diabetes. <i>American Journal of Pathology</i> , 2003, 162, 151-160.	3.8	100
144	Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed-Dose Combination Approaches. <i>Journal of Clinical Hypertension</i> , 2003, 5, 202-209.	2.0	82
145	Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials. <i>Journal of Clinical Hypertension</i> , 2003, 5, 66-75.	2.0	26
146	Evaluation of Angiotensin II Receptor Blockers for 24-Hour Blood Pressure Control: Meta-Analysis of a Clinical Database. <i>Journal of Clinical Hypertension</i> , 2003, 5, 58-63.	2.0	63
147	Meeting the Challenge to Improve the Treatment of Hypertension in Blacks. <i>Journal of Clinical Hypertension</i> , 2003, 5, 393-401.	2.0	17
148	Blockade of the Renin-Angiotensin System in African Americans With Hypertension and Cardiovascular Disease. <i>Journal of Clinical Hypertension</i> , 2003, 5, 12-17.	2.0	13
149	The Economic Impact of Hypertension. <i>Journal of Clinical Hypertension</i> , 2003, 5, 3-13.	2.0	86
150	Hypertension in the Metabolic Syndrome and Diabetes: Pathogenesis, Clinical Studies, and Treatment. <i>Journal of Clinical Hypertension</i> , 2003, 5, 3-10.	2.0	9
151	Rationale for Combination Therapy as Initial Treatment for Hypertension. <i>Journal of Clinical Hypertension</i> , 2003, 5, 4-11.	2.0	16
152	Creating a Combination Antihypertensive Regimen: What Does the Research Show?. <i>Journal of Clinical Hypertension</i> , 2003, 5, 12-20.	2.0	20
153	Who Should Be Treated With Combination Therapy as Initial Treatment for Hypertension?. <i>Journal of Clinical Hypertension</i> , 2003, 5, 21-28.	2.0	4
154	Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial. <i>Current Therapeutic Research</i> , 2003, 64, 422-433.	1.2	5
155	Financial and Health Costs of Uncontrolled Blood Pressure in the United Kingdom. <i>Pharmacoeconomics</i> , 2003, 21, 33-41.	3.3	30
156	Transient Ischaemic Attacks. <i>CNS Drugs</i> , 2003, 17, 293-305.	5.9	0
157	Management of peripheral arterial disease in primary care. <i>BMJ: British Medical Journal</i> , 2003, 326, 584-588.	2.3	139
158	The Diabetes Prevention Program and Its Global Implications. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S103-S107.	6.1	46
159	Extracts from "Concise Clinical Evidence": Diabetic retinopathy * Commentary: Treatment of diabetic retinopathy. <i>BMJ: British Medical Journal</i> , 2003, 326, 1023-1025.	2.3	15
160	What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. <i>BMJ: British Medical Journal</i> , 2003, 327, 266-0.	2.3	63

#	ARTICLE	IF	CITATIONS
161	Type 2 diabetes is cardiovascular disease. <i>Journal of the Royal Society of Medicine</i> , 2003, 96, 371-372.	2.0	1
162	Epidemiology of Peripheral Arterial Disease in Women.. <i>Journal of Epidemiology</i> , 2003, 13, 1-14.	2.4	87
163	Controlled trial of effect of documented cardiovascular risk scores on prescribing. <i>BMJ: British Medical Journal</i> , 2003, 326, 251-252.	2.3	74
164	View 1: Should this patient receive laser treatment?. <i>British Journal of Ophthalmology</i> , 2004, 88, 433-a-435.	3.9	0
165	Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. <i>British Heart Journal</i> , 2004, 90, 732-738.	2.1	58
166	Overview. <i>British Journal of Ophthalmology</i> , 2004, 88, 436-437.	3.9	0
167	Diabetes and atherogenesis. <i>Heart</i> , 2004, 90, 336-340.	2.9	34
168	The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. <i>Clinical Trials</i> , 2004, 1, 532-544.	1.6	54
169	Strategies to curb the epidemic of diabetes and obesity in primary care settings. <i>Journal of General Internal Medicine</i> , 2004, 19, 1242-1243.	2.6	4
170	Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team – a pilot study. <i>International Journal of Clinical Pharmacy</i> , 2004, 26, 18-25.	1.4	60
171	Evolving targets for risk reduction in diabetes. <i>Clinical Cardiology</i> , 2004, 27, 125-128.	1.8	1
172	Clinical variables and their relation to visual outcome after vitrectomy in eyes with diabetic retinal traction detachment. <i>Graefes' Archive for Clinical and Experimental Ophthalmology</i> , 2004, 242, 210-217.	1.9	39
177	Albuminuria is a marker of increasing intracranial and extracranial vascular involvement in Type 2 diabetic Chinese patients. <i>Diabetologia</i> , 2004, 47, 1528-1534.	6.3	23
178	Hopes, disillusion and more hopes from vitamin C. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 209-219.	5.4	69
179	Patterns of antihypertensive drug utilization in primary care. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 135-142.	1.9	73
180	Antihypertensive drugs and the kidney. <i>Current Cardiology Reports</i> , 2004, 6, 403-408.	2.9	4
181	Heart protection study: A focus on diabetic patients. <i>Current Diabetes Reports</i> , 2004, 4, 185-186.	4.2	1
182	Management of hypertension in the cardiometabolic syndrome and diabetes. <i>Current Diabetes Reports</i> , 2004, 4, 199-205.	4.2	2

#	ARTICLE	IF	CITATIONS
183	Hypertension management in patients with diabetic nephropathy. <i>Current Hypertension Reports</i> , 2004, 6, 272-279.	3.5	2
184	Clinical importance of microalbuminuria in diabetes and hypertension. <i>Current Hypertension Reports</i> , 2004, 6, 352-356.	3.5	43
185	Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management. <i>Current Hypertension Reports</i> , 2004, 6, 215-223.	3.5	99
186	Hypertensive renal damage: Insights from animal models and clinical relevance. <i>Current Hypertension Reports</i> , 2004, 6, 145-153.	3.5	41
187	When there is too much to do. <i>Journal of General Internal Medicine</i> , 2004, 19, 646-653.	2.6	56
188	A novel approach to treatment of hypertension in diabetic patients a€” a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 a€” rationale and design [ISRCTN55725285]. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2004, 5, 9.	1.5	6
189	The association of patient trust and self-care among patients with diabetes mellitus. <i>BMC Family Practice</i> , 2004, 5, 26.	2.9	106
190	Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective. <i>Pharmacoeconomics</i> , 2004, 22, 321-341.	3.3	25
192	Irbesartan. <i>Drugs</i> , 2004, 64, 999-1028.	10.9	70
193	Regression of Microalbuminuria in Type 2 Diabetics after Switch to Irbesartan Treatment. <i>Clinical Drug Investigation</i> , 2004, 24, 217-225.	2.2	8
194	Quality of Care and Attributable Healthcare Costs in Diabetic Hypertensive Patients Initiated on Calcium Antagonist Therapy. <i>Clinical Drug Investigation</i> , 2004, 24, 641-649.	2.2	2
195	A mathematical model for the burden of diabetes and its complications. <i>BioMedical Engineering OnLine</i> , 2004, 3, 20.	2.7	60
196	Pharmacological Treatments for Persistent Non-Malignant Pain in Older Persons. <i>Drugs and Aging</i> , 2004, 21, 19-41.	2.7	60
197	Hypertension and the Elderly: More Than Just Blood Pressure Control. <i>Journal of Clinical Hypertension</i> , 2004, 6, 249-255.	2.0	15
198	The JNC 7 Approach Compared to Conventional Treatment in Diabetic Patients With Hypertension: A Double-Blind Trial of Initial Monotherapy vs. Combination Therapy. <i>Journal of Clinical Hypertension</i> , 2004, 6, 437-442.	2.0	12
199	Managing High-Risk Patients With Hypertension: Focus on the Renin-Angiotensin System. <i>Journal of Clinical Hypertension</i> , 2004, 6, 501-508.	2.0	5
200	Metabolic Properties of Vasodilating β^2 Blockers: Management Considerations for Hypertensive Diabetic Patients and Patients With the Metabolic Syndrome. <i>Journal of Clinical Hypertension</i> , 2004, 6, 690-696.	2.0	20
201	Blood Pressure Goal Attainment: Meeting the Challenge of the JNC 7's Blood Pressure Goals and the Role of Renin-Angiotensin-Aldosterone System Blockade. <i>Journal of Clinical Hypertension</i> , 2004, 6, 699-705.	2.0	4

#	ARTICLE	IF	CITATIONS
202	Update on the Management of Hypertension: Recent Clinical Trials and the JNC 7. <i>Journal of Clinical Hypertension</i> , 2004, 6, 4-13.	2.0	30
203	Use of an Olmesartan Medoxomil-Based Treatment Algorithm for Hypertension Control. <i>Journal of Clinical Hypertension</i> , 2004, 6, 168-399.	2.0	42
204	Efficacy and tolerability of a switch to fixed-dose combination therapy with amlodipine besylate/benazepril hydrochloride after monotherapy with amlodipine besylate: Data from the African-American subpopulation of a practice-based, open-label study (the LOGIC study)*1. <i>Current Therapeutic Research</i> , 2004, 65, 138-148.	1.2	0
205	Diabetes Outcomes in the Indian Health System During the Era of the Special Diabetes Program for Indians and the Government Performance and Results Act. <i>American Journal of Public Health</i> , 2005, 95, 1518-1522.	2.7	44
206	The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance. <i>Annals of Internal Medicine</i> , 2005, 142, 323.	3.9	578
207	Prognostic value of I-123 15-(p-iodophenyl)-3-(.) methylpentadecanoic acid myocardial imaging in patients with known or suspected coronary artery disease. <i>Journal of Nuclear Cardiology</i> , 2005, 12, 172-178.	2.1	30
208	Patterns of antihypertensive therapy among patients with diabetes. <i>Journal of General Internal Medicine</i> , 2005, 20, 842-846.	2.6	32
209	Self-Reported Goals of Older Patients with Type 2 Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 306-311.	2.6	119
210	Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the Hypertension Clinic 1996-2004. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 90-97.	2.4	14
211	Changes in the usage of antihypertensive drugs: implications and prospects. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 231-234.	2.4	5
212	Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 483-490.	1.9	44
213	Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. <i>Diabetologia</i> , 2005, 48, 282-289.	6.3	322
214	Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). <i>Diabetologia</i> , 2005, 48, 868-877.	6.3	147
215	Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. <i>Diabetologia</i> , 2005, 48, 856-861.	6.3	142
216	Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?. <i>Diabetologia</i> , 2005, 48, 1445-1453.	6.3	115
217	Differences in the association between type 2 diabetes and impaired microvascular function among Europeans and African Caribbeans. <i>Diabetologia</i> , 2005, 48, 2269-2277.	6.3	24
218	Prevention of type 2 diabetes: what challenges do we have to address?. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2005, 13, 303-308.	1.6	10
220	Risk and potential risk reduction in diabetes type 2 patients in Germany. <i>European Journal of Health Economics</i> , 2005, 6, 152-158.	2.8	6

#	ARTICLE	IF	CITATIONS
221	Prevention of coronary heart disease in diabetes. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 259-271.	0.9	3
222	Hypertrophy in the female heart. Current Cardiology Reports, 2005, 7, 173-177.	2.9	1
223	Stroke prevention in diabetic and other high cardiovascular risk patients. Current Diabetes Reports, 2005, 5, 200-207.	4.2	7
224	Statins and the prevention of stroke in diabetes. Current Diabetes Reports, 2005, 5, 1-3.	4.2	1
225	Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care. Current Hypertension Reports, 2005, 7, 439-449.	3.5	8
226	Does ALLHAT change the management of hypertension in chronic kidney disease?. Current Hypertension Reports, 2005, 7, 474-483.	3.5	5
227	Cardiorenal Disease: A Clinical Intersection. International Urology and Nephrology, 2005, 37, 175-184.	1.4	4
228	A community-based follow-up study on diabetic retinopathy among type 2 diabetics in Kinmen. European Journal of Epidemiology, 2005, 20, 317-323.	5.7	20
229	Implementation of a Pharmacist-Led Clinic for Hypertensive Patients in Primary Care – A Pilot Study. International Journal of Clinical Pharmacy, 2005, 27, 202-207.	1.4	40
230	Characteristics Associated with Neuropathy and/or Retinopathy in a Hospital Outpatient Diabetic Clinic. International Journal of Clinical Pharmacy, 2005, 27, 154-158.	1.4	5
231	Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement – is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I). Current Controlled Trials in Cardiovascular Medicine, 2005, 6, 6.	1.5	29
232	GPs' perspectives of type 2 diabetes patients' adherence to treatment: A qualitative analysis of barriers and solutions. BMC Family Practice, 2005, 6, 20.	2.9	137
233	Progression of kidney disease in type 2 diabetes – beyond blood pressure control: an observational study. BMC Nephrology, 2005, 6, 8.	1.8	43
234	Hypertension control: results from the Diabetes Care Program of Nova Scotia registry and impact of changing clinical practice guidelines. Cardiovascular Diabetology, 2005, 4, 11.	6.8	3
235	Case-Based Study: From Prediabetes to Complications – Opportunities for Prevention. PLoS Medicine, 2005, 2, e40.	8.4	1
236	Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. Cmaj, 2005, 173, 1457-1466.	2.0	54
237	Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. Heart, 2005, 91, 451-455.	2.9	14
238	Applying the 2005 Canadian Hypertension Education Program recommendations: 5. Therapy for patients with hypertension and diabetes mellitus. Cmaj, 2005, 173, 1154-1157.	2.0	0

#	ARTICLE	IF	CITATIONS
239	Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. <i>Cmaj</i> , 2005, 172, 177-180.	2.0	34
240	Cardiovascular risk in patients with type 2 diabetes. <i>Cmaj</i> , 2005, 172, 1160-1160.	2.0	0
241	Quality of Diabetes Care in U.S. Academic Medical Centers: Low rates of medical regimen change. <i>Diabetes Care</i> , 2005, 28, 337-442.	8.6	289
242	QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. <i>Heart</i> , 2005, 91, 44-50.	2.9	71
243	Secondary prevention of coronary heart disease in the elderly. <i>Heart</i> , 2005, 91, 396-400.	2.9	15
245	Strategies to reduce length of stay and costs associated with decompensated heart failure. <i>Current Heart Failure Reports</i> , 2005, 2, 140-147.	3.3	3
246	Combination Therapy in the Management of Hypertension: Focus on Angiotensin Receptor Blockers Combined With Diuretics. <i>Journal of Clinical Hypertension</i> , 2005, 7, 96-101.	2.0	17
248	Hypertensive retinopathy revisited: some answers, more questions. <i>British Journal of Ophthalmology</i> , 2005, 89, 1646-1654.	3.9	101
249	Place of Drug Therapy in the Treatment of Carotid Stenosis. <i>CNS Drugs</i> , 2005, 19, 597-622.	5.9	5
250	The Efficacy and Safety of Low- and High- Dose Fixed Combinations of Irbesartan/Hydrochlorothiazide in Patients With Uncontrolled Systolic Blood Pressure on Monotherapy: The INCLUSIVE Trial. <i>Journal of Clinical Hypertension</i> , 2005, 7, 578-586.	2.0	75
251	Control of Blood Pressure and Other Cardiovascular Risk Factors at Different Practice Settings: Outcomes of Care Provided to Diabetic Women Compared to Men. <i>Journal of Clinical Hypertension</i> , 2005, 7, 73-80.	2.0	49
252	Is There More to Life Than Blood Pressure?. <i>Journal of Clinical Hypertension</i> , 2005, 7, 149-151.	2.0	1
253	Stroke in Patients With Diabetes and Hypertension. <i>Journal of Clinical Hypertension</i> , 2005, 7, 286-294.	2.0	32
254	Treating Stage 2 Hypertension. <i>Journal of Clinical Hypertension</i> , 2005, 7, 464-470.	2.0	6
255	Ethnic Differences in the Treatment and Control of Hypertension in Patients With Diabetes. <i>Journal of Clinical Hypertension</i> , 2005, 7, 445-454.	2.0	15
256	Pathophysiologic, Diagnostic, and Therapeutic Aspects of the Metabolic Syndrome. <i>Journal of Clinical Hypertension</i> , 2005, 7, 669-678.	2.0	15
257	Role of transforming growth factor- β 2 in, and a possible transforming growth factor- β 2 gene polymorphism as a marker of, renal dysfunction in essential hypertension: A study in Turkish patients. <i>Current Therapeutic Research</i> , 2005, 66, 266-278.	1.2	1
258	Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus. <i>Drugs</i> , 2005, 65, 433-445.	10.9	8

#	ARTICLE	IF	CITATIONS
259	Pioglitazone Lowers Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2005, 25, 337-340.	2.2	7
260	Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2005, , CD003638.	2.8	175
261	Hypertension in the Elderly. <i>Drugs and Aging</i> , 2005, 22, 297-314.	2.7	11
262	The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension. <i>Drugs and Aging</i> , 2006, 23, 131-155.	2.7	32
263	A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies. <i>Pharmacoeconomics</i> , 2006, 24, 5-19.	3.3	15
264	Disease Management Programmes in Germany. <i>Pharmacoeconomics</i> , 2006, 24, 55-57.	3.3	4
265	Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus. <i>Pharmacoeconomics</i> , 2006, 24, 425-441.	3.3	42
266	Treatment and blood pressure control in 47,964 people with diabetes and hypertension: A systematic review of observational studies. <i>Canadian Journal of Cardiology</i> , 2006, 22, 855-860.	1.7	47
267	Metabolic syndrome: A marker of patients at high cardiovascular risk. <i>Canadian Journal of Cardiology</i> , 2006, 22, 85B-90B.	1.7	41
268	Management of Global Risk Across the Continuum of Hypertensive Heart Disease. <i>Journal of Clinical Hypertension</i> , 2006, 8, 21-30.	2.0	2
269	Blood Pressure Lowering for the Prevention and Treatment of Diabetic Kidney Disease. <i>Drugs</i> , 2006, 66, 2213-2234.	10.9	36
270	Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil in Achieving 24-Hour Blood Pressure Reductions and Ambulatory Blood Pressure Goals. <i>Clinical Drug Investigation</i> , 2006, 26, 185-193.	2.2	39
272	Comparison of two low-calorie diets: A prospective study of effectiveness and safety. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 633-640.	3.3	11
273	Diabetic Retinopathy in a Multi-ethnic Cohort in the United States. <i>American Journal of Ophthalmology</i> , 2006, 141, 446-455.e1.	3.3	548
274	Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study. <i>Current Therapeutic Research</i> , 2006, 67, 81-102.	1.2	6
275	Management Strategies for Patients With Hypertension and Diabetes: Why Combination Therapy Is Critical. <i>Journal of Clinical Hypertension</i> , 2006, 8, 108-113.	2.0	13
276	Is New Onset Diabetes of Clinical Significance in Treated Hypertensive Patients? Con. <i>Journal of Clinical Hypertension</i> , 2006, 8, 126-132.	2.0	8
277	More Confusing Messages From the Hypertension Treatment Trials. <i>Journal of Clinical Hypertension</i> , 2006, 8, 8-11.	2.0	1

#	ARTICLE	IF	CITATIONS
278	Dispelling the Myth of "Aggressive" Antihypertensive Therapy. <i>Journal of Clinical Hypertension</i> , 2006, 8, 4-11.	2.0	23
279	Building on the Specialist's Antihypertensive Treatment Recommendation: It's Just the Beginning. <i>Journal of Clinical Hypertension</i> , 2006, 8, 31-39.	2.0	1
280	Is the Development of Diabetes With Antihypertensive Therapy a Problem? "Pro. <i>Journal of Clinical Hypertension</i> , 2006, 8, 120-126.	2.0	7
281	Impact of Blood Pressure vs. Glycemic Factors on Target Organ Damage in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2006, 8, 404-410.	2.0	8
282	Attempted Forced Titration of Blood Pressure to <130/85 mm Hg in Type 2 Diabetic Hypertensive Patients in Clinical Practice: The Diastolic Cost. <i>Journal of Clinical Hypertension</i> , 2006, 8, 29-34.	2.0	8
283	Prevalence, Awareness, Treatment, and Control of Hypertension: United States National Health and Nutrition Examination Survey 2001-2002. <i>Journal of Clinical Hypertension</i> , 2006, 8, 93-98.	2.0	82
284	Physician Familiarity With Diagnosis and Management of Hypertension According to JNC 7 Guidelines. <i>Journal of Clinical Hypertension</i> , 2006, 8, 344-350.	2.0	19
285	Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes. <i>Journal of Clinical Hypertension</i> , 2006, 8, 470-480.	2.0	39
286	Achieving Blood Pressure Goals: Why Aren't We?. <i>Journal of Clinical Hypertension</i> , 2006, 8, 865-871.	2.0	41
287	Managing Multiple Cardiovascular Risk Factors: State of the Science. <i>Journal of Clinical Hypertension</i> , 2006, 8, 12-24.	2.0	17
288	Can Stevioside in Combination with a Soy-Based Dietary Supplement Be a New Useful Treatment of Type 2 Diabetes? - An in vivo Study in the Diabetic Goto-Kakizaki Rat. <i>Review of Diabetic Studies</i> , 2006, 3, 189-189.	1.3	36
289	Effectiveness of Diabetes Resource Nurse Case Management and Physician Profiling in a Fee-For-Service Setting: A Cluster Randomized Trial. <i>Baylor University Medical Center Proceedings</i> , 2006, 19, 95-102.	0.5	14
290	Pioglitazone for type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2006, , CD006060.	2.8	49
291	Understanding Diabetes Population Dynamics Through Simulation Modeling and Experimentation. <i>American Journal of Public Health</i> , 2006, 96, 488-494.	2.7	135
292	Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. <i>Cardiovascular Diabetology</i> , 2006, 5, 15.	6.8	62
293	Assessment of diabetes screening by general practitioners in France: the EPIDIA Study. <i>Diabetic Medicine</i> , 2006, 23, 803-807.	2.3	13
294	A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2006, 13, 40-51.	4.4	278
295	Blood pressure as an example of a biomarker that functions as a surrogate. <i>AAPS Journal</i> , 2006, 8, E146-E152.	4.4	51

#	ARTICLE	IF	CITATIONS
296	Prospective Assessment of Proliferative Diabetic Retinopathy with Observations of Posterior Vitreous Detachment. <i>International Ophthalmology</i> , 2006, 26, 15-19.	1.4	45
297	Population-Based Study of Nonproliferative Diabetic Retinopathy Among Type 2 Diabetic Patients in Kinmen, Taiwan. <i>Japanese Journal of Ophthalmology</i> , 2006, 50, 44-52.	1.9	14
299	Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). <i>Diabetologia</i> , 2006, 49, 1761-1769.	6.3	303
300	Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. <i>Diabetologia</i> , 2006, 49, 2514-2524.	6.3	43
301	The effect of diabetes and stroke at baseline and during follow-up on stroke mortality. <i>Diabetologia</i> , 2006, 49, 2309-2316.	6.3	30
305	The diabetic myocardium. <i>Current Diabetes Reports</i> , 2006, 6, 36-41.	4.2	10
306	Metabolic syndrome in the elderly. <i>Current Diabetes Reports</i> , 2006, 6, 64-71.	4.2	46
307	Central nervous system involvement in diabetes mellitus. <i>Current Diabetes Reports</i> , 2006, 6, 431-438.	4.2	34
308	Clinic versus home blood pressure measurements in patients with CKD. <i>Current Diabetes Reports</i> , 2006, 6, 453-454.	4.2	0
309	Metabolic safety of antihypertensive drugs: Myth versus reality. <i>Current Hypertension Reports</i> , 2006, 8, 403-408.	3.5	16
310	Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes. <i>Irish Journal of Medical Science</i> , 2006, 175, 36-41.	1.5	1
311	Structuring diabetes care in general practices: Many improvements, remaining challenges. <i>Irish Journal of Medical Science</i> , 2006, 175, 42-47.	1.5	11
312	A multifocal electroretinogram model predicting the development of diabetic retinopathy. <i>Progress in Retinal and Eye Research</i> , 2006, 25, 425-448.	15.5	211
313	Prevalence of self-reported hypertension and its relation to dietary habits, in adults; a nutrition & health survey in Greece. <i>BMC Public Health</i> , 2006, 6, 206.	2.9	30
314	Prevention and early detection of vascular complications of diabetes. <i>BMJ: British Medical Journal</i> , 2006, 333, 475-480.	2.3	164
315	Evidence of Nephropathy and Peripheral Neuropathy in US Adults With Undiagnosed Diabetes. <i>Annals of Family Medicine</i> , 2006, 4, 427-432.	1.9	55
316	Evidence-Based Prescribing of Statins: A Developing World Perspective. <i>PLoS Medicine</i> , 2006, 3, e50.	8.4	10
317	Measuring Continuity of Care in Diabetes Mellitus: An Experience-Based Measure. <i>Annals of Family Medicine</i> , 2006, 4, 548-555.	1.9	48

#	ARTICLE	IF	CITATIONS
318	Quality of diabetes care and coronary heart disease absolute risk in patients with type 2 diabetes mellitus in Australian general practice. <i>Quality and Safety in Health Care</i> , 2006, 15, 131-135.	2.5	47
319	Prevalence and Risk Factors for Urinary Incontinence in Women With Type 2 Diabetes and Impaired Fasting Glucose: Findings from the National Health and Nutrition Examination Survey (NHANES) 2001-2002. <i>Diabetes Care</i> , 2006, 29, 1307-1312.	8.6	114
320	Diabetic neuropathy. <i>Postgraduate Medical Journal</i> , 2006, 82, 95-100.	1.8	223
321	Effect of crew resource management on diabetes care and patient outcomes in an inner-city primary care clinic. <i>Quality and Safety in Health Care</i> , 2007, 16, 244-247.	2.5	49
322	Patient Perceptions of Quality of Life With Diabetes-Related Complications and Treatments. <i>Diabetes Care</i> , 2007, 30, 2478-2483.	8.6	223
323	Risk assessment in diabetes management: how do general practitioners estimate risks due to diabetes?. <i>Quality and Safety in Health Care</i> , 2007, 16, 208-212.	2.5	8
324	Use of Chronic Care Model Elements Is Associated With Higher-Quality Care for Diabetes. <i>Annals of Family Medicine</i> , 2007, 5, 14-20.	1.9	143
325	Understanding the Quality Chasm for Hypertension Control in Diabetes: A Structured Review of "Co-maneuvers" Used in Clinical Trials. <i>Journal of the American Board of Family Medicine</i> , 2007, 20, 469-478.	1.5	14
326	The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003. <i>Current Medical Research and Opinion</i> , 2007, 23, 1423-1430.	1.9	20
327	Blood pressure and ageing. <i>Postgraduate Medical Journal</i> , 2007, 83, 109-114.	1.8	338
328	Shared medical appointments based on the chronic care model: a quality improvement project to address the challenges of patients with diabetes with high cardiovascular risk. <i>Quality and Safety in Health Care</i> , 2007, 16, 349-353.	2.5	129
329	Development of a Diabetes Prevention Management Program for Clinical Practice. <i>Public Health Reports</i> , 2007, 122, 258-263.	2.5	86
330	Spontaneously reduced blood pressure load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevance. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F647-F654.	2.7	34
331	Pioglitazone Decreases Ambulatory Blood Pressure in Type 2 Diabetics With Difficult-to-Control Hypertension. <i>Journal of Clinical Hypertension</i> , 2007, 9, 530-537.	2.0	15
332	Amlodipine Added to Quinapril vs Quinapril Alone for the Treatment of Hypertension in Diabetes: The Amlodipine in Diabetes (ANDI) Trial. <i>Journal of Clinical Hypertension</i> , 2007, 9, 120-127.	2.0	11
333	Linear Relationship Between Blood Pressure and Stroke: The Jichi Medical School Cohort Study. <i>Journal of Clinical Hypertension</i> , 2007, 9, 677-683.	2.0	16
334	What Should Our Blood Pressure Goal Be in Patients With Diabetes?. <i>Journal of Clinical Hypertension</i> , 2007, 9, 823-826.	2.0	1
335	Reducing Cardiovascular Events in High-Risk Patients: The Challenge of Managing Hypertension in Patients With Diabetic Renal Disease. <i>Journal of Clinical Hypertension</i> , 2007, 9, 16-25.	2.0	3

#	ARTICLE	IF	CITATIONS
336	Antihypertensive Combination Therapy: Optimizing Blood Pressure Control and Cardiovascular Risk Reduction. <i>Journal of Clinical Hypertension</i> , 2007, 9, 26-32.	2.0	20
337	Practical advice for home blood pressure measurement. <i>Canadian Journal of Cardiology</i> , 2007, 23, 577-580.	1.7	8
338	Improving outcomes in diabetes and chronic kidney disease: The basis for Canadian guidelines. <i>Canadian Journal of Cardiology</i> , 2007, 23, 585-590.	1.7	10
339	Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement. <i>Canadian Journal of Cardiology</i> , 2007, 23, 783-787.	1.7	20
340	Loss of taste-induced hypertension – caveat for taste modulation as a therapeutic option in obesity. <i>Eating and Weight Disorders</i> , 2007, 12, e11-e13.	2.5	6
341	Dietary advice for treatment of type 2 diabetes mellitus in adults. <i>The Cochrane Library</i> , 2010, 2010, CD004097.	2.8	83
345	Approaches to Prevention of Cardiovascular Complications and Events in Diabetes Mellitus. <i>Drugs</i> , 2007, 67, 997-1026.	10.9	117
346	Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension. <i>Drugs</i> , 2007, 67, 1309-1327.	10.9	86
347	Blood Pressure-Lowering Effect of Nebivolol in Hypertensive Patients with Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2007, 27, 841-849.	2.2	34
348	Rosiglitazone for type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2007, , CD006063.	2.8	67
349	Overviews of Pathogen Emergence: Which Pathogens Emerge, When and Why?. <i>Current Topics in Microbiology and Immunology</i> , 2007, 315, 85-111.	1.1	114
350	Inhibitory activity of <i>Euonymus alatus</i> against alpha-glucosidase <i>in vitro</i> and <i>in vivo</i> . <i>Nutrition Research and Practice</i> , 2007, 1, 184.	1.9	21
351	Hypoglycemic and hypolipidemic effects of <i>Saururus chinensis</i> Baill in streptozotocin-induced diabetic rats. <i>Nutrition Research and Practice</i> , 2007, 1, 100.	1.9	11
352	Hypolipidemic effect of <i>Salicornia herbacea</i> in animal model of type 2 diabetes mellitus. <i>Nutrition Research and Practice</i> , 2007, 1, 371.	1.9	20
353	Metabolic Effects of a Conversion from Rosiglitazone to Pioglitazone in Native American Patients with Type 2 Diabetes. <i>Baylor University Medical Center Proceedings</i> , 2007, 20, 349-353.	0.5	3
354	Changing illness perceptions in patients with poorly controlled type 2 diabetes, a randomised controlled trial of a family-based intervention: protocol and pilot study. <i>BMC Family Practice</i> , 2007, 8, 36.	2.9	40
355	Peer support in type 2 diabetes: a randomised controlled trial in primary care with parallel economic and qualitative analyses: pilot study and protocol. <i>BMC Family Practice</i> , 2007, 8, 45.	2.9	36
356	Primary care management of diabetes in a low/middle income country: A multi-method, qualitative study of barriers and facilitators to care. <i>BMC Family Practice</i> , 2007, 8, 63.	2.9	42

#	ARTICLE	IF	CITATIONS
357	Microalbuminuria among Type 1 and Type 2 diabetic patients of African origin in Dar Es Salaam, Tanzania. <i>BMC Nephrology</i> , 2007, 8, 2.	1.8	49
358	Prevalence of diabetic retinopathy in the United Arab Emirates: a cross-sectional survey. <i>BMC Ophthalmology</i> , 2007, 7, 11.	1.4	74
359	Clinical and medication profiles stratified by household income in patients referred for diabetes care. <i>Cardiovascular Diabetology</i> , 2007, 6, 11.	6.8	19
360	The prevalence of macrovascular complications among diabetic patients in the United Arab Emirates. <i>Cardiovascular Diabetology</i> , 2007, 6, 24.	6.8	30
361	Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998â€“2004: a longitudinal observational study. <i>Cardiovascular Diabetology</i> , 2007, 6, 25.	6.8	20
362	Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions. <i>Cardiovascular Diabetology</i> , 2007, 6, 33.	6.8	14
363	The Ontario printed educational message (OPEM) trial to narrow the evidence-practice gap with respect to prescribing practices of general and family physicians: a cluster randomized controlled trial, targeting the care of individuals with diabetes and hypertension in Ontario, Canada. <i>Implementation Science</i> , 2007, 2, 37.	6.9	18
364	The prevalence of retinopathy in impaired glucose tolerance and recentâ€“onset diabetes in the Diabetes Prevention Program. <i>Diabetic Medicine</i> , 2007, 24, 137-144.	2.3	306
366	Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. <i>Diabetologia</i> , 2007, 50, 250-258.	6.3	50
367	A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <i>Diabetologia</i> , 2007, 50, 259-267.	6.3	422
368	Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. <i>Diabetologia</i> , 2007, 50, 2388-2397.	6.3	186
369	Combination pharmacotherapy in hypertension. <i>International Urology and Nephrology</i> , 2007, 38, 673-682.	1.4	2
370	The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes. <i>International Journal of Clinical Pharmacy</i> , 2007, 29, 541-545.	1.4	19
371	Cardiovascular disease risk in youth with diabetes mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 7, 197-204.	5.7	28
372	The impact of diabetes on heart failure: Opportunities for intervention. <i>Current Heart Failure Reports</i> , 2007, 4, 70-77.	3.3	5
373	JNC-7 guidelines: Are they still relevant?. <i>Current Hypertension Reports</i> , 2007, 9, 380-386.	3.5	8
374	Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?. <i>Current Hypertension Reports</i> , 2007, 9, 393-402.	3.5	8
375	Can a Chronic Care Model Collaborative Reduce Heart Disease Risk in Patients with Diabetes?. <i>Journal of General Internal Medicine</i> , 2007, 22, 215-222.	2.6	89

#	ARTICLE	IF	CITATIONS
376	Patient Complexity: More Than Comorbidity. The Vector Model of Complexity. <i>Journal of General Internal Medicine</i> , 2007, 22, 382-390.	2.6	268
380	Early diagnosis and prevention of diabetes in developing countries. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2008, 9, 193-201.	5.7	46
381	Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. <i>Diabetologia</i> , 2008, 51, 1127-1134.	6.3	86
382	Retinal and renal complications in patients with a mutation of mitochondrial DNA at position 3,243 (maternally inherited diabetes and deafness). A case-control study. <i>Diabetologia</i> , 2008, 51, 1664-1670.	6.3	37
383	ADVANCE in management of vascular complications of diabetes. <i>Current Hypertension Reports</i> , 2008, 10, 255-257.	3.5	0
384	Race-based therapeutics. <i>Current Hypertension Reports</i> , 2008, 10, 276-285.	3.5	18
385	Diabetes mellitus, insulin resistance, hyperglycemia, and stroke. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 12-19.	4.2	23
386	Failure to Intensify Antihypertensive Treatment by Primary Care Providers: A Cohort Study in Adults with Diabetes Mellitus and Hypertension. <i>Journal of General Internal Medicine</i> , 2008, 23, 543-550.	2.6	51
387	Predictors of Sustained Walking among Diabetes Patients in Managed Care: The Translating Research into Action for Diabetes (TRIAD) Study. <i>Journal of General Internal Medicine</i> , 2008, 23, 1194-1199.	2.6	3
388	Weight Change and Glycemic Control After Diagnosis of Type 2 Diabetes. <i>Journal of General Internal Medicine</i> , 2008, 23, 1339-1345.	2.6	23
389	Missed Opportunities in Diabetes Management: A Longitudinal Assessment of Factors Associated with Sub-optimal Quality. <i>Journal of General Internal Medicine</i> , 2008, 23, 1770-1777.	2.6	23
390	Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2008, 22, 706-716.	2.4	138
391	Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2008, 22, 2670-2678.	2.4	74
392	Metabolic syndrome is not associated with reduction in aortic distensibility in subjects with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2008, 7, 1.	6.8	24
393	Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). <i>Cardiovascular Diabetology</i> , 2008, 7, 10.	6.8	38
394	Diabetic retinopathy is associated with pulse wave velocity, not with the augmentation index of pulse waveform. <i>Cardiovascular Diabetology</i> , 2008, 7, 11.	6.8	24
395	Improved survival in both men and women with diabetes between 1980 and 2004 - a cohort study in Sweden. <i>Cardiovascular Diabetology</i> , 2008, 7, 32.	6.8	48
396	A group randomized trial of a complexity-based organizational intervention to improve risk factors for diabetes complications in primary care settings: study protocol. <i>Implementation Science</i> , 2008, 3, 15.	6.9	18

#	ARTICLE	IF	CITATIONS
397	Improving eye care for veterans with diabetes: An example of using the QUERI steps to move from evidence to implementation: QUERI Series. <i>Implementation Science</i> , 2008, 3, 18.	6.9	12
398	Integrating diabetes self-management with the health goals of older adults: A qualitative exploration. <i>Patient Education and Counseling</i> , 2008, 72, 418-423.	2.2	41
399	Current and Future Status of Beta-blockers in the Treatment of Hypertension. <i>Clinical Cardiology</i> , 2008, 31, 249-252.	1.8	27
400	Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. <i>International Journal of Clinical Practice</i> , 2008, 62, 781-790.	1.7	35
401	Retinal ganglion cells in diabetes. <i>Journal of Physiology</i> , 2008, 586, 4401-4408.	2.9	341
402	Perceptions of Quality of Life Effects of Treatments for Diabetes Mellitus in Vulnerable and Nonvulnerable Older Patients. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1183-1190.	2.6	33
403	Choice of first antihypertensive – comparison between the Irish and Dutch setting. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 313-315.	2.4	1
404	Initial impact and cost of a nationwide population screening campaign for diabetes in Brazil: A follow up study. <i>BMC Health Services Research</i> , 2008, 8, 189.	2.2	25
405	Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross sectional study. <i>BMC Health Services Research</i> , 2008, 8, 226.	2.2	17
406	Initial Combination Therapy Compared With Monotherapy in Diabetic Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2008, 10, 668-676.	2.0	13
407	Effects of Calcium Channel Blockers on Proteinuria in Patients With Diabetic Nephropathy. <i>Journal of Clinical Hypertension</i> , 2008, 10, 761-769.	2.0	21
408	β-Blockers in the Treatment of Hypertension: New Data, New Directions. <i>Journal of Clinical Hypertension</i> , 2008, 10, 234-238.	2.0	7
409	Blood Pressure Control in Patients With Comorbidities. <i>Journal of Clinical Hypertension</i> , 2008, 10, 624-631.	2.0	34
410	Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2010, 2010, CD006739.	2.8	175
412	The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. <i>Health and Quality of Life Outcomes</i> , 2008, 6, 95.	2.4	44
413	Review: Stroke prevention: modifying risk factors. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 287-303.	2.1	92
414	The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII. <i>Ophthalmology</i> , 2008, 115, 1859-1868.	5.2	454
415	The Importance of Prompt Blood Pressure Control. <i>Journal of Clinical Hypertension</i> , 2008, 10, 13-19.	2.0	8

#	ARTICLE	IF	CITATIONS
416	Prompt, Aggressive BP Lowering in High-Risk Patients. <i>Journal of Clinical Hypertension</i> , 2008, 10, 40-48.	2.0	14
417	Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. <i>Current Therapeutic Research</i> , 2008, 69, 1-15.	1.2	13
418	A New Option for Therapeutic Management of Patients with Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 47-51.	2.2	4
419	Diabetic heart disease. <i>Postgraduate Medical Journal</i> , 2008, 84, 188-192.	1.8	77
420	Complication Reducing Effect of the Information Technology-Based Diabetes Management System on Subjects with Type 2 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2008, 2, 76-81.	2.2	11
421	Ambulatory Blood Pressure Is a Better Marker Than Clinic Blood Pressure in Predicting Cardiovascular Events in Patients With/Without Type 2 Diabetes. <i>American Journal of Hypertension</i> , 2008, 21, 443-450.	2.0	182
422	Impact of White-Coat Hypertension on Microvascular Complications in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 2233-2237.	8.6	37
423	Weight Change in Diabetes and Glycemic and Blood Pressure Control. <i>Diabetes Care</i> , 2008, 31, 1960-1965.	8.6	118
424	Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. <i>Cmaj</i> , 2008, 179, 920-926.	2.0	37
425	The Role of Anemia Management in Improving Outcomes for African-Americans with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2008, 28, 732-743.	3.1	20
426	Heritability of Proliferative Diabetic Retinopathy. <i>Diabetes</i> , 2008, 57, 2176-2180.	0.6	155
427	Epidemiology of Diabetes and Diabetes-Related Complications. <i>Physical Therapy</i> , 2008, 88, 1254-1264.	2.4	1,107
428	Slowing Nephropathy Progression. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, S3-S10.	4.5	103
429	Practice-Linked Online Personal Health Records for Type 2 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2008, 168, 1776.	3.8	194
430	Improving Diabetes Care in Practice. <i>Diabetes Care</i> , 2008, 31, 2238-2243.	8.6	114
431	Improving Hypertension Control in Diabetes Mellitus. <i>Circulation</i> , 2008, 117, 1361-1368.	1.6	157
432	Tool to Assess Likelihood of Fasting Glucose Impairment (TAG-IT). <i>Annals of Family Medicine</i> , 2008, 6, 555-561.	1.9	22
433	An Appreciation of Robert Turner. <i>Diabetes</i> , 2008, 57, 2918-2921.	0.6	2

#	ARTICLE	IF	CITATIONS
434	Improved Survival of Diabetic Foot Ulcer Patients 1995â€“2008. <i>Diabetes Care</i> , 2008, 31, 2143-2147.	8.6	129
435	Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 561-574.	2.3	30
436	Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 847-853.	2.3	16
437	Simultaneous transdermal extraction of glucose and lactate from human subjects by reverse iontophoresis. <i>International Journal of Nanomedicine</i> , 2008, 3, 211.	6.7	16
438	Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 753-768.	2.3	125
439	Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. <i>BMJ: British Medical Journal</i> , 2008, 337, a236-a236.	2.3	92
440	Changes in Incidence of Diabetes Mellitusâ€“Related Eye Disease Among US Elderly Persons, 1994-2005. <i>JAMA Ophthalmology</i> , 2008, 126, 1548.	2.4	38
441	Mitigating micro- and macro-vascular complications of diabetes beginning in adolescence. <i>Vascular Health and Risk Management</i> , 2009, 5, 1015.	2.3	36
442	Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. <i>Vascular Health and Risk Management</i> , 2009, 5, 411.	2.3	39
443	Effects of efforts to intensify management on blood pressure control among patients with type 2 diabetes mellitus and hypertension: A pilot study. <i>Vascular Health and Risk Management</i> , 2009, 5, 705.	2.3	12
444	Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 883-892.	6.1	245
445	Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. <i>Vascular Health and Risk Management</i> , 2009, 5, 859.	2.3	30
446	Antioxidant effect of garlic and aged black garlic in animal model of type 2 diabetes mellitus. <i>Nutrition Research and Practice</i> , 2009, 3, 156.	1.9	130
447	Diabetes and the Risk of Multi-System Aging Phenotypes: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2009, 4, e4144.	2.5	315
448	Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema. <i>Korean Journal of Ophthalmology: KJO</i> , 2009, 23, 17.	1.1	24
449	Diabetic Retinal Neurodegeneration Is Associated With Mitochondrial Oxidative Stress and Is Improved by an Angiotensin Receptor Blocker in a Model Combining Hypertension and Diabetes. <i>Diabetes</i> , 2009, 58, 1382-1390.	0.6	123
450	Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study. <i>Circulation</i> , 2009, 120, 212-220.	1.6	223
451	Advances in the Medical Treatment of Diabetic Retinopathy. <i>Diabetes Care</i> , 2009, 32, 1556-1562.	8.6	124

#	ARTICLE	IF	CITATIONS
452	How to Define Prehypertension in Diabetes/Metabolic Syndrome. <i>Diabetes Care</i> , 2009, 32, S275-S279.	8.6	5
453	Identification of Compounds That Inhibit IGF-I Signaling in Hyperglycemia. <i>Experimental Diabetes Research</i> , 2009, 2009, 1-10.	3.8	9
454	Beyond Health Information Technology: Critical Factors Necessary for Effective Diabetes Disease Management. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 452-460.	2.2	21
455	Should We Treat Prehypertension in Diabetes?: What are the cons?. <i>Diabetes Care</i> , 2009, 32, S280-S283.	8.6	4
456	Changes in Albumin Excretion in the Diabetes Prevention Program. <i>Diabetes Care</i> , 2009, 32, 720-725.	8.6	22
457	Differential effects of insulin deprivation and systemic insulin treatment on plasma protein synthesis in type 1 diabetic people. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E889-E897.	3.5	20
458	Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 2068-2074.	8.6	230
459	Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. <i>Cmaj</i> , 2009, 181, 37-44.	2.0	179
460	The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2009, 121, 94-107.	2.0	80
461	Green tea (<i>Camellia sinensis</i>) Attenuates Nephropathy by Downregulating Nox4 NADPH Oxidase in Diabetic Spontaneously Hypertensive Rats. <i>Journal of Nutrition</i> , 2009, 139, 96-100.	2.9	59
462	Health Technologies for Monitoring and Managing Diabetes: A Systematic Review. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 1460-1471.	2.2	77
464	Secular Trends in Diabetes-Related Preventable Hospitalizations in the United States, 1998-2006. <i>Diabetes Care</i> , 2009, 32, 1213-1217.	8.6	53
465	Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1565.	7.4	928
466	The ADDITION-Cambridge trial protocol: a cluster " randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. <i>BMC Public Health</i> , 2009, 9, 136.	2.9	75
467	Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): trial protocol. <i>BMC Public Health</i> , 2009, 9, 63.	2.9	10
468	Cost Effectiveness Analysis of a Hypertension Management Program in Patients With Type 2 Diabetes. <i>Journal of Clinical Hypertension</i> , 2009, 11, 116-124.	2.0	8
469	Blood Pressure Goals and Arterial Stiffness in Chronic Kidney Disease. <i>Journal of Clinical Hypertension</i> , 2009, 11, 201-206.	2.0	5
470	Lower Blood Pressure Goals for Cardiovascular and Renal Risk Reduction: Are They Defensible?. <i>Journal of Clinical Hypertension</i> , 2009, 11, 345-347.	2.0	10

#	ARTICLE	IF	CITATIONS
471	Investing time in health: do socioeconomically disadvantaged patients spend more or less extra time on diabetes self-care?. <i>Health Economics (United Kingdom)</i> , 2009, 18, 645-663.	1.7	27
472	Circulatory parameters in the retrobulbar central retinal artery and vein of patients with diabetes and medically treated systemic hypertension. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 53-58.	1.9	10
473	Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 735-743.	1.9	83
474	Morphometry of surgically removed internal limiting membrane during vitrectomy in diabetic macular edema. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 1307-1314.	1.9	9
475	Anemia and hypertension are risk factors for both renal prognosis and survival in patients with diabetes mellitus. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 473-479.	1.6	8
476	Evidence-based Practice Guideline for the Treatment of CKD. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 537-566.	1.6	106
477	Exercise therapy in Type 2 diabetes. <i>Acta Diabetologica</i> , 2009, 46, 263-278.	2.5	101
479	Improvement of diabetes indices of care by a short pharmaceutical care program. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 689-695.	1.4	19
480	An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care. <i>Irish Journal of Medical Science</i> , 2009, 178, 179-186.	1.5	14
481	Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials. <i>Current Diabetes Reports</i> , 2009, 9, 229-237.	4.2	10
482	Retinal vascular changes and diabetic retinopathy. <i>Current Diabetes Reports</i> , 2009, 9, 277-283.	4.2	88
483	Blood pressure level and kidney disease progression: Do we really need to go to 130/80 mm Hg?. <i>Current Hypertension Reports</i> , 2009, 11, 363-367.	3.5	1
484	Effect of blood pressure lowering on markers of kidney disease progression. <i>Current Hypertension Reports</i> , 2009, 11, 368-374.	3.5	4
485	Trends in hypertension treatment in diabetes. <i>Current Hypertension Reports</i> , 2009, 11, 437-443.	3.5	1
486	Plasma Ghrelin Modulation in Gastric Band Operation and Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2009, 19, 357-362.	2.1	102
487	Key priorities in managing glucose control in older people with diabetes. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 685-691.	3.3	36
488	Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. <i>Diabetologia</i> , 2009, 52, 50-59.	6.3	70
489	Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. <i>Diabetologia</i> , 2009, 52, 2027-2036.	6.3	150

#	ARTICLE	IF	CITATIONS
491	Obesity and Diabetes: The Impact of Bariatric Surgery on Type 2 Diabetes. <i>World Journal of Surgery</i> , 2009, 33, 2014-21.	1.6	55
492	DreamTel; Diabetes risk evaluation and management tele-monitoring study protocol. <i>BMC Endocrine Disorders</i> , 2009, 9, 13.	2.2	1
493	Diabetes prevalence and diagnosis in US states: analysis of health surveys. <i>Population Health Metrics</i> , 2009, 7, 16.	2.7	102
494	Barriers and facilitators to evidence based care of type 2 diabetes patients: experiences of general practitioners participating to a quality improvement program. <i>Implementation Science</i> , 2009, 4, 41.	6.9	42
495	Multiple goals and time constraints: perceived impact on physicians' performance of evidence-based behaviours. <i>Implementation Science</i> , 2009, 4, 77.	6.9	50
496	Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 861-874.	2.4	72
497	Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 417-430.	46.4	285
498	Characteristics of patients with coronary artery disease and hypertension: A report from INVEST. <i>Clinical Cardiology</i> , 2001, 24, V-6-V-8.	1.8	0
499	Angiotensin AT1 Receptor Antagonism Ameliorates Murine Retinal Proteome Changes Induced by Diabetes. <i>Journal of Proteome Research</i> , 2009, 8, 5541-5549.	3.7	28
500	Diabetic nephropathy. <i>Diabetology and Metabolic Syndrome</i> , 2009, 1, 10.	2.7	101
501	Absence of diabetic retinopathy in a patient who has had diabetes mellitus for 69 years, and inadequate glycemic control: case presentation. <i>Diabetology and Metabolic Syndrome</i> , 2009, 1, 13.	2.7	10
502	Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. <i>The Cochrane Library</i> , 2009, , CD006296.	2.8	211
503	The Improvement of Hypertension by Probiotics: Effects on Cholesterol, Diabetes, Renin, and Phytoestrogens. <i>International Journal of Molecular Sciences</i> , 2009, 10, 3755-3775.	4.1	193
504	Standards of Medical Care in Diabetes—2009. <i>Diabetes Care</i> , 2009, 32, S13-S61.	8.6	1,606
505	A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2009, 16, 446-456.	4.4	295
506	The Role of Genetics in Susceptibility to Diabetic Retinopathy. <i>International Ophthalmology Clinics</i> , 2009, 49, 35-52.	0.7	88
507	2009 Canadian Hypertension Education Program recommendations: The scientific summary – an annual update. <i>Canadian Journal of Cardiology</i> , 2009, 25, 271-277.	1.7	35
508	Hypertension in diabetes: A call to action. <i>Canadian Journal of Cardiology</i> , 2009, 25, 299-302.	1.7	32

#	ARTICLE	IF	CITATIONS
509	Blood pressure drugs have no mortality benefit in diabetic patients. Canadian Journal of Cardiology, 2009, 25, 594.	1.7	0
510	Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. Journal of Neurology, 2009, 256, 1603-1619.	3.6	47
511	Î2-Blocker Use for the Stages of Heart Failure. Mayo Clinic Proceedings, 2009, 84, 718-729.	3.0	74
512	Diabetes and Poor Disease Control: Is Comorbid Depression Associated With Poor Medication Adherence or Lack of Treatment Intensification?. Psychosomatic Medicine, 2009, 71, 965-972.	2.0	119
513	Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. British Journal of General Practice, 2009, 59, 43-48.	1.4	66
514	Characteristics of Insured Patients With Persistent Gaps in Diabetes Care Services. Medical Care, 2010, 48, 31-37.	2.4	26
515	Variation in the Net Benefit of Aggressive Cardiovascular Risk Factor Control Across the US Population of Patients With Diabetes Mellitus. Archives of Internal Medicine, 2010, 170, 1037.	3.8	52
516	Clinical Complexity in Middle-Aged and Older Adults With Diabetes. Medical Care, 2010, 48, 327-334.	2.4	79
517	Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. Journal of Hypertension, 2010, 28, 2076-2083.	0.5	31
518	Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vascular Health and Risk Management, 2010, 6, 821.	2.3	14
520	High normal fasting glucose level in obese youth: a marker for insulin resistance and beta cell dysregulation. Diabetologia, 2010, 53, 1199-1209.	6.3	48
521	Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia, 2010, 53, 2442-2451.	6.3	68
522	The big fat bariatric bandwagon. Diabetologia, 2010, 53, 1815-1822.	6.3	31
523	Individualised treatment of proliferative diabetic retinopathy: optimal surgical timing improves long-term outcomes. EPMA Journal, 2010, 1, 78-81.	6.1	9
524	Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. Endocrine, 2010, 37, 455-459.	2.3	30
525	Legacy Effects from DCCT and UKPDS: What They Mean and Implications for Future Diabetes Trials. Current Atherosclerosis Reports, 2010, 12, 432-439.	4.8	72
526	Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes. Current Diabetes Reports, 2010, 10, 16-23.	4.2	17
527	The "œ Curve" Problem Revisited: Old and New Findings. Current Hypertension Reports, 2010, 12, 290-295.	3.5	18

#	ARTICLE	IF	CITATIONS
528	Patient and Physician Beliefs About Control over Health: Association of Symmetrical Beliefs with Medication Regimen Adherence. <i>Journal of General Internal Medicine</i> , 2010, 25, 397-402.	2.6	60
529	The Pharmaceutical care of patients with type 2 diabetes mellitus. <i>International Journal of Clinical Pharmacy</i> , 2010, 32, 730-736.	1.4	37
530	Blood Pressure Control in Type 2 Diabetes Mellitus. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1029-1031.	1.9	4
531	Comparison of diabetes management in five countries for general and indigenous populations: an internet-based review. <i>BMC Health Services Research</i> , 2010, 10, 169.	2.2	48
532	Small artery remodeling in diabetes. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, no-no.	3.6	22
533	Antihypertensive Therapy in African Americans: Findings From an Inner-City Ambulatory Clinic. <i>Journal of Clinical Hypertension</i> , 2010, 12, 187-192.	2.0	4
534	Efficacy and Safety of Irbesartan/HCTZ in Severe Hypertension According to Cardiometabolic Factors. <i>Journal of Clinical Hypertension</i> , 2010, 12, 487-494.	2.0	3
535	Is There Accord in ACCORD? Lower Blood Pressure Targets in Type 2 Diabetes Does Not Lead to Fewer Cardiovascular Events Except for Reductions in Stroke. <i>Journal of Clinical Hypertension</i> , 2010, 12, 472-477.	2.0	5
536	Diabetes: cost of illness in Norway. <i>BMC Endocrine Disorders</i> , 2010, 10, 15.	2.2	31
537	Daily steps are low year-round and dip lower in fall/winter: findings from a longitudinal diabetes cohort. <i>Cardiovascular Diabetology</i> , 2010, 9, 81.	6.8	50
538	Evaluation of a toolkit to improve cardiovascular disease screening and treatment for people with type 2 diabetes: protocol for a cluster-randomized pragmatic trial. <i>Trials</i> , 2010, 11, 44.	1.6	17
539	Short- and long-term effects of a quality improvement collaborative on diabetes management. <i>Implementation Science</i> , 2010, 5, 94.	6.9	22
540	Diminishing Efficacy of Combination Therapy, Response Heterogeneity, and Treatment Intolerance Limit the Attainability of Tight Risk Factor Control in Patients with Diabetes. <i>Health Services Research</i> , 2010, 45, 437-456.	2.0	26
541	Reducing Potentially Avoidable Complications in Patients with Chronic Diseases: The Prometheus Payment Approach. <i>Health Services Research</i> , 2010, 45, 1854-1871.	2.0	17
542	Improvements in Indicators of Diabetes-related Health Status Among First Nations Individuals Enrolled in a Community-driven Diabetes Complications Mobile Screening Program in Alberta, Canada. <i>Canadian Journal of Public Health</i> , 2010, 101, 410-414.	2.3	17
543	Evidence-based approach for managing hypertension in type 2 diabetes. <i>Integrated Blood Pressure Control</i> , 2010, 3, 31.	1.2	2
544	Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. <i>Vascular Health and Risk Management</i> , 2010, 6, 883.	2.3	167
545	Retinal Nerve Fiber Layer Decrease during Glycemic Control in Type 2 Diabetes. <i>Journal of Ophthalmology</i> , 2010, 2010, 1-6.	1.3	20

#	ARTICLE	IF	CITATIONS
546	Family Practices' Achievement of Diabetes Quality of Care Targets and Risk of Screen-Detected Diabetic Retinopathy. PLoS ONE, 2010, 5, e10424.	2.5	4
547	Improving Blood Pressure Control in Patients with Diabetes Mellitus and High Cardiovascular Risk. International Journal of Hypertension, 2010, 2010, 1-8.	1.3	7
548	Diabetic microvascular complications: possible targets for improved macrovascular outcomes. International Journal of Nephrology and Renovascular Disease, 2011, 4, 1.	1.8	9
549	Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update. Vascular Health and Risk Management, 2010, 6, 253.	2.3	14
550	Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine. Vascular Health and Risk Management, 2010, 6, 87.	2.3	8
551	Prevention of diabetic eye disease: the commonest cause of blindness in individuals younger than 65 years. Clinical Ophthalmology, 2010, 4, 1291.	1.8	3
552	Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control. Integrated Blood Pressure Control, 2010, 3, 133.	1.2	3
553	Optimal use of β-blockers in high-risk hypertension: A guide to dosing equivalence. Vascular Health and Risk Management, 2010, 6, 363.	2.3	12
554	Prevalence of Diabetic Retinopathy in the United States, 2005-2008. JAMA - Journal of the American Medical Association, 2010, 304, 649.	7.4	895
555	Review Paper: The Use of Quality Improvement and Health Information Technology Approaches to Improve Diabetes Outcomes in African American and Hispanic Patients. Medical Care Research and Review, 2010, 67, 163S-197S.	2.1	34
556	Blood Pressure Control in Diabetes: Temporal progress yet persistent racial disparities: national results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Diabetes Care, 2010, 33, 798-803.	8.6	24
557	Cardiovascular risk and prevention in diabetes mellitus. Clinical Medicine, 2010, 10, 495-499.	1.9	5
558	Evidence-based mechanistic reasoning. Journal of the Royal Society of Medicine, 2010, 103, 433-441.	2.0	81
559	Are Individuals With Diabetes Seeing Better?. Diabetes, 2010, 59, 1853-1860.	0.6	83
560	Health Systems, Patients Factors, and Quality of Care for Diabetes. Diabetes Care, 2010, 33, 940-947.	8.6	69
561	Encounter Frequency and Blood Pressure in Hypertensive Patients With Diabetes Mellitus. Hypertension, 2010, 56, 68-74.	2.7	53
562	A Survey of the Management, Control, and Complications of Diabetes Mellitus in Patients Attending a Diabetes Clinic in Blantyre, Malawi, an Area of High HIV Prevalence. American Journal of Tropical Medicine and Hygiene, 2010, 83, 575-581.	1.4	46
563	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2010, 304, 61.	7.4	578

#	ARTICLE	IF	CITATIONS
564	BP reduction in patients with diabetes—uncertainties remain. <i>Nature Reviews Cardiology</i> , 2010, 7, 609-611.	13.7	0
565	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2010, 362, 1575-1585.	27.0	3,117
566	Managing diabetic nephropathy. <i>Clinical Medicine</i> , 2010, 10, 500-504.	1.9	20
567	Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, F125-F132.	2.7	60
568	The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat. <i>Mediators of Inflammation</i> , 2010, 2010, 1-12.	3.0	15
569	Incidence of Treatment for End-Stage Renal Disease Among Individuals With Diabetes in the U.S. Continues to Decline. <i>Diabetes Care</i> , 2010, 33, 73-77.	8.6	135
570	Quality of diabetes care at Armed Forces Hospital, Southern Region, Kingdom of Saudi Arabia, 2006. <i>Journal of Family and Community Medicine</i> , 2010, 17, 129.	1.1	5
571	Mortality Trends in Subjects With and Without Diabetes During 33 Years of Follow-up. <i>Diabetes Care</i> , 2010, 33, 551-556.	8.6	65
572	Control of Hypertension among Type II Diabetics. <i>Oman Medical Journal</i> , 2010, 25, 32-6.	1.0	10
573	Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 233-244.	27.0	1,091
574	Effect of systemic medications on onset and progression of diabetic retinopathy. <i>Nature Reviews Endocrinology</i> , 2010, 6, 494-508.	9.6	42
575	Glucose, Obesity, Metabolic Syndrome, and Diabetes. <i>Journal of the American College of Cardiology</i> , 2010, 55, 283-293.	2.8	174
576	Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema. <i>Drugs</i> , 2010, 70, 2171-2200.	10.9	34
577	Diabetic Macular Edema. <i>Drug Safety</i> , 2010, 33, 643-652.	3.2	13
578	The 25-Year Incidence of Visual Impairment in Type 1 Diabetes Mellitus. <i>Ophthalmology</i> , 2010, 117, 63-70.	5.2	151
579	Effects of blood pressure and the renin-angiotensin system on platelet activation in type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2010, 1, 196-201.	2.4	1
580	Candesartan Cilexetil/Hydrochlorothiazide Treatment in High-Risk Patients with Type 2 Diabetes Mellitus and Microalbuminuria. <i>Clinical Drug Investigation</i> , 2010, 30, 301-311.	2.2	5
581	Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension. <i>Clinical Drug Investigation</i> , 2010, 30, 843-854.	2.2	15

#	ARTICLE	IF	CITATIONS
582	Level of blood pressure above goal and clinical inertia in a Medicaid population. <i>Journal of the American Society of Hypertension</i> , 2010, 4, 244-254.	2.3	27
583	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. <i>Lancet, The</i> , 2010, 376, 419-430.	13.7	1,182
584	Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. <i>Canadian Journal of Cardiology</i> , 2010, 26, 297-302.	1.7	89
585	Standards of Medical Care in Diabetes—2010. <i>Diabetes Care</i> , 2010, 33, S11-S61.	8.6	2,863
586	Association Between Albuminuria and Duration of Diabetes and Myocardial Dysfunction and Peripheral Arterial Disease Among Patients With Stable Coronary Artery Disease in the BARI 2D Study. <i>Mayo Clinic Proceedings</i> , 2010, 85, 41-46.	3.0	20
587	Concerns About Meta-analysis of Glucose Control and Cardiovascular Disease in Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2010, 152, 63.	3.9	5
588	Polypharmacy and Combination Therapy in the Management of Hypertension in Elderly Patients with Co-Morbid Diabetes Mellitus. <i>Drugs and Aging</i> , 2010, 27, 871-883.	2.7	41
589	Multifocal Electroretinograms Predict Onset of Diabetic Retinopathy in Adult Patients with Diabetes. <i>Diabetes Care</i> , 2011, 34, 772.		176
590	Blood pressure lowering in patients with diabetes—“one level might not fit all. <i>Nature Reviews Cardiology</i> , 2011, 8, 42-49.	13.7	16
591	Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 444-456.	3.0	104
592	Manidipine for Hypertension not Controlled by Dual Therapy in Patients with Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2011, 31, 427-434.	2.2	9
593	Endothelial dysfunction as a potential contributor in diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2011, 7, 36-44.	9.6	159
594	Are primary care practitioners in Barbados following diabetes guidelines? - a chart audit with comparison between public and private care sectors. <i>BMC Research Notes</i> , 2011, 4, 199.	1.4	12
595	Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus. <i>Drugs and Aging</i> , 2011, 28, 945-960.	2.7	15
596	Seated Cuff Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil-Based Treatment Regimen in Patients with Type 2 Diabetes Mellitus. <i>Drugs in R and D</i> , 2011, 11, 251-257.	2.2	3
597	Artist® Tablets (Carvedilol) for Hypertensive Patients in Japan. <i>Drugs in R and D</i> , 2011, 11, 191-205.	2.2	2
598	Advances in the treatment of diabetic retinopathy. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 113-122.	0.3	12
599	Diabetic retinopathy — An update. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 99-111.	0.3	58

#	ARTICLE	IF	CITATIONS
600	Endothelial Factors and Diabetic Nephropathy. <i>Diabetes Care</i> , 2011, 34, S291-S296.	8.6	33
601	Therapeutic management of diabetic kidney disease. <i>Journal of Diabetes Investigation</i> , 2011, 2, 248-254.	2.4	12
602	Comparison of effects of azelnidipine and trichlormethiazide in combination with olmesartan on blood pressure and metabolic parameters in hypertensive type 2 diabetic patients. <i>Journal of Diabetes Investigation</i> , 2011, 2, 490-496.	2.4	2
603	Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. <i>Lancet</i> , The, 2011, 378, 156-167.	13.7	406
604	High-sensitivity C-reactive Protein Can Predict Major Adverse Cardiovascular Events in Korean Patients with Type 2 Diabetes. <i>Journal of Korean Medical Science</i> , 2011, 26, 1322.	2.5	14
605	Management of Blood Pressure in Patients with Type 2 Diabetes Mellitus: A Nationwide Survey in Korean. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 348.	4.7	6
606	Ambulatory Blood Pressure Monitoring in Diabetes and Obesity—A Review. <i>International Journal of Hypertension</i> , 2011, 2011, 1-8.	1.3	20
607	Effect on Glycemic, Blood Pressure, and Lipid Control according to Education Types. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 580.	4.7	5
608	Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. <i>Patient Related Outcome Measures</i> , 2011, 2, 27.	1.2	6
609	Prevalence, Awareness, and Control of Hypertension among Diabetic Koreans. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 337.	4.7	6
610	Hypertension in Chronic Kidney Disease: Navigating the Evidence. <i>International Journal of Hypertension</i> , 2011, 2011, 1-9.	1.3	98
611	Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. <i>Journal of Ophthalmology</i> , 2011, 2011, 1-13.	1.3	44
612	Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 571.	4.7	41
613	Hypertension, poor glycemic control, and microalbuminuria in Cuban Americans with type 2 diabetes. <i>International Journal of Nephrology and Renovascular Disease</i> , 2011, 4, 35.	1.8	6
614	Update on the management of diabetic polyneuropathies. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2011, 4, 289.	2.4	31
615	The Wrong Tool for the Job: Diabetes Public Health Programs and Practice Guidelines. <i>American Journal of Public Health</i> , 2011, 101, 1871-1873.	2.7	0
616	Encounter Frequency and Serum Glucose Level, Blood Pressure, and Cholesterol Level Control in Patients With Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2011, 171, 1542.	3.8	94
617	Medication Use in Older U.S. Adults with Diabetes Mellitus and the Potential Ramifications of Raising the Glycemic Target. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2381-2383.	2.6	4

#	ARTICLE	IF	CITATIONS
618	Prioritization of care in adults with diabetes and comorbidity. <i>Annals of the New York Academy of Sciences</i> , 2011, 1243, 69-87.	3.8	39
619	Hypertension, Dyslipidemia, and Insulin Resistance in Patients With Diabetes Mellitus or the Cardiometabolic Syndrome: Benefits of Vasodilating β -Blockers. <i>Journal of Clinical Hypertension</i> , 2011, 13, 52-59.	2.0	66
620	Efficacy of Amlodipine and Olmesartan Medoxomil in Hypertensive Patients With Diabetes and Obesity. <i>Journal of Clinical Hypertension</i> , 2011, 13, 422-430.	2.0	9
621	Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. <i>Journal of Clinical Hypertension</i> , 2011, 13, 244-251.	2.0	333
622	Hypertension in Diabetes: Treatment Considerations. <i>Journal of Clinical Hypertension</i> , 2011, 13, 314-318.	2.0	5
623	Diabetes and Hypertension: A Comprehensive Report on Management and the Prevention of Cardiovascular and Renal Complications. <i>Journal of Clinical Hypertension</i> , 2011, 13, 221-223.	2.0	2
624	Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2011, 13, 889-897.	2.0	6
625	Inflammation in diabetic retinopathy. <i>Progress in Retinal and Eye Research</i> , 2011, 30, 343-358.	15.5	879
627	Target blood pressure in diabetes patients with hypertension – What is the accumulated evidence in 2011?. <i>Journal of Zhejiang University: Science B</i> , 2011, 12, 611-623.	2.8	12
629	Lack of correlation between short-term dynamics of diabetic retinopathy lesions and the arterial blood pressure. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 267-271.	1.9	12
630	Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 58-63.	1.6	13
631	Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 848-853.	1.6	17
632	Uncontrolled home blood pressure in the morning is associated with nephropathy in Japanese type 2 diabetes. <i>Heart and Vessels</i> , 2011, 26, 609-615.	1.2	27
633	Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. <i>Diabetologia</i> , 2011, 54, 2237-2246.	6.3	55
634	Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. <i>Diabetologia</i> , 2011, 54, 2525-2532.	6.3	122
635	Racial and Ethnic Differences in Longitudinal Blood Pressure Control in Veterans with Type 2 Diabetes Mellitus. <i>Journal of General Internal Medicine</i> , 2011, 26, 1278-1283.	2.6	18
636	Optimal treatment for coronary artery disease in patients with diabetes: percutaneous coronary intervention, coronary artery bypass graft, and medications. <i>General Thoracic and Cardiovascular Surgery</i> , 2011, 59, 6-13.	0.9	1
637	Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus. <i>Current Atherosclerosis Reports</i> , 2011, 13, 176-185.	4.8	16

#	ARTICLE	IF	CITATIONS
638	The Goal of Blood Pressure Control for Prevention of Early Diabetic Microvascular Complications. <i>Current Diabetes Reports</i> , 2011, 11, 323-329.	4.2	8
639	Does Therapy Targeting Normal SBP of Less than 120Âmm Hg Reduce Major CV Events in T2DM Patients?. <i>Current Diabetes Reports</i> , 2011, 11, 233-235.	4.2	0
640	Is Nocturnal Blood Pressure Reduction the Secret to Reducing the Rate of Progression of Hypertensive Chronic Kidney Disease?. <i>Current Hypertension Reports</i> , 2011, 13, 378-385.	3.5	27
641	Blood Pressure Targets for Patients with Diabetes or Kidney Disease. <i>Current Hypertension Reports</i> , 2011, 13, 452-455.	3.5	17
642	Protocol for the ADDITION-Plus study: a randomised controlled trial of an individually-tailored behaviour change intervention among people with recently diagnosed type 2 diabetes under intensive UK general practice care. <i>BMC Public Health</i> , 2011, 11, 211.	2.9	21
643	Assessment of quality of care given to diabetic patients at Jimma University Specialized Hospital diabetes follow-up clinic, Jimma, Ethiopia. <i>BMC Endocrine Disorders</i> , 2011, 11, 19.	2.2	54
644	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2011, 10, 22.	6.8	137
645	Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. <i>Cardiovascular Diabetology</i> , 2011, 10, 31.	6.8	54
646	Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study. <i>Cardiovascular Diabetology</i> , 2011, 10, 39.	6.8	40
647	Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. <i>Eye</i> , 2011, 25, 843-849.	2.1	58
648	Telehealth Practice Recommendations for Diabetic Retinopathy, Second Edition. <i>Telemedicine Journal and E-Health</i> , 2011, 17, 814-837.	2.8	99
649	Self-Monitoring Technologies for Type 2 Diabetes and the Prevention of Cardiovascular Complications: Perspectives from End Users. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 394-401.	2.2	11
650	Blood Pressure Trajectories Prior to Death in Patients With Diabetes. <i>Diabetes Care</i> , 2011, 34, 1534-1539.	8.6	17
651	Review of therapeutic advances in diabetic retinopathy. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2011, 2, 39-53.	3.2	18
652	Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2011, 2, 17-26.	3.2	28
653	Diabetes and Technology for Increased Activity (DaTA) Study: Results of a Remote Monitoring Intervention for Prevention of Metabolic Syndrome. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 928-935.	2.2	44
654	Candidate Gene Association Study for Diabetic Retinopathy in Persons with Type 2 Diabetes: The Candidate Gene Association Resource (CARE). , 2011, 52, 7593.		82
655	Prediction, by Retinal Location, of the Onset of Diabetic Edema in Patients with Nonproliferative Diabetic Retinopathy. , 2011, 52, 6825.		31

#	ARTICLE	IF	CITATIONS
656	Blood Pressure and Cardiovascular Disease Risk in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> , 2011, 34, 34-38.	8.6	83
657	Long-Term and Recent Progress in Blood Pressure Levels Among U.S. Adults With Diagnosed Diabetes, 1988-2008. <i>Diabetes Care</i> , 2011, 34, 1579-1581.	8.6	42
658	Blood Pressure: The Lower, the Better: The con side. <i>Diabetes Care</i> , 2011, 34, S308-S312.	8.6	24
659	Adherence to Guidelines for Youths With Diabetes Mellitus. <i>Pediatrics</i> , 2011, 128, 531-538.	2.1	48
660	Management of diabetic hypertensives. <i>Indian Journal of Endocrinology and Metabolism</i> , 2011, 15, 374.	0.4	15
661	Evaluation of Dosing Time-Related Anti-Hypertensive Efficacy of Valsartan in Patients with Type 2 Diabetes. <i>Clinical and Experimental Hypertension</i> , 2011, 33, 56-62.	1.3	12
662	Benefits of Tight Blood Pressure Control in Diabetic Patients With Hypertension. <i>Diabetes Care</i> , 2011, 34, S297-S303.	8.6	34
663	Standards of Medical Care in Diabetes—2011. <i>Diabetes Care</i> , 2011, 34, S11-S61.	8.6	2,448
664	Cardiovascular Outcomes in Framingham Participants With Diabetes. <i>Hypertension</i> , 2011, 57, 891-897.	2.7	217
665	Diabetic Retinopathy in 2011: Further Insights From New Epidemiological Studies and Clinical Trials. <i>Diabetes Care</i> , 2011, 34, 1066-1067.	8.6	23
666	Diabetes, Hypertension, and Outcome Studies: Overview 2010. <i>Diabetes Care</i> , 2011, 34, S109-S113.	8.6	16
667	Response of Rat Retinal Capillary Pericytes and Endothelial Cells to Glucose. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 7-15.	1.4	16
668	Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration. <i>Diabetes Care</i> , 2011, 34, 968-974.	8.6	213
669	Microalbuminuria and low hemoglobin as risk factors for the occurrence and increasing severity of diabetic retinopathy. <i>Indian Journal of Ophthalmology</i> , 2011, 59, 207.	1.1	42
670	Similar cardiovascular risk factor profile in screen-detected and known type 2 diabetic subjects. <i>Scandinavian Journal of Primary Health Care</i> , 2011, 29, 85-91.	1.5	4
671	Pitavastatin: finding its place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 101-117.	2.5	13
672	Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001293.	8.4	389
673	Diabetes and Coronary Heart Disease: A Risk Factor for the Global Epidemic. <i>International Journal of Hypertension</i> , 2012, 2012, 1-7.	1.3	67

#	ARTICLE	IF	CITATIONS
674	The Relationship Between Financial Incentives and Quality of Diabetes Care in Ontario, Canada. <i>Diabetes Care</i> , 2012, 35, 1038-1046.	8.6	61
675	Type 2 diabetes and cardiovascular diseases: do they share a common soil? The Asian Indian experience. <i>Heart Asia</i> , 2012, 4, 69-76.	1.1	4
676	Monitoring Performance for Blood Pressure Management Among Patients With Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2012, 172, 938.	3.8	56
677	New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. <i>Eye</i> , 2012, 26, 485-493.	2.1	104
678	Therapeutic Interventions against Inflammatory and Angiogenic Mediators in Proliferative Diabetic Retinopathy. <i>Mediators of Inflammation</i> , 2012, 2012, 1-10.	3.0	73
679	Chronic Kidney Disease in Disadvantaged Populations. <i>International Journal of Nephrology</i> , 2012, 2012, 1-6.	1.3	22
680	Primary Prevention of Heart Failure. <i>ISRN Cardiology</i> , 2012, 2012, 1-15.	1.6	18
681	Prescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India. <i>International Journal of Hypertension</i> , 2012, 2012, 1-9.	1.3	26
682	Improving Blood Pressure Control Through a Clinical Pharmacist Outreach Program in Patients With Diabetes Mellitus in 2 High-Performing Health Systems. <i>Circulation</i> , 2012, 125, 2863-2872.	1.6	105
683	Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment. <i>Diabetes Care</i> , 2012, 35, 218-225.	8.6	108
684	Hyperglycemia and Renin-Dependent Hypertension Synergize to Model Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 405-411.	6.1	40
685	Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. <i>BMJ, The</i> , 2012, 345, e5567-e5567.	6.0	76
686	Glycemic and blood-pressure control "lower is not better. <i>Nature Reviews Nephrology</i> , 2012, 8, 199-200.	9.6	0
687	Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus. <i>Kidney International Supplements</i> , 2012, 2, 363-369.	14.2	24
688	Diabetic Autonomic Imbalance and Glycemic Variability. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 1207-1215.	2.2	59
689	Effect of Intensive Multifactorial Treatment Compared With Routine Care on Aortic Stiffness and Central Blood Pressure Among Individuals With Screen-Detected Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2207-2214.	8.6	24
690	New Bundled World: Quality of Care and Readmission in Diabetes Patients. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 563-571.	2.2	24
691	Pharmacist Interventions to Improve Cardiovascular Disease Risk Factors in Diabetes. <i>Diabetes Care</i> , 2012, 35, 2706-2717.	8.6	126

#	ARTICLE	IF	CITATIONS
692	Lifestyle Counseling in Routine Care and Long-Term Glucose, Blood Pressure, and Cholesterol Control in Patients With Diabetes. <i>Diabetes Care</i> , 2012, 35, 334-341.	8.6	48
693	Diabetic macular edema: Current and emerging therapies. <i>Middle East African Journal of Ophthalmology</i> , 2012, 19, 4.	0.3	38
694	Initial Choice of Antihypertensive on Long-Term Cardiovascular Outcomes in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 884-886.	4.5	0
695	Current therapeutic agents and anesthetic considerations for diabetes mellitus. <i>Korean Journal of Anesthesiology</i> , 2012, 63, 195.	2.5	3
696	Genetic Predisposition to High Blood Pressure Associates With Cardiovascular Complications Among Patients With Type 2 Diabetes. <i>Diabetes</i> , 2012, 61, 3026-3032.	0.6	12
697	Blood Pressure, Vessel Caliber, and Retinal Thickness in Diabetes. <i>Optometry and Vision Science</i> , 2012, 89, 1715-1720.	1.2	11
698	Cardiovascular risk reduction following diagnosis of diabetes by screening: 1-year results from the ADDITION-Cambridge trial cohort. <i>British Journal of General Practice</i> , 2012, 62, e396-e402.	1.4	9
699	Ageing, Diabetes, and the Public Health System in the United States. <i>American Journal of Public Health</i> , 2012, 102, 1482-1497.	2.7	123
700	Discrepancy Between Tonometric Ambulatory and Cuff-Based Office Blood Pressure Measurements in Patients With Type 1 Diabetes. <i>Journal of Clinical Hypertension</i> , 2012, 14, 686-693.	2.0	3
701	Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2489.	7.4	571
702	Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. <i>American Heart Journal</i> , 2012, 164, 672-680.	2.7	56
703	Extended longitudinal analysis of arterial pressure and heart rate control in unanesthetized rats with type 1 diabetes. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2012, 170, 20-29.	2.8	1
704	Diabetes and the Risk of Heart Failure. <i>Heart Failure Clinics</i> , 2012, 8, 125-133.	2.1	55
705	High Risk of ESRD in Type 1 Diabetes: New Strategies Are Needed to Retard Progressive Renal Function Decline. <i>Seminars in Nephrology</i> , 2012, 32, 407-414.	1.6	37
706	Vitamin D Insufficiency in Diabetic Retinopathy. <i>Endocrine Practice</i> , 2012, 18, 185-193.	2.1	103
707	Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension. <i>Journal of Drug Assessment</i> , 2012, 1, 1-10.	2.2	3
708	Standards of Medical Care in Diabetes—2012. <i>Diabetes Care</i> , 2012, 35, S11-S63.	8.6	1,956
709	DialBetics: Smartphone-Based Self-Management for Type 2 Diabetes Patients. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 983-985.	2.2	18

#	ARTICLE	IF	CITATIONS
710	A Methodological Review of Faith-Based Health Promotion Literature: Advancing the Science to Expand Delivery of Diabetes Education to Black Americans. <i>Journal of Religion and Health</i> , 2012, 51, 1075-1097.	1.7	66
711	Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1717-1724.	6.1	80
712	Combined intensive blood pressure and glyceimic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. <i>Kidney International</i> , 2012, 81, 586-594.	5.2	53
713	Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1741-1748.	13.7	199
714	Hypertension resistant to antihypertensive agents commonly occurs with the progression of diabetic nephropathy in Japanese patients with type 2 diabetes mellitus: a prospective observational study. <i>BMC Nephrology</i> , 2012, 13, 48.	1.8	12
715	Hospitalized cardiovascular events in patients with diabetic macular edema. <i>BMC Ophthalmology</i> , 2012, 12, 11.	1.4	32
716	What are patient factors associated with the quality of diabetes care?: results from the Korean National Health and Nutrition Examination Survey. <i>BMC Public Health</i> , 2012, 12, 689.	2.9	16
717	Improving treatment intensification to reduce cardiovascular disease risk: a cluster randomized trial. <i>BMC Health Services Research</i> , 2012, 12, 183.	2.2	10
718	A simple diabetes vascular severity staging instrument and its application to a Torres Strait Islander and Aboriginal adult cohort of north Australia. <i>BMC Health Services Research</i> , 2012, 12, 185.	2.2	15
719	A pilot qualitative study to explore stakeholder opinions regarding prescribing quality indicators. <i>BMC Health Services Research</i> , 2012, 12, 191.	2.2	7
720	Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or hyperlipidaemia in primary care settings. <i>BMC Health Services Research</i> , 2012, 12, 388.	2.2	37
721	Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure. <i>Cardiovascular Diabetology</i> , 2012, 11, 118.	6.8	7
722	Vascular memory: can we broaden the concept of the metabolic memory?. <i>Cardiovascular Diabetology</i> , 2012, 11, 44.	6.8	27
723	Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial. <i>Diabetic Medicine</i> , 2012, 29, e409-16.	2.3	15
724	Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin. <i>Clinical Pharmacokinetics</i> , 2012, 51, 147-162.	3.5	90
725	Heart Failure in Hypertension. <i>Drugs</i> , 2012, 72, 1373-1398.	10.9	16
726	Diabetes and Cardiovascular Disease: Changing the Focus from Glycemic Control to Improving Long-Term Survival. <i>American Journal of Cardiology</i> , 2012, 110, 58B-68B.	1.6	64
727	Blood Pressure Measurement: Clinic, Home, Ambulatory, and Beyond. <i>American Journal of Kidney Diseases</i> , 2012, 60, 449-462.	1.9	81

#	ARTICLE	IF	CITATIONS
728	In Vitro Antioxidant Effects of Aloe barbadensis Miller Extracts and the Potential Role of These Extracts as Antidiabetic and Antilipidemic Agents on Streptozotocin-Induced Type 2 Diabetic Model Rats. <i>Molecules</i> , 2012, 17, 12851-12867.	3.8	45
729	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). <i>International Journal of Behavioral Medicine</i> , 2012, 19, 403-488.	1.7	224
730	What Is the Ideal Blood Pressure Goal for Patients with Diabetes Mellitus and Nephropathy?. <i>Current Cardiology Reports</i> , 2012, 14, 651-659.	2.9	14
731	Should African Americans Have a Lower Blood Pressure Goal than Other Ethnic Groups to Prevent Organ Damage?. <i>Current Cardiology Reports</i> , 2012, 14, 660-666.	2.9	9
732	Impact of Arterial Hypertension on the Eye. <i>Current Hypertension Reports</i> , 2012, 14, 581-590.	3.5	27
733	Therapeutic Modalities in Diabetic Nephropathy: <i>Future Approaches&/i>. <i>Open Journal of Nephrology</i> , 2012, 02, 5-18.	0.1	11
734	The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. <i>Diabetologia</i> , 2012, 55, 2946-2953.	6.3	84
736	Fixed-Dose Combination Therapy in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2012, 19, 51-54.	2.2	15
737	Colesevelam for type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2012, 12, CD009361.	2.8	23
738	Diabetes MILES â€œ The Netherlands: rationale, design and sample characteristics of a national survey examining the psychosocial aspects of living with diabetes in Dutch adults. <i>BMC Public Health</i> , 2012, 12, 925.	2.9	28
739	Combination Therapy for Diabetic Macular Edema. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-6.	1.3	8
740	Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. <i>Vascular Health and Risk Management</i> , 2012, 8, 255.	2.3	21
741	Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. <i>World Journal of Diabetes</i> , 2012, 3, 161.	3.5	19
742	Hypertensive chronic kidney disease in African Americans: Strategies for improving care. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 726-734.	1.3	23
743	Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. <i>Patient Preference and Adherence</i> , 2012, 6, 449.	1.8	14
744	The effect of glucagon-like peptide 1 on cardiovascular risk. <i>Nature Reviews Cardiology</i> , 2012, 9, 209-222.	13.7	131
745	Diabetic Macular Edema: Therapeutic Options. <i>Diabetes Therapy</i> , 2012, 3, 1-14.	2.5	5
747	Protective Effects of Adeno-associated Virus Mediated Brain-derived Neurotrophic Factor Expression on Retinal Ganglion Cells in Diabetic Rats. <i>Cellular and Molecular Neurobiology</i> , 2012, 32, 467-475.	3.3	32

#	ARTICLE	IF	CITATIONS
748	Evaluation of educational needs in patients with diabetes mellitus in respect of medication use in Austria. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 490-500.	2.1	5
749	Surgical Treatment of Type 2 Diabetes in Patients with BMI Below 35: Mid-term Outcomes of the Laparoscopic Ileal Interposition Associated with a Sleeve Gastrectomy in 202 Consecutive Cases. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 967-976.	1.7	53
750	Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. <i>Journal of General Internal Medicine</i> , 2012, 27, 458-468.	2.6	46
751	Impact of Delaying Blood Pressure Control in Patients with Type 2 Diabetes: Results of a Decision Analysis. <i>Journal of General Internal Medicine</i> , 2012, 27, 640-646.	2.6	6
752	Corticosteroid Use for Diabetic Macular Edema: Old Fad or New Trend?. <i>Current Diabetes Reports</i> , 2012, 12, 364-375.	4.2	67
753	Screening for Diabetic Retinopathy and Diabetic Macular Edema in the United Kingdom. <i>Current Diabetes Reports</i> , 2012, 12, 338-345.	4.2	59
754	Analysis of various etiologies of hypertension in patients hospitalized in the endocrinology division. <i>Endocrine</i> , 2012, 42, 174-181.	2.3	6
755	Prevention of Type 2 Diabetes and Its Complications in Developing Countries: A Review. <i>International Journal of Behavioral Medicine</i> , 2012, 19, 121-133.	1.7	113
756	Prehypertension: how low to go and do drugs have a role?. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 187-193.	2.4	8
757	Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain. <i>International Journal of Clinical Practice</i> , 2012, 66, 281-288.	1.7	11
758	Aggressive Blood Pressure Lowering Therapy Guided by Home Blood Pressure Monitoring Improves Target Organ Damage in Hypertensive Patients With Type 2 Diabetes/Prediabetes. <i>Journal of Clinical Hypertension</i> , 2012, 14, 422-428.	2.0	22
759	Provider and Systems Factors in Diabetes Quality of Care. <i>Current Cardiology Reports</i> , 2012, 14, 97-105.	2.9	0
760	Tight Blood Pressure Control in Diabetes: Evidence-Based Review of Treatment Targets in Patients with Diabetes. <i>Current Cardiology Reports</i> , 2012, 14, 89-96.	2.9	21
761	Diabetes in rural towns: effectiveness of continuing education and feedback for healthcare providers in altering diabetes outcomes at a population level: protocol for a cluster randomised controlled trial. <i>Implementation Science</i> , 2013, 8, 30.	6.9	16
762	Clinical course and visual outcome in patients with diabetes mellitus and uveitis. <i>BMC Research Notes</i> , 2013, 6, 167.	1.4	26
763	Adherence to clinical guidelines in management of diabetes and prevention of cardiovascular disease in Qatar. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 101-112.	2.1	18
764	Study design of DIACORE (DIAbetes COHoRtE) – a cohort study of patients with diabetes mellitus type 2. <i>BMC Medical Genetics</i> , 2013, 14, 25.	2.1	25
765	Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report. <i>Cardiovascular Diabetology</i> , 2013, 12, 71.	6.8	8

#	ARTICLE	IF	CITATIONS
766	Is the Risk and Nature of CVD the Same in Type 1 and Type 2 Diabetes?. <i>Current Diabetes Reports</i> , 2013, 13, 350-361.	4.2	28
767	Diabetes Mellitus and Periodontal Diseases. <i>Current Diabetes Reports</i> , 2013, 13, 445-452.	4.2	43
768	Role of Ambulatory Blood Pressure Monitoring in Hypertension and Diabetes. <i>Current Hypertension Reports</i> , 2013, 15, 137-142.	3.5	3
769	Type 2 Diabetes in Older People; The Importance of Blood Pressure Control. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 233-237.	2.0	8
770	Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data. <i>Diabetes Care</i> , 2013, 36, 1541-1546.	8.6	21
771	Using Benefit-Based Tailored Treatment to Improve the Use of Antihypertensive Medications. <i>Circulation</i> , 2013, 128, 2309-2317.	1.6	80
772	Tailored Case Management for Diabetes and Hypertension (TEACH-DM) in a community population: Study design and baseline sample characteristics. <i>Contemporary Clinical Trials</i> , 2013, 36, 298-306.	1.8	19
773	Optimal treatment of diabetic retinopathy. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2013, 4, 61-71.	3.2	18
774	Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. <i>Diabetologia</i> , 2013, 56, 2601-2608.	6.3	142
775	Hypertension management algorithm for type 2 diabetic patients applied in primary care. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 52.	2.7	5
776	Management of diabetes mellitus and associated cardiovascular risk factors in Brazil – the Brazilian study on the practice of diabetes care. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 46.	2.7	4
777	Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study. <i>Cardiovascular Diabetology</i> , 2013, 12, 131.	6.8	9
778	A systematic review of evidence on the association between hospitalisation for chronic disease related ambulatory care sensitive conditions and primary health care resourcing. <i>BMC Health Services Research</i> , 2013, 13, 336.	2.2	107
779	Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. <i>BMC Medical Research Methodology</i> , 2013, 13, 107.	3.1	10
780	Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic. <i>BMC Medicine</i> , 2013, 11, 157.	5.5	50
781	Structured personal care of type 2 diabetes: a 19-year follow-up of the study Diabetes Care in General Practice (DCGP). <i>Diabetologia</i> , 2013, 56, 1243-1253.	6.3	41
782	Blood Pressure Control and Primary Prevention of Stroke: Summary of the Recent Clinical Trial Data and Meta-Analyses. <i>Current Hypertension Reports</i> , 2013, 15, 559-574.	3.5	78
783	Coming full circle in diabetes mellitus: from complications to initiation. <i>Nature Reviews Endocrinology</i> , 2013, 9, 113-123.	9.6	66

#	ARTICLE	IF	CITATIONS
784	Diabetic Kidney Disease and the Cardiorenal Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013, 42, 789-808.	3.2	33
785	Temporal Trends in Prevalence of CKD: The Glass Is Half Full and Not Half Empty. <i>American Journal of Kidney Diseases</i> , 2013, 62, 214-216.	1.9	6
786	Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis. <i>Diabetologia</i> , 2013, 56, 457-466.	6.3	170
787	Mortality and excess risk in US adults with pre-diabetes and diabetes: a comparison of two nationally representative cohorts, 1988-2006. <i>Population Health Metrics</i> , 2013, 11, 3.	2.7	14
788	All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database. <i>Diabetes Care</i> , 2013, 36, 2366-2371.	8.6	121
789	Standards of Medical Care in Diabetes-2013. <i>Diabetes Care</i> , 2013, 36, S11-S66.	8.6	3,076
790	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 62, 201-213.	1.9	174
791	Aggressive Blood Pressure Control Increases Coronary Heart Disease Risk Among Diabetic Patients. <i>Diabetes Care</i> , 2013, 36, 3287-3296.	8.6	47
792	Blood Pressure and Stroke Risk Among Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3653-3662.	3.6	37
793	Screening, Prevention, and Ambitious Management of Diabetic Macular Edema in Patients with Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2013, 13, 679-686.	4.2	4
794	The Lower, the Better?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 135-138.	2.2	2
796	Current and future management of diabetic retinopathy: a personalized evidence-based approach. <i>Diabetes Management</i> , 2013, 3, 481-494.	0.5	10
797	Association Between Depression and Functional Vision Loss in Persons 20 Years of Age or Older in the United States, NHANES 2005-2008. <i>JAMA Ophthalmology</i> , 2013, 131, 573.	2.5	191
798	Blood pressure goals in T2DM: a Latin American perspective. <i>Nature Reviews Endocrinology</i> , 2013, 9, 138-139.	9.6	1
799	Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease. <i>International Journal of Inflammation</i> , 2013, 2013, 1-8.	1.5	51
800	Challenges in the Management of Type 2 Diabetes Mellitus and Cardiovascular Risk Factors in Obese Subjects: What Is the Evidence and What Are the Myths?. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-10.	1.5	11
801	Primary Prevention of Macroangiopathy in Patients With Short-Duration Type 2 Diabetes by Intensified Multifactorial Intervention. <i>Diabetes Care</i> , 2013, 36, 978-984.	8.6	28
802	Prevalence of microvascular complications in newly diagnosed patients with Type 2 diabetes. <i>Pakistan Journal of Medical Sciences</i> , 2013, 29, 899-902.	0.6	43

#	ARTICLE	IF	CITATIONS
803	Should we start all patients with diabetic retinopathy on fenofibrates?. Middle East African Journal of Ophthalmology, 2013, 20, 309.	0.3	1
804	Does contact with a podiatrist prevent the occurrence of a lower extremity amputation in people with diabetes? A systematic review and meta-analysis. BMJ Open, 2013, 3, e002331.	1.9	11
805	Systemic medical management of diabetic retinopathy. Middle East African Journal of Ophthalmology, 2013, 20, 301.	0.3	17
806	Inflammation and Pharmacological Treatment in Diabetic Retinopathy. Mediators of Inflammation, 2013, 2013, 1-8.	3.0	72
807	Impact of lifestyle modification on glycemic control in patients with type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism, 2013, 17, 1030.	0.4	34
808	Prevalence, Awareness, and Treatment of Hypertension in Patients with Type 1 Diabetes: A Nationwide Multicenter Study in Brazil. International Journal of Hypertension, 2013, 2013, 1-8.	1.3	4
809	Prognostic Value of Blood Pressure Variability and Average Blood Pressure Levels in Patients With Hypertension and Diabetes. Diabetes Care, 2013, 36, S312-S324.	8.6	130
810	Evaluation of Serum Zinc Status and Glycated Hemoglobin of Type 2 Diabetes Mellitus Patients in a Tertiary Care Hospital of Assam. Journal of Laboratory Physicians, 2013, 5, 30-33.	1.1	18
811	Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ, The, 2013, 347, f5680-f5680.	6.0	209
812	Renal Lesions Predict Progression of Diabetic Nephropathy in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2013, 24, 1175-1181.	6.1	99
813	Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. Cmaj, 2013, 185, 963-967.	2.0	15
815	Effect of Pay-for-Performance Incentives on Quality of Care in Small Practices With Electronic Health Records. JAMA - Journal of the American Medical Association, 2013, 310, 1051.	7.4	101
816	Anti-vascular endothelial growth factor therapy for diabetic macular edema. Therapeutic Advances in Endocrinology and Metabolism, 2013, 4, 151-169.	3.2	145
817	Generic Medications and Blood Pressure Control in Diabetic Hypertensive Subjects: Results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Diabetes Care, 2013, 36, 591-597.	8.6	11
818	Evolving strategies in the management of diabetic retinopathy. Middle East African Journal of Ophthalmology, 2013, 20, 273.	0.3	22
819	Epidemiological issues in diabetic retinopathy. Middle East African Journal of Ophthalmology, 2013, 20, 293.	0.3	80
820	Diabetic retinopathy and its risk factors at the University Hospital in Jamaica. Middle East African Journal of Ophthalmology, 2013, 20, 321.	0.3	12
821	Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension, 2013, 2013, 1-15.	1.3	321

#	ARTICLE	IF	CITATIONS
822	An evidence-based shared decision making programme on the prevention of myocardial infarction in type 2 diabetes: protocol of a randomised-controlled trial. <i>BMC Family Practice</i> , 2013, 14, 155.	2.9	7
823	Insulin Sensitivity and Beta-Cell Function Are Associated with Arterial Stiffness in Individuals without Hypertension. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-8.	2.3	10
824	The Rising Burden of Diabetes and Hypertension in Southeast Asian and African Regions: Need for Effective Strategies for Prevention and Control in Primary Health Care Settings. <i>International Journal of Hypertension</i> , 2013, 2013, 1-14.	1.3	121
825	Sex Disparities in Diabetes Process of Care Measures and Self-Care in High-Risk Patients. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-8.	2.3	44
826	The Evolving Treatment Options for Diabetic Macular Edema. <i>International Journal of Inflammation</i> , 2013, 2013, 1-10.	1.5	13
827	Evidence underlying the clinical management of diabetic macular oedema. <i>Clinical Medicine</i> , 2013, 13, 353-357.	1.9	3
828	Management of Cardiovascular Disease Risk Factors in Older Adults with Type 2 Diabetes Mellitus: 2002-2012 Literature Review. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 2027-2037.	2.6	56
829	Feasibility and Effectiveness in Clinical Practice of a Multifactorial Intervention for the Reduction of Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2566-2572.	8.6	20
830	Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. <i>Cmaj</i> , 2013, 185, 949-957.	2.0	232
831	Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3388-3395.	8.6	46
832	Benefits of Early Hypertension Control on Cardiovascular Outcomes in Patients With Diabetes. <i>Diabetes Care</i> , 2013, 36, 322-327.	8.6	20
833	A social network analysis on clinical education of diabetic foot. <i>Journal of Diabetes and Metabolic Disorders</i> , 2013, 12, 44.	1.9	4
834	Association of chronic kidney disease (CKD) and failure to monitor renal function with adverse outcomes in people with diabetes: a primary care cohort study. <i>BMC Nephrology</i> , 2013, 14, 198.	1.8	17
835	Comparison of Choroidal Thickness in Patients with Diabetes by Spectral-domain Optical Coherence Tomography. <i>Korean Journal of Ophthalmology: KJO</i> , 2013, 27, 433.	1.1	65
836	Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 31.	2.4	31
837	Glucose-6-Phosphate Dehydrogenase Deficiency and Diabetes Mellitus with Severe Retinal Complications in a Sardinian Population, Italy. <i>International Journal of Medical Sciences</i> , 2013, 10, 1907-1913.	2.5	24
838	Diabetic retinopathy is associated with oxidative stress and mitigation of gene expression of antioxidant enzymes. <i>International Journal of General Medicine</i> , 2013, 6, 799.	1.8	25
839	Refocusing Peroxisome Proliferator Activated Receptor- α : A New Insight for Therapeutic Roles in Diabetes. <i>Diabetes and Metabolism Journal</i> , 2013, 37, 326.	4.7	34

#	ARTICLE	IF	CITATIONS
840	Changes in quality of care and costs induced by implementation of a diabetes program in a social security entity of Argentina. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 337.	1.9	2
841	Four-Year Incidence of Diabetic Retinopathy in a Spanish Cohort: The MADIABETES Study. <i>PLoS ONE</i> , 2013, 8, e76417.	2.5	52
842	The Potential Association between Obstructive Sleep Apnea and Diabetic Retinopathy in Severe Obesityâ€”The Role of Hypoxemia. <i>PLoS ONE</i> , 2013, 8, e79521.	2.5	52
843	The Impact of a Diabetes Local Enhanced Service on Quality Outcome Framework Diabetes Outcomes. <i>PLoS ONE</i> , 2013, 8, e83738.	2.5	8
844	Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 327.	2.4	255
845	Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema. <i>Drug Design, Development and Therapy</i> , 2013, 7, 425.	4.3	7
846	The Genetics of Diabetic Nephropathy. <i>Genes</i> , 2013, 4, 596-619.	2.4	36
847	Genetics in Diabetic Retinopathy: Current Concepts and New Insights. <i>Current Genomics</i> , 2013, 14, 289-299.	1.6	62
848	Proteinuria and its relation to cardiovascular disease. <i>International Journal of Nephrology and Renovascular Disease</i> , 2013, 7, 13.	1.8	67
849	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 169.	2.4	135
850	Trends in Hypertension Prevalence, Awareness, Treatment and Control in an Adult Type 2 Diabetes Spanish Population between 2003 and 2009. <i>PLoS ONE</i> , 2014, 9, e86713.	2.5	27
851	Cardiometabolic Risk Profiles Associated with Chronic Complications in Overweight and Obese Type 2 Diabetes Patients in South China. <i>PLoS ONE</i> , 2014, 9, e101289.	2.5	13
852	All-Cause Mortality in Patients with Type 2 Diabetes in Association with Achieved Hemoglobin A1c, Systolic Blood Pressure, and Low-Density Lipoprotein Cholesterol Levels. <i>PLoS ONE</i> , 2014, 9, e109501.	2.5	18
853	Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. <i>British Journal of General Practice</i> , 2014, 64, e208-e216.	1.4	11
854	Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes. <i>Patient Preference and Adherence</i> , 2014, 8, 1185.	1.8	38
855	Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis. <i>Vascular Health and Risk Management</i> , 2014, 10, 651.	2.3	6
856	The Burden of Diabetes in Argentina. <i>Global Journal of Health Science</i> , 2014, 7, 124-33.	0.2	7
857	Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?. <i>World Journal of Diabetes</i> , 2014, 5, 444.	3.5	588

#	ARTICLE	IF	CITATIONS
858	State of the art paper Heart failure in the diabetic population – pathophysiology, diagnosis and management. Archives of Medical Science, 2014, 3, 546-556.	0.9	74
859	Design, implementation, and evaluation of a pediatric and adolescent type 2 diabetes management program at a tertiary pediatric center. Journal of Multidisciplinary Healthcare, 2014, 7, 321.	2.7	7
860	Risk of death and the economic accessibility at the dialysis therapy for the renal insufficient patients in Lubumbashi city, Democratic Republic of Congo. Pan African Medical Journal, 2014, 19, 61.	0.8	12
861	Clinical features of diabetic patients referred by general physicians due to less ophthalmic examinations. Clinical Ophthalmology, 2014, 8, 1331.	1.8	0
862	Rationale and design of the Miami Healthy Heart Initiative: a randomized controlled study of a community health worker intervention among Latino patients with poorly controlled diabetes. International Journal of General Medicine, 2014, 7, 115.	1.8	21
863	Glycated hemoglobin HbA 1c – a new risk marker for the outcome of cardiac surgery?. Kardiochirurgia I Torakochirurgia Polska, 2014, 1, 7-11.	0.1	3
864	Stage A: Can Heart Failure Be Prevented?. Current Cardiology Reviews, 2014, 11, 4-9.	1.5	4
865	Factors Influencing the Decline in Stroke Mortality. Stroke, 2014, 45, 315-353.	2.0	655
866	Endothelial Progenitor Cells in Diabetic Retinopathy. Frontiers in Endocrinology, 2014, 5, 44.	3.5	67
867	Mesenchymal Stem Cell-Based Treatment for Microvascular and Secondary Complications of Diabetes Mellitus. Frontiers in Endocrinology, 2014, 5, 86.	3.5	72
868	Effect of Aerobic Training on Glucose Control and Blood Pressure in T2DDM East African Males. Isrn Endocrinology, 2014, 2014, 1-6.	2.0	17
869	Low utilisation of diabetes medicines in Iran, despite their affordability (2000–2012): a time-series and benchmarking study. BMJ Open, 2014, 4, e005859.	1.9	30
870	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. Journal of the American Heart Association, 2014, 3, e001098.	3.7	24
871	Challenges in Elucidating the Genetics of Diabetic Retinopathy. JAMA Ophthalmology, 2014, 132, 96.	2.5	85
872	Trends of hypertension prevalence, awareness, treatment and control in rural areas of northern China during 1991–2011. Journal of Human Hypertension, 2014, 28, 25-31.	2.2	75
873	Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. The Cochrane Library, 2014, , CD008721.	2.8	43
874	Cardiovascular Autonomic Neuropathy Is Associated With Macrovascular Risk Factors in Type 2 Diabetes. Journal of Diabetes Science and Technology, 2014, 8, 874-880.	2.2	19
875	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Clinical Hypertension, 2014, 16, 14-26.	2.0	768

#	ARTICLE	IF	CITATIONS
876	Bariatric Surgery and Microvascular Complications of Type 2 Diabetes Mellitus. <i>Current Atherosclerosis Reports</i> , 2014, 16, 453.	4.8	27
877	Sex-based disparities in cardioprotective medication use in adults with diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 117.	2.7	12
878	Decreased diabetes-induced glycemic impairment in WKY and SHR involves enhanced skeletal muscle Slc2a4/GLUT4 expression. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 97.	2.7	11
879	Renal effects of dapagliflozin in patients with type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2014, 5, 53-61.	3.2	55
880	The Synergistic Effects of HIV, Diabetes, and Aging on Cognition. <i>Journal of Neuroscience Nursing</i> , 2014, 46, 292-305.	1.1	28
881	Characteristics of diabetic patients associated with achieving and maintaining blood pressure targets in the Adherence and Intensification of Medications program. <i>Chronic Illness</i> , 2014, 10, 60-73.	1.5	4
882	Revolution to a New Standard Treatment of Diabetic Macular Edema. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2269.	7.4	40
883	Listening to Older Adults' Values and Preferences for Type 2 Diabetes Care: A Qualitative Study. <i>Diabetes Spectrum</i> , 2014, 27, 44-49.	1.0	26
884	Rates of Complications and Mortality in Older Patients With Diabetes Mellitus. <i>JAMA Internal Medicine</i> , 2014, 174, 251.	5.1	397
885	Systolic Blood Pressure Levels Among Adults With Hypertension and Incident Cardiovascular Events. <i>JAMA Internal Medicine</i> , 2014, 174, 1252.	5.1	50
886	Clinical therapeutic strategies for early stage of diabetic kidney disease. <i>World Journal of Diabetes</i> , 2014, 5, 342.	3.5	42
887	Activation of adenosine receptors improves renal antioxidant status in diabetic Wistar but not SHR rats. <i>Uppsala Journal of Medical Sciences</i> , 2014, 119, 10-18.	0.9	16
888	Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study. <i>BMC Family Practice</i> , 2014, 15, 8.	2.9	35
889	High prevalence in Malawi of sight-threatening retinopathy and visual impairment caused by diabetes: identification of population-specific targets for intervention. <i>Diabetic Medicine</i> , 2014, 31, 1643-1650.	2.3	26
890	Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 399-405.	2.3	75
892	The changing role of the endocrinologist in the care of patients with diabetic retinopathy. <i>Endocrine</i> , 2014, 46, 199-208.	2.3	9
893	Anti-hyperglycemic activity of <i>Centella asiatica</i> is partly mediated by carbohydrase inhibition and glucose-fiber binding. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 31.	3.7	50
894	The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?. <i>Nature Reviews Nephrology</i> , 2014, 10, 88-103.	9.6	155

#	ARTICLE	IF	CITATIONS
895	Comparison of four cardiovascular risk prediction functions among Chinese patients with diabetes mellitus in the primary care setting. <i>Journal of Diabetes Investigation</i> , 2014, 5, 606-614.	2.4	12
896	Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. <i>Diabetes Care</i> , 2014, 37, 1721-1728.	8.6	217
897	Cardiovascular Complications of Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 273-280.	1.4	181
898	The pathobiology of diabetic vascular complications—cardiovascular and kidney disease. <i>Journal of Molecular Medicine</i> , 2014, 92, 441-452.	3.9	58
899	Efficacy of Single-Pill Perindopril/Indapamide in Patients with Hypertension and Type 2 Diabetes. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 63-69.	2.2	5
900	Guidelines for the Primary Prevention of Stroke. <i>Stroke</i> , 2014, 45, 3754-3832.	2.0	1,621
901	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. <i>Current Atherosclerosis Reports</i> , 2014, 16, 457.	4.8	30
902	Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2014, 5, 313-319.	2.4	84
903	Multifocal Electroretinography in Diabetic Retinopathy and Diabetic Macular Edema. <i>Current Diabetes Reports</i> , 2014, 14, 526.	4.2	29
904	Blood Pressure and Pulse Pressure Effects on Renal Outcomes in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetes Care</i> , 2014, 37, 2782-2788.	8.6	23
905	Progress in reducing vascular complications of diabetes. <i>Nature Reviews Endocrinology</i> , 2014, 10, 451-453.	9.6	5
906	Updated National and International Hypertension Guidelines: A Review of Current Recommendations. <i>Drugs</i> , 2014, 74, 2033-2051.	10.9	95
907	Evaluating the effectiveness of opportunistic eye screening model for people with Diabetes attending Diabetes clinic at Mnazi Mmoja hospital, Zanzibar. <i>BMC Ophthalmology</i> , 2014, 14, 81.	1.4	5
908	Prevalence of retinopathy among adults with self-reported diabetes mellitus: the Sri Lanka diabetes and Cardiovascular Study. <i>BMC Ophthalmology</i> , 2014, 14, 100.	1.4	28
909	Coincidence of diabetes mellitus and hypertension in a semi-urban Cameroonian population: a cross-sectional study. <i>BMC Public Health</i> , 2014, 14, 696.	2.9	23
910	Effects of glucose and blood pressure control on diabetic kidney disease in old patients with type 2 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 81.	2.7	5
911	The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 31.	2.7	28
912	Association of classical risk factors and coronary artery disease in type 2 diabetic patients submitted to coronary angiography. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 46.	2.7	21

#	ARTICLE	IF	CITATIONS
913	The association of body mass index with the risk of type 2 diabetes: a caseâ€“control study nested in an electronic health records system in the United States. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 50.	2.7	151
914	Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial. <i>Diabetes Therapy</i> , 2014, 5, 267-283.	2.5	67
915	Clinical Implications of the 2013 ESH/ESC Hypertension Guidelines: Targets, Choice of Therapy, and Blood Pressure Monitoring. <i>Drugs in R and D</i> , 2014, 14, 31-43.	2.2	14
916	DialBetics. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 209-215.	2.2	175
917	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.7	106
918	Association between Physical Activity Advice Only or Structured Exercise Training with Blood Pressure Levels in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Sports Medicine</i> , 2014, 44, 1557-1572.	6.5	49
919	Type 2 Diabetes Mellitus and Hypertension. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 103-122.	3.2	231
920	Diabetic kidney disease: from physiology to therapeutics. <i>Journal of Physiology</i> , 2014, 592, 3997-4012.	2.9	142
921	Combined effects of type 2 diabetes and hypertension associated with cortical thinning and impaired cerebrovascular reactivity relative to hypertension alone in older adults. <i>NeuroImage: Clinical</i> , 2014, 5, 36-41.	2.7	69
922	Diabetes and age-related demographic differences in risk factor control. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 394-404.	2.3	11
923	Biomarkers in diabetic nephropathy: Present and future. <i>World Journal of Diabetes</i> , 2014, 5, 763.	3.5	116
924	The Kidney Awareness Registry and Education (KARE) study: protocol of a randomized controlled trial to enhance provider and patient engagement with chronic kidney disease. <i>BMC Nephrology</i> , 2015, 16, 166.	1.8	30
925	Effects of the <scp>DASH</scp> Diet and Walking on Blood Pressure in Patients With Type 2 Diabetes and Uncontrolled Hypertension: A Randomized Controlled Trial. <i>Journal of Clinical Hypertension</i> , 2015, 17, 895-901.	2.0	76
926	Diabetic kidney disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15018.	30.5	542
927	Head-to-head comparison of intensive lifestyle intervention (U-TURN) versus conventional multifactorial care in patients with type 2 diabetes: protocol and rationale for an assessor-blinded, parallel group and randomised trial. <i>BMJ Open</i> , 2015, 5, e009764.	1.9	23
928	Trends in the treatment of risk factors for stroke in a Czech stroke unit. <i>Open Medicine (Poland)</i> , 2015, 10, 364-369.	1.3	0
929	Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial. <i>BMJ Open</i> , 2015, 5, e009116-e009116.	1.9	36
930	Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 15, 28.	1.9	2

#	ARTICLE	IF	CITATIONS
931	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. <i>Cardiovascular Diabetology</i> , 2015, 14, 116.	6.8	39
932	Comparison of the Adherence to the American Diabetes Association Guidelines of Diabetes Care in Primary Care and Subspecialty Clinics. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 14, 35.	1.9	9
933	Long-term effects of the multidisciplinary risk assessment and management program for patients with diabetes mellitus (RAMP-DM): a population-based cohort study. <i>Cardiovascular Diabetology</i> , 2015, 14, 105.	6.8	38
934	Assessment of dipyridamole stress echocardiography for risk stratification of diabetic patients. <i>Cardiovascular Ultrasound</i> , 2015, 13, 35.	1.6	4
935	Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. <i>Eye and Vision (London, England)</i> , 2015, 2, 17.	3.0	1,032
936	Association of inpatient and outpatient glucose management with inpatient mortality among patients with and without diabetes at a major academic medical center. <i>Journal of Hospital Medicine</i> , 2015, 10, 228-235.	1.4	3
937	Prevalence, incidence and concomitant co-morbidities of type 2 diabetes mellitus in South Western Germany - a retrospective cohort and case control study in claims data of a large statutory health insurance. <i>BMC Public Health</i> , 2015, 15, 855.	2.9	55
938	Feasibility and impact of implementing a private care system's diabetes quality improvement intervention in the safety net: a cluster-randomized trial. <i>Implementation Science</i> , 2015, 10, 83.	6.9	17
939	Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 95.	2.7	16
940	The Association between Hypertension Comorbidity and Microvascular Complications in Type 2 Diabetes Patients: A Nationwide Cross-Sectional Study in Thailand. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 395.	4.7	33
941	Do Perceptions of Empowerment Affect Glycemic Control and Self-Care Among Adults with Type 2 Diabetes?. <i>Global Journal of Health Science</i> , 2015, 7, 80-90.	0.2	19
942	Biomarkers in Diabetic Retinopathy. <i>Review of Diabetic Studies</i> , 2015, 12, 159-195.	1.3	198
943	2014 Hypertension Guideline: Recommendation for a Change in Goal Systolic Blood Pressure. , 2015, 19, 64-8.		3
944	New Therapeutic Approaches in Diabetic Retinopathy. <i>Review of Diabetic Studies</i> , 2015, 12, 196-210.	1.3	28
945	Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review. <i>Current Medicinal Chemistry</i> , 2015, 22, 2580-2589.	2.4	23
946	Incidence Density and Risk Factors of Diabetic Retinopathy Within Type 2 Diabetes: A Five-Year Cohort Study in China (Report 1). <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 7899-7909.	2.6	45
947	Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. <i>Vascular Health and Risk Management</i> , 2015, 11, 71.	2.3	5
948	Ocular complications of diabetes mellitus. <i>World Journal of Diabetes</i> , 2015, 6, 92.	3.5	225

#	ARTICLE	IF	CITATIONS
949	Five-Year Incidence of Chronic Kidney Disease (Stage 3-5) and Associated Risk Factors in a Spanish Cohort: The MADIABETES Study. PLoS ONE, 2015, 10, e0122030.	2.5	24
950	Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study. PLoS ONE, 2015, 10, e0127188.	2.5	46
951	Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010. PLoS ONE, 2015, 10, e0132228.	2.5	23
952	The Role of Patients' Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes. PLoS ONE, 2015, 10, e0139755.	2.5	11
953	Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell Contractility. PLoS ONE, 2015, 10, e0145109.	2.5	26
954	Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World Journal of Diabetes, 2015, 6, 1246.	3.5	718
955	PPAR- α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. PPAR Research, 2015, 2015, 1-8.	2.4	17
956	Yang Deficiency Body Constitution Acts as a Predictor of Diabetic Retinopathy in Patients with Type 2 Diabetes: Taichung Diabetic Body Constitution Study. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-8.	1.2	13
957	Protective Effects of Scutellarin on Type II Diabetes Mellitus-Induced Testicular Damages Related to Reactive Oxygen Species/Bcl-2/Bax and Reactive Oxygen Species/Microcirculation/Staving Pathway in Diabetic Rat. Journal of Diabetes Research, 2015, 2015, 1-11.	2.3	52
958	Assessment of Glomerular Filtration Rate Based on Alterations of Serum Brain-Derived Neurotrophic Factor in Type 2 Diabetic Subjects Treated with Amlodipine/Benazepril or Valsartan/Hydrochlorothiazide. Disease Markers, 2015, 2015, 1-8.	1.3	1
959	Adherence to the American Diabetes Association standards of care among patients with type 2 diabetes in primary care in Saudi Arabia. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 221-227.	1.1	18
960	Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Review of Diabetic Studies, 2015, 12, 48-62.	1.3	150
961	Benefit of Blood Pressure Control in Diabetic Patients. Current Hypertension Reports, 2015, 17, 50.	3.5	4
962	Limited evidence to assess the impact of primary health care system or service level attributes on health outcomes of Indigenous people with type 2 diabetes: a systematic review. BMC Health Services Research, 2015, 15, 154.	2.2	16
963	Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus. Current Diabetes Reports, 2015, 15, 44.	4.2	14
964	INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA. Retina, 2015, 35, 2440-2449.	1.7	80
965	Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain). British Journal of Ophthalmology, 2015, 99, 1628-1633.	3.9	40
966	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovascular Diabetology, 2015, 14, 133.	6.8	101

#	ARTICLE	IF	CITATIONS
967	Supervised pharmacy student-led medication review in primary care for patients with type 2 diabetes: a randomised controlled pilot study. <i>BMJ Open</i> , 2015, 5, e009246.	1.9	16
968	Blood pressure control for diabetic retinopathy. <i>The Cochrane Library</i> , 2015, 1, CD006127.	2.8	91
969	Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials. <i>Journal of Human Hypertension</i> , 2015, 29, 473-477.	2.2	6
970	The prognosis of diabetic retinopathy in patients with type 2 diabetes since 1996â€“1998: the Skaraborg Diabetes Register. <i>International Ophthalmology</i> , 2015, 35, 503-511.	1.4	8
971	Prevalence of and Racial Disparities in Risk Factor Control in Older Adults With Diabetes: The Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2015, 38, 1290-1298.	8.6	30
972	Food protein-derived bioactive peptides in management of type 2 diabetes. <i>European Journal of Nutrition</i> , 2015, 54, 863-880.	3.9	149
973	Novel pharmacotherapies in diabetic retinopathy. <i>Middle East African Journal of Ophthalmology</i> , 2015, 22, 164.	0.3	18
974	Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. <i>Medical Principles and Practice</i> , 2015, 24, 401-415.	2.4	1,060
975	The Health System and Population Health Implications of Large-Scale Diabetes Screening in India: A Microsimulation Model of Alternative Approaches. <i>PLoS Medicine</i> , 2015, 12, e1001827.	8.4	25
976	Update on Blood Pressure Goals in Diabetes Mellitus. <i>Current Cardiology Reports</i> , 2015, 17, 37.	2.9	6
977	Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register. <i>Diabetologia</i> , 2015, 58, 1203-1211.	6.3	18
978	Diabetes: Christian Worldview, Medical Distrust and Self-Management. <i>Journal of Religion and Health</i> , 2015, 54, 1157-1172.	1.7	6
979	Implementing Quality Measures for Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2015, 17, 14.	2.5	21
980	An informed shared decision making programme on the prevention of myocardial infarction for patients with type 2 diabetes in primary care: protocol of a cluster randomised, controlled trial. <i>BMC Family Practice</i> , 2015, 16, 43.	2.9	8
981	Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2015, 14, 14.	6.8	23
983	Standardized nursing care plans in patients with type 2 diabetes mellitus: Are they effective in the long-term?. <i>Atencion Primaria</i> , 2015, 47, 186-189.	1.4	2
984	Economics of Team-based Care in Controlling Blood Pressure. <i>American Journal of Preventive Medicine</i> , 2015, 49, 772-783.	3.0	34
985	Hypoxia and Dark Adaptation in Diabetic Retinopathy: Interactions, Consequences, and Therapy. <i>Current Diabetes Reports</i> , 2015, 15, 118.	4.2	39

#	ARTICLE	IF	CITATIONS
986	Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus. <i>JAMA Internal Medicine</i> , 2015, 175, 1942.	5.1	137
987	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence. <i>Circulation</i> , 2015, 132, 691-718.	1.6	303
988	Cardiovascular disease and type 1 diabetes: prevalence, prediction and management in an ageing population. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 347-374.	2.5	41
989	Hypertension Management in Diabetic Kidney Disease. <i>Diabetes Spectrum</i> , 2015, 28, 175-180.	1.0	26
990	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , 2015, 38, 1777-1803.	8.6	346
991	Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. <i>Advances in Therapy</i> , 2015, 32, 768-782.	2.9	43
993	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). <i>BMJ, The</i> , 2015, 351, h5364.	6.0	53
994	Hypertension and Diabetic Kidney Disease in Children and Adolescents. <i>Diabetes Spectrum</i> , 2015, 28, 220-224.	1.0	5
995	Sex-Specific Differential in Risk of Diabetes-Related Macrovascular Outcomes. <i>Current Diabetes Reports</i> , 2015, 15, 85.	4.2	12
996	Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. <i>Advances in Therapy</i> , 2015, 32, 1085-1103.	2.9	21
997	Selecting an A1C Point-of-Care Instrument. <i>Diabetes Spectrum</i> , 2015, 28, 201-208.	1.0	42
998	An estimation of the prevalence of diabetes mellitus and diabetic retinopathy in adults in Timor-Leste. <i>BMC Research Notes</i> , 2015, 8, 249.	1.4	10
999	The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 108-114.	2.3	26
1000	Clinical Course and Risk Factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Korea. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 482.	4.7	40
1001	Intravitreal bevacizumab injections for diabetic macular edema – predictors of response: a retrospective study. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 2093-2098.	1.8	9
1002	Stroke in patients with diabetes mellitus: a study from North Western Nigeria. <i>African Health Sciences</i> , 2016, 16, 781.	0.7	13
1003	The relationship of management modality in Saudi patients with type 2 diabetes to components of metabolic syndrome, I ³ glutamyl transferase and highly sensitive C-reactive protein. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 246-254.	2.5	5
1004	Risk Factors for Macro- and Microvascular Complications among Older Adults with Diagnosed Type 2 Diabetes: Findings from The Irish Longitudinal Study on Ageing. <i>Journal of Diabetes Research</i> , 2016, 1-9.	2.3	15

#	ARTICLE	IF	CITATIONS
1005	Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-13.	2.3	66
1006	Patients With Type 2 Diabetes: Anesthetic Management in the Ambulatory Setting. Part 1: Pathophysiology and Associated Disease States. <i>Anesthesia Progress</i> , 2016, 63, 208-215.	0.5	6
1007	Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 393-405.	2.3	51
1008	Is myopia a protective factor against central serous chorioretinopathy?. <i>International Journal of Ophthalmology</i> , 2016, 9, 266-70.	1.1	25
1009	Timeline of History of Hypertension Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2016, 3, 3.	2.4	65
1010	Clinical biomarkers and molecular basis for optimized treatment of diabetic retinopathy: current status and future prospects. <i>Eye and Brain</i> , 2016, 8, 1.	2.5	14
1011	Diabetes Mellitus, ArterialWall, and Cardiovascular Risk Assessment. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 201.	2.6	57
1012	Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1498.	4.1	82
1013	Uncontrolled Hypertension and Its Determinants in Patients with Concomitant Type 2 Diabetes Mellitus (T2DM) in Rural South Africa. <i>PLoS ONE</i> , 2016, 11, e0150033.	2.5	67
1014	Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients. <i>Chinese Medical Journal</i> , 2016, 129, 1224-1228.	2.3	10
1015	Future opportunities in diabetic retinopathy research. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 91-96.	2.3	11
1016	Limited sampling strategy for determining metformin area under the plasma concentration"time curve. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1002-1010.	2.4	9
1017	Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. <i>Journal of Hypertension</i> , 2016, 34, 788-797.	0.5	26
1018	Diabetes and Hypertension: A Comparative Review of Current Guidelines. <i>Journal of Clinical Hypertension</i> , 2016, 18, 95-100.	2.0	94
1019	Synergistic association of combined glycemic and blood pressure level with risk of complications in US veterans with diabetes. <i>Journal of Hypertension</i> , 2016, 34, 907-913.	0.5	18
1020	Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals. <i>The Cochrane Library</i> , 2016, 2016, CD011745.	2.8	15
1021	Several Aspects of Internet and Web-Based Technology in Diabetes Management. <i>Diabetes Spectrum</i> , 2016, 29, 245-248.	1.0	3
1022	The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2016, 15, 101.	6.8	17

#	ARTICLE	IF	CITATIONS
1024	Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals. <i>Annals of Internal Medicine</i> , 2016, 165, 399.	3.9	87
1025	Management Protocols of stable coronary artery disease in India: Executive summary. <i>Indian Heart Journal</i> , 2016, 68, 868-873.	0.5	6
1026	Management standards for stable coronary artery disease in India. <i>Indian Heart Journal</i> , 2016, 68, S31-S49.	0.5	11
1027	Retrospective data suggests that the higher prevalence of benign paroxysmal positional vertigo in individuals with type 2 diabetes is mediated by hypertension. <i>Journal of Vestibular Research: Equilibrium and Orientation</i> , 2016, 25, 233-239.	2.0	41
1028	Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications. <i>Diabetes Spectrum</i> , 2016, 29, 44-49.	1.0	4
1029	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2016, 37, 2315-2381.	2.2	5,370
1030	Influence of Race, Ethnicity and Social Determinants of Health on Diabetes Outcomes. <i>American Journal of the Medical Sciences</i> , 2016, 351, 366-373.	1.1	304
1031	When should we treat hypertension in patients with diabetes?. <i>Nature Reviews Cardiology</i> , 2016, 13, 252-253.	13.7	0
1032	Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. <i>American Journal of the Medical Sciences</i> , 2016, 351, 380-386.	1.1	371
1034	LEADER-4. <i>Journal of Hypertension</i> , 2016, 34, 1140-1150.	0.5	13
1035	Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 922-932.	11.4	26
1036	Development and validation of a Diabetes Risk Score for screening undiagnosed diabetes in Sri Lanka (SLDRISK). <i>BMC Endocrine Disorders</i> , 2016, 16, 42.	2.2	12
1037	Effective Utilization of Oral Hypoglycemic Agents to Achieve Individualized HbA1c Targets in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2016, 7, 387-399.	2.5	6
1038	Standards of care for type 2 diabetes in China. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 442-458.	4.0	236
1039	Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1045-1053.	2.0	2
1040	Diabetic retinopathy in Tanzania: prevalence and risk factors at entry into a regional screening programme. <i>Tropical Medicine and International Health</i> , 2016, 21, 417-426.	2.3	30
1041	Fenofibrate and Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2016, 16, 90.	4.2	31
1042	Trends in Prevalence of Chronic Kidney Disease in the United States. <i>Annals of Internal Medicine</i> , 2016, 165, 473.	3.9	432

#	ARTICLE	IF	CITATIONS
1043	Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 2218-2224.	8.6	25
1044	Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 2004-2010.	8.6	15
1045	Osmotic expression of aldose reductase in retinal pigment epithelial cells: involvement of NFAT5. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 2387-2400.	1.9	10
1046	First Prospective Cohort Study of Diabetic Retinopathy from Sub-Saharan Africa. <i>Ophthalmology</i> , 2016, 123, 1919-1925.	5.2	11
1047	Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. <i>Diabetes Therapy</i> , 2016, 7, 621-639.	2.5	21
1048	Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes. <i>Current Cardiology Reports</i> , 2016, 18, 114.	2.9	3
1049	How information about the time requirements and legacy effects of treatments influence decision-making in patients with diabetes and hypertension. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000210.	2.8	3
1050	Correlation of global risk assessment with cardiovascular complications in patients with diabetes mellitus living in Puerto Rico. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000279.	2.8	3
1051	Sex and age differences in the achievement of control targets in patients with type 2 diabetes: results from a population-based study in a South European region. <i>BMC Family Practice</i> , 2016, 17, 144.	2.9	14
1052	Prevalence of undiagnosed diabetic retinopathy among inpatients with diabetes: the diabetic retinopathy inpatient study (DRIPS). <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000164.	2.8	21
1053	Identifying the optimal blood pressure target for ideal health. <i>Journal of Translational Internal Medicine</i> , 2016, 4, 1-6.	2.5	7
1054	Economic aspects in the management of diabetes in Italy. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000197.	2.8	22
1055	Relation between primary care physician supply and diabetes care and outcomes: a cross-sectional study. <i>CMAJ Open</i> , 2016, 4, E80-E87.	2.4	13
1056	Acute effect of fast walking on postprandial blood glucose control in type 2 diabetes. <i>Diabetology International</i> , 2016, 7, 119-123.	1.4	4
1057	Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population. <i>BMC Research Notes</i> , 2016, 9, 187.	1.4	15
1058	International Models of Care that Address the Growing Diabetes Prevalence in Developing Countries. <i>Current Diabetes Reports</i> , 2016, 16, 69.	4.2	7
1059	What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. <i>European Journal of Health Economics</i> , 2016, 17, 1125-1140.	2.8	29
1060	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. <i>Endocrine</i> , 2016, 54, 32-37.	2.3	1

#	ARTICLE	IF	CITATIONS
1061	Exploring interprofessional collaboration during the integration of diabetes teams into primary care. BMC Family Practice, 2016, 17, 12.	2.9	60
1062	Risk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional study. BMC Health Services Research, 2016, 16, 124.	2.2	14
1063	Shared care management of patients with type 2 diabetes across the primary and secondary healthcare sectors: study protocol for a randomised controlled trial. Trials, 2016, 17, 277.	1.6	7
1064	Simulation of a computed HbA1c using a weighted average glucose. SpringerPlus, 2016, 5, 226.	1.2	5
1065	Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care, 2016, 39, 1089-1100.	8.6	119
1066	Compression of disability between two birth cohorts of US adults with diabetes, 1992-2012: a prospective longitudinal analysis. Lancet Diabetes and Endocrinology, 2016, 4, 686-694.	11.4	15
1067	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. Circulation, 2016, 133, 2459-2502.	1.6	766
1068	Renal denervation with standard radiofrequency ablation catheter is effective in 24-hour ambulatory blood pressure reduction - follow-up at 1/3/6/12 months. Netherlands Heart Journal, 2016, 24, 449-455.	0.8	4
1069	Blood pressure and all-cause mortality among patients with type 2 diabetes. International Journal of Cardiology, 2016, 206, 116-121.	1.7	10
1070	Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure). Nephrology Dialysis Transplantation, 2016, 31, 447-454.	0.7	18
1071	Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, 2016, 352, i717.	6.0	288
1072	The Affordable Care Act and Diabetes Diagnosis and Care: Exploring the Potential Impacts. Current Diabetes Reports, 2016, 16, 27.	4.2	28
1073	Undiagnosed hypertension in a rural district in Bangladesh: The Bangladesh Population-based Diabetes and Eye Study (BPDES). Journal of Human Hypertension, 2016, 30, 252-259.	2.2	31
1074	The impact of gender on the long-term morbidity and mortality of patients with type 2 diabetes receiving structured personal care: a 13-year follow-up study. Diabetologia, 2016, 59, 275-285.	6.3	37
1075	Cardiovascular risk profiles of adults with type-2 diabetes treated at urban hospitals in Riyadh, Saudi Arabia. Journal of Epidemiology and Global Health, 2016, 6, 29.	2.9	10
1076	Toward Big Data Analytics. Journal of Diabetes Science and Technology, 2016, 10, 27-34.	2.2	73
1077	Structural Changes by Spectral Domain Optical Coherence Tomography in Patients With Type 1 Diabetes Mellitus. Journal of Diabetes Science and Technology, 2016, 10, 271-276.	2.2	10
1078	The impact of comorbid chronic conditions on quality of life in type 2 diabetes patients. Quality of Life Research, 2016, 25, 175-182.	3.1	78

#	ARTICLE	IF	CITATIONS
1079	Diabetic nephropathy: What does the future hold?. International Urology and Nephrology, 2016, 48, 99-113.	1.4	33
1080	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Journal of Human Hypertension, 2016, 30, 46-52.	2.2	13
1081	Diabetes 2030: Insights from Yesterday, Today, and Future Trends. Population Health Management, 2017, 20, 6-12.	1.7	445
1082	Blood pressure control in type 2 diabetic patients. Cardiovascular Diabetology, 2017, 16, 3.	6.8	77
1083	Diabetic retinopathy: Knowledge, awareness and practices of physicians in primary-care centers in Riyadh, Saudi Arabia. Saudi Journal of Ophthalmology, 2017, 31, 2-6.	0.3	29
1084	Beta-blockers for hypertension. The Cochrane Library, 2017, 2017, CD002003.	2.8	205
1085	Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nature Reviews Endocrinology, 2017, 13, 365-374.	9.6	29
1086	Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2877.	4.0	2
1087	Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40, 412-418.	8.6	596
1088	Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials. Diabetology International, 2017, 8, 76-86.	1.4	12
1089	Diagnosis and Management of Type 2 Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1366-1373.	4.5	227
1090	Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2017, 8, 416-427.	2.4	59
1091	Population trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK: a cohort study in the Clinical Practice Research Datalink 2004-2014. BMJ Open, 2017, 7, e014444.	1.9	79
1092	Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovascular Endocrinology, 2017, 6, 8-16.	0.8	109
1093	Hypertension in diabetes and the risk of cardiovascular disease. Cardiovascular Endocrinology, 2017, 6, 33-38.	0.8	20
1094	Blood pressure control and cardiovascular risk in hypertensive patients with type 2 diabetes: The German T2Target registry. Journal of Clinical Hypertension, 2017, 19, 757-763.	2.0	8
1095	Blood pressure management in patients with type 2 diabetes mellitus. Hypertension Research, 2017, 40, 721-729.	2.7	7
1096	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation, 2017, 136, 1193-1203.	1.6	47

#	ARTICLE	IF	CITATIONS
1097	Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. <i>Eye</i> , 2017, 31, S1-S20.	2.1	25
1098	Black patients sustain vision loss while White and South Asian patients gain vision following delamination or segmentation surgery for tractional complications associated with proliferative diabetic retinopathy. <i>Eye</i> , 2017, 31, 1468-1474.	2.1	11
1099	Screening for Diabetic Eye Disease among Samoan Adults: A Pilot Study. <i>Ophthalmology and Therapy</i> , 2017, 6, 187-194.	2.3	1
1100	The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease. <i>Nurse Practitioner</i> , 2017, 42, 31-38.	0.3	5
1101	Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. <i>Physiological Reports</i> , 2017, 5, e13228.	1.7	64
1102	Trajectory of systolic blood pressure in a low-income, racial-ethnic minority cohort with diabetes and baseline uncontrolled hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 722-730.	2.0	3
1103	Renin angiotensin aldosterone system altered in resistant hypertension in Sub-Saharan African diabetes patients without evidence of primary hyperaldosteronism. <i>JRSM Cardiovascular Disease</i> , 2017, 6, 204800401769500.	0.7	1
1104	Screening for Diabetic Retinopathy in Youth-Onset Diabetes. <i>Ophthalmology</i> , 2017, 124, 422-423.	5.2	3
1105	Anti-hyperglycaemic activity of <i>Moringa oleifera</i> is partly mediated by carbohydrase inhibition and glucose-fibre binding. <i>Bioscience Reports</i> , 2017, 37, .	2.4	37
1106	The Real Role of Î²-Blockers in Daily Cardiovascular Therapy. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 361-373.	2.2	79
1107	Factors determining uptake of diabetic retinopathy screening in Oxfordshire. <i>Diabetic Medicine</i> , 2017, 34, 993-999.	2.3	31
1108	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 321-419.	1.7	84
1109	Long-term excess risk of stroke in people with Type 2 diabetes in Sweden according to blood pressure level: a population-based case-control study. <i>Diabetic Medicine</i> , 2017, 34, 522-530.	2.3	16
1110	Effect of exercise on the quality of life in type 2 diabetes mellitus: a systematic review. <i>Quality of Life Research</i> , 2017, 26, 515-530.	3.1	55
1111	Structured lifestyle intervention based on a trans-cultural diabetes-specific nutrition algorithm (tDNA) in individuals with type 2 diabetes: a randomized controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000384.	2.8	25
1112	Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). <i>Diabetic Medicine</i> , 2017, 34, 1747-1755.	2.3	32
1113	Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. <i>Medicine (United States)</i> , 2017, 96, e7638.	1.0	28
1114	A Practical Approach to Hypertension Management in Diabetes. <i>Diabetes Therapy</i> , 2017, 8, 981-989.	2.5	17

#	ARTICLE	IF	CITATIONS
1115	Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5. <i>JAMA Internal Medicine</i> , 2017, 177, 1498.	5.1	158
1116	Life Expectancy Predictions for Older Diabetic Patients as Estimated by Physicians and a Prognostic Model. <i>MDM Policy and Practice</i> , 2017, 2, 238146831771371.	0.9	4
1117	Comorbidities, complications and mortality in people of South Asian ethnicity with type 1 diabetes compared with other ethnic groups: a systematic review. <i>BMJ Open</i> , 2017, 7, e015005.	1.9	9
1118	The Elusive Search for Optimal Blood Pressure Targets. <i>Current Hypertension Reports</i> , 2017, 19, 63.	3.5	2
1119	Academic and Government Partnerships to Address Diabetes in the USA: a Narrative Review. <i>Current Diabetes Reports</i> , 2017, 17, 75.	4.2	2
1120	Diabetes Care in Brazil. <i>Journal of Ambulatory Care Management</i> , 2017, 40, S12-S23.	1.1	29
1121	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 70, 883-893.	2.8	125
1122	Pharmacotherapy for hypertension in adults aged 18 to 59 years. <i>The Cochrane Library</i> , 2017, 2017, CD008276.	2.8	32
1123	Type 2 diabetes in general practice in Norway 2005–2014: moderate improvements in risk factor control but still major gaps in complication screening. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000459.	2.8	35
1124	Initial Single-Pill Blood Pressure Lowering Therapy: Should It Be for Most People?. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	3
1125	Amelioration of arterial pressure lability: an unmissable target for diabetes management. <i>Hypertension Research</i> , 2017, 40, 629-631.	2.7	1
1126	Clinical Implications of Different Blood Pressure Measurement Techniques. <i>Current Hypertension Reports</i> , 2017, 19, 54.	3.5	12
1127	Diabetes care in a complex humanitarian emergency setting: a qualitative evaluation. <i>BMC Health Services Research</i> , 2017, 17, 431.	2.2	31
1128	Introduction of the DiaGene study: clinical characteristics, pathophysiology and determinants of vascular complications of type 2 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 47.	2.7	18
1129	Mechanistic Insights into Pathological Changes in the Diabetic Retina. <i>American Journal of Pathology</i> , 2017, 187, 9-19.	3.8	157
1130	Optimizing Medical Management in Patients with Sight-Threatening Diabetic Retinopathy. <i>Ophthalmology and Therapy</i> , 2017, 6, 105-114.	2.3	3
1132	Visit-to-visit systolic blood pressure variability and microvascular complications among patients with diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 195-201.	2.3	24
1133	Adapting clinical guidelines in low-resources countries: a study on the guideline on the management and prevention of type 2 diabetes mellitus in Indonesia. <i>Journal of Evaluation in Clinical Practice</i> , 2017, 23, 121-127.	1.8	12

#	ARTICLE	IF	CITATIONS
1134	Exploring Approaches to Facilitate Diabetes Therapy Intensification in Primary Care. <i>Clinical Diabetes</i> , 2017, 35, 100-105.	2.2	0
1135	Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4343-4410.	3.6	323
1136	Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995-2015. <i>BMJ: British Medical Journal</i> , 2017, 358, j3984.	2.3	57
1137	Patients With Type 2 Diabetes: Anesthetic Management in the Ambulatory Setting: Part 2: Pharmacology and Guidelines for Perioperative Management. <i>Anesthesia Progress</i> , 2017, 64, 39-44.	0.5	10
1138	Combined Interval Training and Post-exercise Nutrition in Type 2 Diabetes: A Randomized Control Trial. <i>Frontiers in Physiology</i> , 2017, 8, 528.	2.8	32
1139	Awareness and Use of mHealth Apps: A Study from England. <i>Pharmacy (Basel, Switzerland)</i> , 2017, 5, 33.	1.6	105
1140	Type 2 diabetes and quality of life. <i>World Journal of Diabetes</i> , 2017, 8, 120.	3.5	374
1141	Cerebral Hemodynamic and White Matter Changes of Type 2 Diabetes Revealed by Multi-TI Arterial Spin Labeling and Double Inversion Recovery Sequence. <i>Frontiers in Neurology</i> , 2017, 8, 717.	2.4	19
1142	Treatment Gaps Found in the Management of Type 2 Diabetes at a Community Health Centre in Johannesburg, South Africa. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-6.	2.3	13
1143	Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. <i>International Journal of Chronic Diseases</i> , 2017, 2017, 1-11.	1.0	1
1144	Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society). <i>Journal of Ophthalmology</i> , 2017, 2017, 1-10.	1.3	54
1145	Applying artificial intelligence to disease staging: Deep learning for improved staging of diabetic retinopathy. <i>PLoS ONE</i> , 2017, 12, e0179790.	2.5	183
1146	Control of hypertension among diabetic patients in a referral hospital in Tanzania: a cross-sectional study. <i>Ethiopian Journal of Health Sciences</i> , 2017, 27, 473.	0.4	15
1147	Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 603-611.	2.0	5
1148	Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 79-87.	2.4	24
1149	Effect of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease: A randomized controlled trial. <i>PLoS ONE</i> , 2017, 12, e0186554.	2.5	8
1150	Sensitivity and specificity of automated analysis of single-field non-mydratric fundus photographs by Bosch DR Algorithmâ€”Comparison with mydratric fundus photography (ETDRS) for screening in undiagnosed diabetic retinopathy. <i>PLoS ONE</i> , 2017, 12, e0189854.	2.5	39
1151	Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988â€”2014. <i>BMC Public Health</i> , 2017, 17, 893.	2.9	20

#	ARTICLE	IF	CITATIONS
1152	A combination of process of care and clinical target among type 2 diabetes mellitus patients in general medical clinics and specialist diabetes clinics at hospital levels. <i>BMC Health Services Research</i> , 2017, 17, 533.	2.2	5
1153	Diabetic retinopathy: research to clinical practice. <i>Clinical Diabetes and Endocrinology</i> , 2017, 3, 9.	2.7	41
1154	Antihypertensive drug prescription patterns and their impact on outcome of blood pressure in Ethiopia: a hospital-based cross-sectional study. <i>Integrated Pharmacy Research & Practice</i> , 2017, Volume 6, 29-35.	1.5	14
1155	Hypertension and blood pressure variability management practices among physicians in Singapore. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 275-285.	2.3	14
1156	Diabetic Retinopathy: Focus on Minority Populations. <i>International Journal of Clinical Endocrinology and Metabolism</i> , 2017, 3, 034-045.	1.2	30
1157	Response: Clinical Course and Risk Factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Korea (Diabetes Metab J2016;40:482-93). <i>Diabetes and Metabolism Journal</i> , 2017, 41, 77.	4.7	0
1158	Frequency of diabetic retinopathy and associated risk factors in Khartoum, Sudan: population based study. <i>International Journal of Ophthalmology</i> , 2017, 10, 948-954.	1.1	24
1159	Pros and Cons of Intensive Systolic Blood Pressure Lowering. <i>Current Hypertension Reports</i> , 2018, 20, 16.	3.5	2
1160	Burden of high blood pressure as a contributing factor to stroke in the Japanese community-based diabetic population. <i>Hypertension Research</i> , 2018, 41, 531-538.	2.7	9
1161	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Journal of Diabetes Investigation</i> , 2018, 9, 657-697.	2.4	158
1162	Awareness of diabetic retinopathy among people with diabetes in Jeddah, Saudi Arabia. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2018, 9, 103-112.	3.2	45
1163	Cost-effectiveness of interventions to control cardiovascular diseases and diabetes mellitus in South Asia: a systematic review. <i>BMJ Open</i> , 2018, 8, e017809.	1.9	16
1164	Obstructive sleep apnoea. <i>Eye</i> , 2018, 32, 889-903.	2.1	37
1165	Functional interplay between liver X receptor and AMP-activated protein kinase \pm inhibits atherosclerosis in apolipoprotein E-deficient mice \sim a new anti-atherogenic strategy. <i>British Journal of Pharmacology</i> , 2018, 175, 1486-1503.	5.4	39
1166	Increased serum periostin concentrations are associated with the presence of diabetic retinopathy in patients with type 2 diabetes mellitus. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 937-945.	3.3	14
1167	The National Diabetes Education Program at 20 Years: Lessons Learned and Plans for the Future. <i>Diabetes Care</i> , 2018, 41, 209-218.	8.6	20
1168	Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. <i>Diabetologia</i> , 2018, 61, 517-525.	6.3	19
1169	Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study. <i>American Journal of Ophthalmology</i> , 2018, 187, 138-147.	3.3	17

#	ARTICLE	IF	CITATIONS
1170	Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease. <i>Pharmacotherapy</i> , 2018, 38, 309-318.	2.6	35
1171	Impact of an integrated care program on glycemic control and cardiovascular risk factors in patients with type 2 diabetes in Saudi Arabia: an interventional parallel-group controlled study. <i>BMC Family Practice</i> , 2018, 19, 1.	2.9	96
1172	The prevalence and systemic risk factors of diabetic macular edema: a cross-sectional study from Turkey. <i>BMC Ophthalmology</i> , 2018, 18, 91.	1.4	35
1173	Peripheral vascular disease risk in diabetic individuals without coronary heart disease. <i>Atherosclerosis</i> , 2018, 275, 419-425.	0.8	25
1174	First-line drugs for hypertension. <i>The Cochrane Library</i> , 2018, 2018, CD001841.	2.8	197
1175	Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 727-734.	4.5	7
1176	BP Measurement in Clinical Practice: Time to SPRINT to Guideline-Recommended Protocols. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 383-388.	6.1	31
1177	Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 629-637.	4.4	5
1178	Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. <i>Canadian Journal of Cardiology</i> , 2018, 34, 575-584.	1.7	945
1179	Management of diabetic macular edema in Japan: a review and expert opinion. <i>Japanese Journal of Ophthalmology</i> , 2018, 62, 1-23.	1.9	44
1180	Influence of comorbidities on the implementation of the fundus examination in patients with newly diagnosed type 2 diabetes. <i>Japanese Journal of Ophthalmology</i> , 2018, 62, 68-76.	1.9	5
1181	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2176-2198.	2.8	138
1182	Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels. <i>JAMA Internal Medicine</i> , 2018, 178, 28.	5.1	329
1183	Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark. <i>BMJ Open</i> , 2018, 8, e019214.	1.9	15
1184	Patient expectations of hypertension and diabetes medication: Excessive focus on short-term benefits. <i>SAGE Open Medicine</i> , 2018, 6, 205031211882111.	1.8	9
1185	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. <i>The Cochrane Library</i> , 2018, 9, CD011798.	2.8	48
1186	Influence of self-efficacy management on adherence to self-care activities and treatment outcome among diabetes mellitus type 2 Sudanese patients. <i>Pharmacy Practice</i> , 2018, 16, 1274.	1.5	33
1187	Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPR40) Agonist, May Induce Hepatotoxicity through Reactive Oxygen Species Generation in a GPR40-Dependent Manner. <i>Biomolecules and Therapeutics</i> , 2018, 26, 599-607.	2.4	19

#	ARTICLE	IF	CITATIONS
1188	The Ongoing Saga of Optimal Blood Pressure Level in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2018, 7, e010752.	3.7	9
1189	Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications. <i>Journal of Clinical Hypertension</i> , 2019, 21, 4-15.	2.0	51
1190	Nurse-Led Diabetes Self-Management Education Improves Clinical Parameters in Ethiopia. <i>Frontiers in Public Health</i> , 2018, 6, 302.	2.7	29
1191	Single herbal medicine for diabetic retinopathy. <i>The Cochrane Library</i> , 2018, 2018, CD007939.	2.8	32
1192	Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. <i>BMJ Open</i> , 2018, 8, e020584.	1.9	28
1193	Optimal medical treatment of hypertension in patients with coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 815-823.	1.5	4
1194	Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. <i>Current Cardiology Reports</i> , 2018, 20, 112.	2.9	6
1195	Antihypertensive treatment and renal protection: Is there a J-curve relationship?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1560-1574.	2.0	17
1196	CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB. <i>Retina</i> , 2018, 38, 1896-1904.	1.7	38
1197	Asymptomatic Carotid Stenosis: Intervention or Best Medical Therapy?. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 80.	4.2	36
1198	Incidence of microvascular complications of type 2 diabetes: A 12 year longitudinal study from Karachi-Pakistan. <i>Pakistan Journal of Medical Sciences</i> , 2018, 34, 1058-1063.	0.6	19
1199	Combined effect of glycemic and blood pressure control on diabetic retinopathy among Chinese with type-2 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 73.	2.7	8
1200	How good are GPs at adhering to a pragmatic trial protocol in primary care? Results from the ADDITION-Cambridge cluster-randomised pragmatic trial. <i>BMJ Open</i> , 2018, 8, e015295.	1.9	3
1201	An Overview of Our Current Understanding of Diabetic Macular Ischemia (DMI). <i>Cureus</i> , 2018, 10, e3064.	0.5	14
1202	Therapeutic Apheresis in Metabolic Syndrome. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2018, 18, 38-54.	0.5	4
1203	Control of blood pressure and cardiovascular outcomes in type 2 diabetes. <i>Open Medicine (Poland)</i> , 2018, 13, 304-323.	1.3	7
1204	Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. <i>BioMed Research International</i> , 2018, 2018, 1-16.	1.9	49
1205	Hypertension Management in Diabetes: 2018 Update. <i>Diabetes Spectrum</i> , 2018, 31, 218-224.	1.0	51

#	ARTICLE	IF	CITATIONS
1207	Increasing SBP variability is associated with an increased risk of developing incident diabetic foot ulcers. <i>Journal of Hypertension</i> , 2018, 36, 2177-2184.	0.5	8
1208	The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2371-2378.	4.4	14
1209	Is there a relationship between body mass index and diabetic retinopathy in type II diabetic patients? A cross sectional study. <i>Journal of Diabetes and Metabolic Disorders</i> , 2018, 17, 63-69.	1.9	15
1210	Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2598-2607.	4.4	48
1211	Prevalence of Chronic Complications, Their Risk Factors, and the Cardiovascular Risk Factors among Patients with Type 2 Diabetes Attending the Diabetic Clinic at a Tertiary Care Hospital in Sri Lanka. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-10.	2.3	32
1212	The Constellation of Macrovascular Risk Factors in Early Onset T2DM: A Cross-Sectional Study in Xinjiang Province, China. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-8.	2.3	4
1213	The optimal blood pressure target in diabetes mellitus: a quest coming to an end?. <i>Journal of Human Hypertension</i> , 2018, 32, 641-650.	2.2	12
1214	The Relationship between Diabetes-Related Complications and Obstructive Sleep Apnea in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-9.	2.3	40
1215	Prehypertension increases the risk of atherosclerosis in drug-naïve Japanese patients with type 2 diabetes mellitus. <i>PLoS ONE</i> , 2018, 13, e0201055.	2.5	5
1216	Primary care provider adherence to an alert for intensification of diabetes blood pressure medications before and after the addition of a "chart closure" hard stop. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 1167-1174.	4.4	19
1217	Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2018, 15, 72.	4.6	216
1218	Association Trends Between Antihypertensive Drug Therapies and Diastolic Hypotension in Emirati Patients with Type 2 Diabetes: A Single-Center Retrospective Longitudinal Study. <i>Diabetes Therapy</i> , 2018, 9, 1853-1868.	2.5	0
1219	Modeling of Diabetes and Its Clinical Impact. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 976-984.	2.2	20
1220	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Diabetology International</i> , 2018, 9, 1-45.	1.4	215
1221	Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. <i>Cardiovascular Diabetology</i> , 2018, 17, 9.	6.8	31
1222	Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. <i>Cardiovascular Diabetology</i> , 2018, 17, 56.	6.8	135
1223	Predicting diabetic retinopathy and identifying interpretable biomedical features using machine learning algorithms. <i>BMC Bioinformatics</i> , 2018, 19, 283.	2.6	69
1224	Risk factors for retinal microvascular impairment in type 2 diabetic patients without diabetic retinopathy. <i>PLoS ONE</i> , 2018, 13, e0202103.	2.5	26

#	ARTICLE	IF	CITATIONS
1225	Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2018, 19, 147032031878932.	1.7	20
1226	Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46). <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000521.	2.8	42
1227	Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi. <i>PLoS ONE</i> , 2018, 13, e0190742.	2.5	13
1228	Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial. <i>Endocrine</i> , 2019, 63, 252-258.	2.3	7
1229	2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations. <i>Clinical Hypertension</i> , 2019, 25, 19.	2.0	31
1230	2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. <i>Clinical Hypertension</i> , 2019, 25, 20.	2.0	193
1231	HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000668.	2.8	2
1232	The Status of Metabolic Control in Patients With Type 2 Diabetes Attending Dasman Diabetes Institute, Kuwait. <i>Frontiers in Endocrinology</i> , 2019, 10, 412.	3.5	8
1233	Current Management of Patients With Acquired Solitary Kidney. <i>Kidney International Reports</i> , 2019, 4, 1205-1218.	0.8	55
1234	Evaluation of Dyslipidaemia Using an Algorithm of Lipid Profile Measures among Newly Diagnosed Type II Diabetes Mellitus Patients: A Cross-Sectional Study at Dormaa Presbyterian Hospital, Ghana. <i>Medicina (Lithuania)</i> , 2019, 55, 392.	2.0	4
1235	Treatment of Diabetic Macular Edema. <i>Current Diabetes Reports</i> , 2019, 19, 68.	4.2	83
1236	Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: a real-world Korean study. <i>PLoS ONE</i> , 2019, 14, e0224549.	2.5	23
1237	Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis. <i>International Journal of Hypertension</i> , 2019, 2019, 1-9.	1.3	8
1238	The effect of guideline revisions on vascular complications of type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881987540.	3.2	4
1239	Interventions to Improve Blood Pressure Control Among Socioeconomically Disadvantaged Patients With CKD: Kidney Awareness Registry and Education Pilot Randomized Controlled Trial. <i>Kidney Medicine</i> , 2019, 1, 242-252.	2.0	10
1240	Risk factors for ischemic stroke in patients with non-valvular atrial fibrillation and therapeutic international normalized ratio range. <i>Archives of Medical Science</i> , 2019, 15, 1217-1222.	0.9	13
1241	Quality of Life and Associated Factors among Primary Care Asian Patients with Type 2 Diabetes Mellitus. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3561.	2.6	22
1242	Aldosterone as a mediator of severity in retinal vascular disease: Evidence and potential mechanisms. <i>Experimental Eye Research</i> , 2019, 188, 107788.	2.6	15

#	ARTICLE	IF	CITATIONS
1243	A deletion in the Ctns gene causes renal tubular dysfunction and cystine accumulation in LEA/Tohm rats. <i>Mammalian Genome</i> , 2019, 30, 23-33.	2.2	12
1244	The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study. <i>Scientific Reports</i> , 2019, 9, 7709.	3.3	19
1245	Individualised screening for diabetic retinopathy: the ISDR studyâ€”rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening. <i>BMJ Open</i> , 2019, 9, e025788.	1.9	18
1246	Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2218-2227.	2.4	7
1247	Enablers and barriers to effective diabetes self-management: A multi-national investigation. <i>PLoS ONE</i> , 2019, 14, e0217771.	2.5	171
1248	The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. <i>Advances in Therapy</i> , 2019, 36, 2034-2051.	2.9	11
1249	Short-term effects of perindoprilâ€”amlodipine vs perindoprilâ€”indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blind randomized controlled trial. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1002-1008.	2.0	5
1250	The profile of sight-threatening diabetic retinopathy in patients attending a specialist eye clinic in Hangzhou, China. <i>BMJ Open Ophthalmology</i> , 2019, 4, e000236.	1.6	16
1251	Pulse Pressure and Diabetic Eye Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e012491.	3.7	1
1252	Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. <i>Diabetes Therapy</i> , 2019, 10, 1297-1317.	2.5	23
1253	Incidence and prognosis of heart failure in persons with type 2 diabetes compared with individuals without diabetes â€” a nation-wide study from Finland in 1996â€”2012. <i>Annals of Medicine</i> , 2019, 51, 174-181.	3.8	5
1254	Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COHoRtE (DIACORE) study. <i>PLoS ONE</i> , 2019, 14, e0213157.	2.5	8
1255	Maximum morning home systolic blood pressure is an indicator of the development of diabetic nephropathy: The KAMOGAWAâ€”HBP study. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1543-1549.	2.4	7
1256	Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 1284-1289.	8.6	42
1257	Epidemiology of Diabetes Mellitus and Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2019, 21, 21.	2.9	363
1258	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. <i>American Journal of Kidney Diseases</i> , 2019, 73, 437-458.	1.9	24
1259	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1520-1574.	3.6	305
1260	Decision Making in Proliferative Diabetic Retinopathy Treatment. <i>Current Ophthalmology Reports</i> , 2019, 7, 45-50.	1.2	3

#	ARTICLE	IF	CITATIONS
1261	The Importance and Role of Multiple Risk Factor Control in Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2019, 21, 35.	2.9	14
1262	Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0215362.	2.5	28
1265	Insights for Care: The Healthcare Utilisation and Cost Impact of Managing Type 2 Diabetes-Associated Microvascular Complications. <i>Diabetes Therapy</i> , 2019, 10, 575-585.	2.5	19
1266	Applications of stem cells and bioprinting for potential treatment of diabetes. <i>World Journal of Stem Cells</i> , 2019, 11, 13-32.	2.8	23
1267	The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. <i>Drugs</i> , 2019, 79, 231-242.	10.9	18
1268	Evaluating All Potential Oral Complications of Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2019, 10, 56.	3.5	155
1269	Association between Continuity of Care and the Onset of Thyroid Disorder among Diabetes Patients in Korea. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 233.	2.6	4
1270	Rapid increase in the incidence of end-stage renal disease in patients with type 1 diabetes having HbA1c 10% or higher for 15 years. <i>Clinical Pediatric Endocrinology</i> , 2019, 28, 113-125.	0.8	2
1271	Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment. <i>BMJ Open</i> , 2019, 9, e028438.	1.9	6
1272	Describing medicine therapy management of type 2 diabetes mellitus at primary health care facilities in Cape Town. <i>Health SA Gesondheid</i> , 2019, 24, 1051.	0.8	5
1273	Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000705.	2.8	26
1274	Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study. <i>BMJ Open</i> , 2019, 9, e026807.	1.9	13
1275	Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease. <i>Cardiovascular Diabetology</i> , 2019, 18, 160.	6.8	14
1276	Emerging Concepts in the Treatment of Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2019, 19, 137.	4.2	23
1277	Epigenetic Modifications in Peripheral Blood as Potential Noninvasive Biomarker of Diabetic Retinopathy. <i>Translational Vision Science and Technology</i> , 2019, 8, 43.	2.2	22
1279	PPARG Polymorphisms Are Associated with Unexplained Mild Vision Loss in Patients with Type 2 Diabetes Mellitus. <i>Journal of Ophthalmology</i> , 2019, 2019, 1-7.	1.3	9
1280	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 454-466.	4.4	129
1281	Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. <i>Diabetes Therapy</i> , 2019, 10, 159-176.	2.5	11

#	ARTICLE	IF	CITATIONS
1282	Impact of Duodeno-Jejunal Bypass Liner (EndoBarrier™) Implantation on Insulin Sensitivity in Patients with Type 2 Diabetes Mellitus (T2DM): A Study Protocol for a Pilot Trial. <i>Diabetes Therapy</i> , 2019, 10, 299-309.	2.5	5
1283	Rapid decline of renal function in patients with type 2 diabetes with heavy proteinuria: a report of three cases. <i>BMC Nephrology</i> , 2019, 20, 22.	1.8	8
1284	Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. <i>BMC Endocrine Disorders</i> , 2019, 19, 4.	2.2	30
1285	Association of High Levels of Spot Urine Protein with High Blood Pressure, Mean Arterial Pressure and Pulse Pressure with the Development of Diabetic Chronic Kidney Dysfunction or Failure among Diabetic Patients. <i>Statistical Regression Modeling to Predict Diabetic Proteinuria. Current Diabetes Reviews</i> , 2019, 15, 486-496.	1.3	6
1286	Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 611-621.	4.4	35
1287	Personalized risk-based screening for diabetic retinopathy: A multivariate approach versus the use of stratification rules. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 560-568.	4.4	16
1288	Are large simple trials for dementia prevention possible?. <i>Age and Ageing</i> , 2020, 49, 154-160.	1.6	17
1289	Trends in Diabetes Management Among US Adults: 1999–2016. <i>Journal of General Internal Medicine</i> , 2020, 35, 1427-1434.	2.6	40
1290	Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 900-905.	1.4	4
1291	Healthful aging mediated by inhibition of oxidative stress. <i>Ageing Research Reviews</i> , 2020, 64, 101194.	10.9	118
1292	Aspirin for primary prevention of ST segment elevation myocardial infarction in persons with diabetes and multiple risk factors. <i>EclinicalMedicine</i> , 2020, 27, 100548.	7.1	6
1293	Chronic Kidney Disease among Diabetes Patients in Ethiopia: A Systematic Review and Meta-Analysis. <i>International Journal of Nephrology</i> , 2020, 2020, 1-15.	1.3	11
1294	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 175.	6.8	1
1295	Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLANCE Study. <i>Diabetes Therapy</i> , 2020, 11, 2887-2908.	2.5	3
1296	Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2020, 6, 13.	1.0	7
1297	The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-6.	2.3	20
1298	Association between interarm blood pressure differences and diabetic retinopathy in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412094591.	2.0	3
1299	Implication of Hyperhomocysteinemia in Blood Retinal Barrier (BRB) Dysfunction. <i>Biomolecules</i> , 2020, 10, 1119.	4.0	40

#	ARTICLE	IF	CITATIONS
1300	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1020-1076.	2.4	159
1301	Retinopathy in adults with hypertension and diabetes mellitus in Western Tanzania: a cross-sectional study. <i>Tropical Medicine and International Health</i> , 2020, 25, 1214-1225.	2.3	6
1302	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Diabetology International</i> , 2020, 11, 165-223.	1.4	266
1303	Reversal of diabetic tractional retinal detachment attributed to keto diet. <i>BMJ Case Reports</i> , 2020, 13, e235873.	0.5	9
1304	Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseoglitazone on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. <i>BMJ Open</i> , 2020, 10, e034883.	1.9	2
1305	<p></p>Prevalence and Determinants of Hypertension Among Diabetic Patients in Jimma University Medical Center, Southwest Ethiopia, 2019</p><p></p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 2317-2325.	2.4	23
1306	Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States. <i>Journal of Clinical Hypertension</i> , 2020, 22, 2084-2092.	2.0	3
1307	Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 522-530.	2.9	6
1308	Blood pressure targets in adults with hypertension. <i>The Cochrane Library</i> , 2020, 2020, CD004349.	2.8	12
1309	Stroke Type, Etiology, Clinical Features and Prognosis of Diabetic Patients in Southern China. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962097309.	1.7	1
1310	Effects of Mesenchymal Stem Cells Therapy on Cardiovascular Risk Factors in Experimental Diabetic Kidney Disease. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812095742.	1.1	2
1311	Impact of glycemic control over cardiac autonomic neuropathy. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1339-1344.	1.9	4
1312	Genetics of diabetes mellitus and diabetes complications. <i>Nature Reviews Nephrology</i> , 2020, 16, 377-390.	9.6	657
1313	Early-onset type 2 diabetes. <i>Medicine (United States)</i> , 2020, 99, e20189.	1.0	7
1314	Impact of age on clinical outcomes of antihypertensive therapy in patients with hypertension and coronary artery disease: A sub-analysis of the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1070-1079.	2.0	5
1315	Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. <i>Eye</i> , 2020, 34, 1-51.	2.1	104
1316	Frequency and Antimicrobial Susceptibility Patterns of Diabetic Foot Infection of Patients from Bandar Abbas District, Southern Iran. <i>Journal of Pathogens</i> , 2020, 2020, 1-10.	1.4	11
1317	Proliferative diabetic retinopathy without preoperative pan-retinal photocoagulation is associated with higher levels of intravitreal IL-6 and postoperative inflammation. <i>International Journal of Retina and Vitreous</i> , 2020, 6, 24.	1.9	10

#	ARTICLE	IF	CITATIONS
1318	Hypertension, blood pressure control and diabetic retinopathy in a large population-based study. PLoS ONE, 2020, 15, e0229665.	2.5	48
1319	Systemic Factors Associated with Treatment Response in Diabetic Macular Edema. Journal of Ophthalmology, 2020, 2020, 1-6.	1.3	14
1320	Dopamine metabolite levels in the vitreous of diabetic and non-diabetic humans. Experimental Eye Research, 2020, 195, 108040.	2.6	4
1321	The Renin-Angiotensin-Aldosterone System (RAAS) Is One of the Effectors by Which Vascular Endothelial Growth Factor (VEGF)/Anti-VEGF Controls the Endothelial Cell Barrier. American Journal of Pathology, 2020, 190, 1971-1981.	3.8	22
1322	Care Team Integration in Primary Care Improves One-Year Clinical and Financial Outcomes in Diabetes: A Case for Value-Based Care. Population Health Management, 2020, 23, 467-475.	1.7	13
1323	Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. Journal of Clinical Hypertension, 2020, 22, 212-220.	2.0	14
1324	Access to CKD Care in Rural Communities of India: a qualitative study exploring the barriers and potential facilitators. BMC Nephrology, 2020, 21, 26.	1.8	17
1325	Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. BMJ Open Diabetes Research and Care, 2020, 8, e000902.	2.8	31
1326	Genotypes and Phenotypes: A Search for Influential Genes in Diabetic Retinopathy. International Journal of Molecular Sciences, 2020, 21, 2712.	4.1	20
1327	Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future. Frontiers in Pharmacology, 2020, 11, 108.	3.5	79
1328	Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transplant International, 2021, 34, 27-48.	1.6	57
1329	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. Annals of Internal Medicine, 2021, 174, 58-68.	3.9	47
1330	Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. Journal of Diabetes Investigation, 2021, 12, 1322-1325.	2.4	137
1331	Commentary: Systemic versus imaging biomarkers for diabetic macular oedema – Where do we stand?. Indian Journal of Ophthalmology, 2021, 69, 1202.	1.1	1
1332	Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110206.	3.2	8
1333	Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin. Journal of Research in Medical Sciences, 2021, 26, 35.	0.9	2
1334	Diabetic retinopathy screening guidelines in India: All India Ophthalmological Society diabetic retinopathy task force and Vitreoretinal Society of India Consensus Statement. Indian Journal of Ophthalmology, 2021, 69, 678.	1.1	31
1335	Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes. Diabetes Care, 2021, 44, 699-706.	8.6	31

#	ARTICLE	IF	CITATIONS
1336	Compliance of secondary prevention strategies in coronary artery disease patients with and without diabetes mellitus – A cross-sectional analytical survey from Kerala, India. <i>Indian Journal of Endocrinology and Metabolism</i> , 2021, 25, 129.	0.4	1
1337	Metformin - its anti-cancer effects in hematologic malignancies. <i>Oncology Reviews</i> , 2021, 15, 514.	1.8	14
1338	How Should We Measure and Deal with Office Blood Pressure in 2021?. <i>Diagnostics</i> , 2021, 11, 235.	2.6	6
1339	Predicting adverse outcomes due to diabetes complications with machine learning using administrative health data. <i>Npj Digital Medicine</i> , 2021, 4, 24.	10.9	49
1340	The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathy – A Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 705.	2.4	9
1341	The Role of Lipoxidation in the Pathogenesis of Diabetic Retinopathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 621938.	3.5	34
1342	Predicting unplanned medical visits among patients with diabetes: translation from machine learning to clinical implementation. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 111.	3.0	6
1343	Integrative Biology of Diabetic Retinal Disease: Lessons from Diabetic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 1254.	2.4	10
1344	The contribution of the English NHS Diabetic Eye Screening Programme to reductions in diabetes-related blindness, comparisons within Europe, and future challenges. <i>Acta Diabetologica</i> , 2021, 58, 521-530.	2.5	26
1345	Prevalence of Hypertension and Albuminuria in Pediatric Type 2 Diabetes. <i>JAMA Network Open</i> , 2021, 4, e216069.	5.9	25
1346	Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>European Cardiology Review</i> , 2021, 16, e14.	2.2	4
1347	Rates and risk factors for amputation in people with diabetes in Japan: a historical cohort study using a nationwide claims database. <i>Journal of Foot and Ankle Research</i> , 2021, 14, 29.	1.9	9
1348	Role of Oral Antioxidant Supplementation in the Current Management of Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4020.	4.1	15
1349	Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire. <i>Acta Ophthalmologica</i> , 2022, 100, .	1.1	10
1350	Visual acuity outcomes after cataract surgery in type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. <i>British Journal of Ophthalmology</i> , 2022, 106, 1496-1502.	3.9	2
1351	Blood pressure control in patients with chronic kidney disease. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 780-794.	1.7	6
1352	Thermo-Responsive Hydrogels: From Recent Progress to Biomedical Applications. <i>Gels</i> , 2021, 7, 77.	4.5	92
1353	Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. <i>New England Journal of Medicine</i> , 2021, 384, 2219-2228.	27.0	327

#	ARTICLE	IF	CITATIONS
1354	2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 461-481.	4.7	146
1355	Kinins and Their Receptors as Potential Therapeutic Targets in Retinal Pathologies. <i>Cells</i> , 2021, 10, 1913.	4.1	12
1356	The Role of Biofactors in Diabetic Microvascular Complications. <i>Current Diabetes Reviews</i> , 2022, 18, .	1.3	16
1357	Visualizing the intellectual structure and recent research trends of diabetic retinopathy. <i>International Journal of Ophthalmology</i> , 2021, 14, 1248-1259.	1.1	4
1358	Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population. <i>Journal of Clinical Medicine</i> , 2021, 10, 3851.	2.4	11
1359	Cardiovascular disease in diabetes, beyond glucose. <i>Cell Metabolism</i> , 2021, 33, 1519-1545.	16.2	87
1360	Different impacts of metabolic profiles on future risk of cardiovascular disease between diabetes with and without established cardiovascular disease: the Japan diabetes complication and its prevention prospective study 7 (JDCP study 7). <i>Acta Diabetologica</i> , 2021, , 1.	2.5	1
1361	The role of Optical Coherence Tomography Angiography to detect early microvascular changes in Diabetic Retinopathy: a systematic review. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021, 20, 1957-1974.	1.9	9
1362	Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese. <i>Cardiovascular Diabetology</i> , 2021, 20, 174.	6.8	4
1363	Incidence and risk factors of severe non-proliferative/proliferative diabetic retinopathy: More than a decade follow up in the Tehran Lipids and Glucose Study. <i>Journal of Diabetes Investigation</i> , 2021, , .	2.4	5
1364	The Importance of Close Follow-Up in Patients with Early-Grade Diabetic Retinopathy: A Taiwan Population-Based Study Grading via Deep Learning Model. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9768.	2.6	4
1365	Low prevalence of diabetic retinopathy in patients with long-term type 1 diabetes and current good glycemic control - one-center retrospective assessment. <i>Endocrine</i> , 2022, 75, 427-436.	2.3	3
1366	Using Metabolic and Biochemical Indicators to Predict Diabetic Retinopathy by Back-Propagation Artificial Neural Network. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4031-4041.	2.4	2
1367	Screening for Diabetes and Prediabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 369-385.	3.2	26
1368	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2021, 17, e618-e630.	3.2	3
1369	The Related Risk Factors of Diabetic Retinopathy in Elderly Patients with Type 2 Diabetes Mellitus: A Hospital-Based Cohort Study in Taiwan. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 307.	2.6	5
1370	Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110263.	2.5	5
1371	Diet and risk of diabetic retinopathy: a systematic review. <i>European Journal of Epidemiology</i> , 2018, 33, 141-156.	5.7	81

#	ARTICLE	IF	CITATIONS
1372	Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clinic Proceedings, 2009, 84, 741-57.	3.0	57
1373	National screening programme for diabetic retinopathy. BMJ: British Medical Journal, 2002, 324, 849-849.	2.3	3
1374	Associations between multimorbidity and glycaemia (HbA1c) in people with type 2 diabetes: cross-sectional study in Australian general practice. BMJ Open, 2020, 10, e039625.	1.9	8
1375	Case-control study of 10 years of comprehensive diabetes care. Western Journal of Medicine, 2000, 172, 85-90.	0.3	44
1376	Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. Journal of Clinical Investigation, 2004, 114, 877-883.	8.2	91
1377	Sex-specific effects of social networks on the prevalence, awareness, and control of hypertension among older Korean adults. Journal of Geriatric Cardiology, 2016, 13, 580-6.	0.2	15
1378	Prognostic Value of Hemoglobin A1c Levels in Postmenopausal Diabetic Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute Coronary Syndrome. Medical Science Monitor, 2018, 24, 9399-9405.	1.1	1
1379	Multiple Bioinformatics Analyses of Integrated Gene Expression Profiling Data and Verification of Hub Genes Associated with Diabetic Retinopathy. Medical Science Monitor, 2020, 26, e923146.	1.1	6
1380	Randomized controlled trials in ophthalmology: a bibliometric study. F1000Research, 2019, 8, 1718.	1.6	16
1381	Clinical Audit of Diabetes Care in the Bahrain Defence Forces Hospital = ù...ø±øšø-ø¹ø© ø¥ùfù,,ùšù†ùšùfùšø© ù,,ø-ùrøøø© ø	1.0	5
1382	Imaging and Quantification of Subbasal Nerve Plexus in Healthy Volunteers and Diabetic Patients with or without Retinopathy. PLoS ONE, 2013, 8, e52157.	2.5	85
1383	Evidence That Multiple Defects in Lipid Regulation Occur before Hyperglycemia during the Prodrome of Type-2 Diabetes. PLoS ONE, 2014, 9, e103217.	2.5	40
1384	Prevalence and Control of Hypertension and Albuminuria in South Korea: Focus on Obesity and Abdominal Obesity in the Korean National Health and Nutrition Examination Survey, 2011â€“2012. PLoS ONE, 2014, 9, e111179.	2.5	5
1385	The Effects of Comorbidity on the Benefits and Harms of Treatment for Chronic Disease: A Systematic Review. PLoS ONE, 2014, 9, e112593.	2.5	15
1386	Hba1c, Blood Pressure, and Lipid Control in People with Diabetes: Japan Epidemiology Collaboration on Occupational Health Study. PLoS ONE, 2016, 11, e0159071.	2.5	40
1387	Association between Sickle Cell Trait and the Prevalence and Severity of Diabetic Retinopathy. PLoS ONE, 2016, 11, e0159215.	2.5	11
1388	Probit Models to Investigate Prevalence of Total Diagnosed and Undiagnosed Diabetes among Aged 45 Years or Older Adults in China. PLoS ONE, 2016, 11, e0164481.	2.5	11
1389	Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLoS ONE, 2016, 11, e0165629.	2.5	23

#	ARTICLE	IF	CITATIONS
1390	Incidence and progression of diabetic retinopathy in Sub-Saharan Africa: A five year cohort study. PLoS ONE, 2017, 12, e0181359.	2.5	5
1391	Hypertension Treatment ACCORDing to SPRINT. Texas Heart Institute Journal, 2016, 43, 324-327.	0.3	3
1392	Primary Aldosteronism With Type 2 Diabetes Mellitus Requires More Antihypertensive Drugs for Blood Pressure Control: A Retrospective Observational Study. Journal of Clinical Medicine Research, 2018, 10, 56-62.	1.2	6
1393	Effect of Biphasic Insulin Aspart 30 Combined with Metformin on Glycaemic Control in Obese People with Type 2 Diabetes. Bosnian Journal of Basic Medical Sciences, 2008, 7, 335-338.	1.0	1
1394	Effects of Aggressive Approach to the Multiple Risk Factors for Diabetic Nephropathy on Proteinuria Reduction in Diabetes Type 2 Patients. Bosnian Journal of Basic Medical Sciences, 2009, 9, 44-48.	1.0	1
1395	Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema. European Endocrinology, 2014, 10, 111.	1.5	4
1396	Diabetic Retinopathyâ€”Update on Prevention Techniques, Present Therapies, and New Leads. US Ophthalmic Review, 2014, 07, 54.	0.2	14
1397	Nomogram for the prediction of diabetic nephropathy risk among patients with type 2 diabetes mellitus based on a questionnaire and biochemical indicators: a retrospective study. Aging, 2020, 12, 10317-10336.	3.1	21
1398	The Diterpene Glycoside, Rebaudioside A, Does not Improve Glycemic Control or Affect Blood Pressure After Eight Weeks Treatment in the Goto-Kakizaki Rat. Review of Diabetic Studies, 2005, 2, 84-84.	1.3	22
1399	The Incidence of Microalbuminuria and its Associated Risk Factors in Type 2 Diabetic Patients in Isfahan, Iran. Review of Diabetic Studies, 2007, 4, 242-248.	1.3	13
1400	Quality of Care for First-Degree Relatives of Type 2 Diabetes Patients Diagnosed with Diabetes at a Screening Program One Year After Diagnosis. Review of Diabetic Studies, 2008, 5, 52-58.	1.3	3
1401	Prevalence of Diabetic Retinopathy and Cataract in Adult Patients With Type 1 And Type 2 Diabetes in Russia. Review of Diabetic Studies, 2009, 6, 124-129.	1.3	20
1402	Novel Genetic Actors of Diabetes-Associated Microvascular Complications: Retinopathy, Kidney Disease and Neuropathy. Review of Diabetic Studies, 2015, 12, 243-259.	1.3	11
1403	Blood pressure targets for hypertension in patients with type 2 diabetes. Annals of Translational Medicine, 2018, 6, 199-199.	1.7	9
1404	Many Faces of Renin-angiotensin System - Focus on Eye. Open Ophthalmology Journal, 2017, 11, 122-142.	0.2	109
1405	Considerations for the Development of Mobile Phone Apps to Support Diabetes Self-Management: Systematic Review. JMIR MHealth and UHealth, 2018, 6, e10115.	3.7	49
1406	Predicting Current Glycated Hemoglobin Values in Adults: Development of an Algorithm From the Electronic Health Record. JMIR Medical Informatics, 2018, 6, e10780.	2.6	12
1407	Information Literacy in Food and Activity Tracking Among Parkrunners, People With Type 2 Diabetes, and People With Irritable Bowel Syndrome: Exploratory Study. Journal of Medical Internet Research, 2019, 21, e13652.	4.3	8

#	ARTICLE	IF	CITATIONS
1408	Mapping the Evidence on the Effectiveness of Telemedicine Interventions in Diabetes, Dyslipidemia, and Hypertension: An Umbrella Review of Systematic Reviews and Meta-Analyses. <i>Journal of Medical Internet Research</i> , 2020, 22, e16791.	4.3	141
1409	Using mHealth to Provide Mobile App Users With Visualization of Health Checkup Data and Educational Videos on Lifestyle-Related Diseases: Methodological Framework for Content Development. <i>JMIR MHealth and UHealth</i> , 2020, 8, e20982.	3.7	8
1410	Efficacy of Mobile Apps to Support the Care of Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>JMIR MHealth and UHealth</i> , 2017, 5, e4.	3.7	223
1411	Hepatic steatosis: A benign disease or a silent killer. <i>World Journal of Gastroenterology</i> , 2008, 14, 4120.	3.3	72
1412	Current status of managing diabetes mellitus in Korea. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 845-850.	1.7	35
1413	Spousal Support in Diabetes Self-Management Among Korean Immigrant Older Adults. <i>Research in Gerontological Nursing</i> , 2015, 8, 94-104.	0.6	13
1414	Therapeutic insight into molsidomine, a nitric oxide donor in streptozotocin-induced diabetic nephropathy in rats. <i>Indian Journal of Pharmacology</i> , 2016, 48, 544.	0.7	8
1415	Does tight control of systemic factors help in the management of diabetic retinopathy?. <i>Indian Journal of Ophthalmology</i> , 2016, 64, 62.	1.1	19
1416	Updates on the clinical trials in diabetic macular edema. <i>Middle East African Journal of Ophthalmology</i> , 2016, 23, 3.	0.3	19
1417	Surgery for proliferative diabetic retinopathy: New tips and tricks. <i>Journal of Ophthalmic and Vision Research</i> , 2016, 11, 93.	1.0	30
1418	Cardiovascular risk factors, micro and macrovascular complications at diagnosis in patients with young onset type 2 diabetes in India: CINDI 2. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 114.	0.4	22
1419	Adherence to diabetes care processes at general practices in the National Capital Region-Delhi, India. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 329.	0.4	7
1420	Study of Vitamin B12 deficiency and peripheral neuropathy in metformin-treated early Type 2 diabetes mellitus. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 631.	0.4	34
1421	Control of type 2 diabetes in King Abdulaziz Housing City (Iskan) population, Saudi Arabia. <i>Journal of Family and Community Medicine</i> , 2016, 23, 1.	1.1	18
1422	Diabetic retinopathy and the associated risk factors in diabetes type 2 patients in Abha, Saudi Arabia. <i>Journal of Family and Community Medicine</i> , 2016, 23, 18.	1.1	56
1423	Predictors of all-cause and cardiovascular-specific mortality in type 2 diabetes: A competing risk modeling of an Iranian population. <i>Advanced Biomedical Research</i> , 2016, 5, 82.	0.5	7
1424	Diabetic retinopathy awareness and associations with multiple comorbidities: Insights from DIAMOND Study. <i>Indian Journal of Endocrinology and Metabolism</i> , 2018, 22, 30.	0.4	22
1425	Diabetic macular edema: Evidence-based management. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 1736.	1.1	126

#	ARTICLE	IF	CITATIONS
1426	Community care for diabetic retinopathy and glaucoma in India: A panel discussion. Indian Journal of Ophthalmology, 2018, 66, 916.	1.1	10
1427	Structural Alterations of the Glomerular Wall and Vessels in Early stages of DM. Libyan Journal of Medicine, 2007, 2, 135-138.	1.6	5
1428	Comparison of awareness of diabetes mellitus type II with treatment's outcome in term of direct cost in a hospital in Saudi Arabia. World Journal of Diabetes, 2019, 10, 463-472.	3.5	8
1429	ApoE isoforms, treatment of diabetes and the risk of coronary heart disease. World Journal of Diabetes, 2012, 3, 54.	3.5	7
1430	Diabetic macular edema: Current management 2013. World Journal of Diabetes, 2013, 4, 231.	3.5	17
1431	Ranibizumab in diabetic macular edema. World Journal of Diabetes, 2013, 4, 310.	3.5	20
1432	Diabetic macular edema: New promising therapies. World Journal of Diabetes, 2013, 4, 324.	3.5	23
1433	Cardiac autonomic neuropathy in patients with diabetes mellitus. World Journal of Diabetes, 2014, 5, 17.	3.5	239
1434	Alphabet Strategy for diabetes care: A multi-professional, evidence-based, outcome-directed approach to management. World Journal of Diabetes, 2015, 6, 874.	3.5	11
1435	Role of lipid-lowering agents in the management of diabetic retinopathy. World Journal of Diabetes, 2017, 8, 1.	3.5	15
1436	Bariatric Surgery to Correct Morbid Obesity Also Ameliorates Atherosclerosis in Patients with Type 2 Diabetes Mellitus. American Journal of Biomedical Sciences, 2009, 1, 56-69.	0.2	10
1437	Diabetes care and control: the effect of frequent visits to diabetes care center. Annals of Saudi Medicine, 2014, 34, 229-234.	1.1	14
1438	Quality of diabetes care in Dutch care groups: no differences between diabetes patients with and without co-morbidity. International Journal of Integrated Care, 2013, 13, e057.	0.2	12
1439	Prevalence and risk factors of diabetic retinopathy among Jordanian patients with type 2 diabetes. Digital Journal of Ophthalmology: DJO, 2008, 14, 42.	0.6	17
1440	Urinary Total Protein as the Predictor of Albuminuria in Diabetic Patients. International Journal of Endocrinology and Metabolism, 2012, 10, 523-526.	1.0	5
1441	Glycaemic, blood pressure and cholesterol control in 25 629 diabetics. Cardiovascular Journal of Africa, 2015, 26, 188-192.	0.4	23
1442	Therapeutic approaches to slowing the progression of diabetic nephropathy "is less best?". Drugs in Context, 2013, 2013, 1-12.	2.2	13
1443	The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs in Context, 2018, 7, 1-10.	2.2	108

#	ARTICLE	IF	CITATIONS
1444	Implementation and Methodology of a Multidisciplinary Disease-State-Management Program for Comprehensive Diabetes Care. , 2011, 15, 43-8.		18
1445	Peripheral Insensate Neuropathy- Is Height a Risk Factor?. Journal of Clinical and Diagnostic Research JCDR, 2013, 7, 296-301.	0.8	7
1446	Awareness, knowledge, and practice regarding to diabetic retinopathy among KKU students besides medical students in Abha, Saudi Arabia. Journal of Family Medicine and Primary Care, 2021, 10, 3233.	0.9	6
1447	The importance of addressing multiple risk markers in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2022, 24, 281-288.	4.4	5
1448	Clinical predictors of severe dengue: a systematic review and meta-analysis. Infectious Diseases of Poverty, 2021, 10, 123.	3.7	32
1449	Targeting the renin-angiotensin system in patients with renal disease. Journal of the Royal Society of Medicine, 2002, 95, 391-397.	2.0	0
1450	Effect of macular photocoagulation on visual acuity of Omani patients with clinically significant macular edema. Oman Journal of Ophthalmology, 2009, 2, 62.	0.3	6
1451	Achievement of cardiovascular risk factor targets in young adults with diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 387.	2.4	1
1452	Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes. European Endocrinology, 2014, 10, 117.	1.5	3
1453	Relevance of Target-Organ Lesions as Predictors of Mortality in Patients with Diabetes Mellitus. Arquivos Brasileiros De Cardiologia, 2014, 103, 272-81.	0.8	1
1454	Epidemiological Aspects of Atherosclerosis in Patients Treated for Acute Atherothrombosis of Extremity Arteries. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2014, 68, 329.	0.9	1
1455	Treating type 2 diabetes. BMJ: British Medical Journal, 1999, 318, 666-666.	2.3	0
1456	Yonder: Grandparenthood, rural health, diabetes, & perinatal psychiatry. British Journal of General Practice, 2014, 64, 299-299.	1.4	0
1457	Authorsâ€™ reply. Singapore Medical Journal, 2014, 55, 554-554.	0.6	1
1458	Patient-centered blood pressure: Thresholds, targets, and tools in diabetes. Indian Journal of Endocrinology and Metabolism, 2017, 21, 261.	0.4	1
1459	Demographic features and visual outcomes of patients presenting to diabetic photo-screening and treated for sight threatening retinopathy in Fiji. International Journal of Ophthalmology, 2017, 10, 790-795.	1.1	3
1460	Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. Indian Journal of Ophthalmology, 2018, 66, 98.	1.1	3
1461	Interaction of renin-angiotensin system gene polymorphisms with hypertension in Chinese patients with type 1 diabetes and retinopathy. Oncotarget, 2018, 9, 7582-7589.	1.8	1

#	ARTICLE	IF	CITATIONS
1462	An mHealth Diabetes Intervention for Glucose Control: Health Care Utilization Analysis. JMIR MHealth and UHealth, 2018, 6, e10776.	3.7	9
1463	Relationships between the diabetes awareness and clinical indices/nutrient intakes in Korean adults: Based on the 2012-2013 Korea National Health and Nutrition Examination Survey Data. Nutrition Research and Practice, 2019, 13, 240.	1.9	1
1464	Lifetime Risk of Heart Failure and Trends in Incidence Rates Among Individuals With Type 2 Diabetes Between 1995 and 2018. Journal of the American Heart Association, 2021, 10, e021230.	3.7	2
1466	Cardiovascular disease risk assessment and treatment among person with type 2 diabetes mellitus at the primary care level in rural central India. Journal of Family Medicine and Primary Care, 2020, 9, 2033.	0.9	4
1467	REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy. Journal of Lipid and Atherosclerosis, 2020, 9, 406.	3.5	4
1468	Influence of gender on the distribution of type 2 diabetic complications at the obafemi awolowo teaching hospital, Ile-Ife, Nigeria. African Health Sciences, 2020, 20, 294-307.	0.7	5
1469	Blood Pressure and Cardiovascular Disease in Older Patients With Diabetes: Retrospective Cohort Study. Journal of the American Heart Association, 2021, 10, e020999.	3.7	3
1470	Trends in cardiovascular risk factors and treatment goals in patients with diabetes in Singapore-analysis of the SingHealth Diabetes Registry. PLoS ONE, 2021, 16, e0259157.	2.5	6
1471	Effects of intensive control of blood glucose and blood pressure on microvascular complications in patients with type II diabetes mellitus. International Journal of Ophthalmology, 2013, 6, 141-5.	1.1	11
1472	Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ: British Medical Journal, 1998, 317, 713-20.	2.3	319
1473	Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ: British Medical Journal, 1998, 317, 720-6.	2.3	76
1474	Microalbuminuria in diabetes mellitus. Cmaj, 2002, 167, 499-503.	2.0	7
1475	Numbers needed to treat derived from meta-analysis. Are an absurdity. BMJ: British Medical Journal, 1999, 319, 1199.	2.3	0
1476	Glycaemia and vascular effects of type 2 diabetes. Lowering glucose concentrations may not be of any value in itself. BMJ: British Medical Journal, 2001, 322, 1245-6; author reply 1247.	2.3	0
1478	Comparison of different measures of blood pressure. Use sphygmomanometers more, not less. BMJ, The, 2002, 325, 1360.	6.0	0
1479	Diabetes care needs evidence based interventions to reduce risk of vascular disease. BMJ: British Medical Journal, 2000, 320, 1554-5.	2.3	3
1480	The accuracy of digital-video retinal imaging to screen for diabetic retinopathy: an analysis of two digital-video retinal imaging systems using standard stereoscopic seven-field photography and dilated clinical examination as reference standards. Transactions of the American Ophthalmological Society, 2004, 102, 321-40.	1.4	27
1481	Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?. Clinical Biochemist Reviews, 2005, 26, 123-34.	3.3	27

#	ARTICLE	IF	CITATIONS
1482	Understanding of blood pressure by people with type 2 diabetes: a primary care focus group study. <i>British Journal of General Practice</i> , 2005, 55, 298-304.	1.4	14
1483	Diagnosis and treatment of non-hemodynamically significant coronary heart disease: where to start?. <i>Transactions of the American Clinical and Climatological Association</i> , 2005, 116, 273-80; discussion 281.	0.5	0
1484	Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. <i>British Journal of General Practice</i> , 2005, 55, 875-82.	1.4	68
1485	The Informatics for Diabetes and Education Telemedicine (IDEATel) project. <i>Transactions of the American Clinical and Climatological Association</i> , 2007, 118, 289-304.	0.5	23
1486	Patients' experiences of continuity in the care of type 2 diabetes: a focus group study in primary care. <i>British Journal of General Practice</i> , 2006, 56, 488-95.	1.4	24
1487	Executive summary of the African-American Initiative. <i>MedGenMed: Medscape General Medicine</i> , 2007, 9, 28.	0.2	3
1488	Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis. <i>Vascular Health and Risk Management</i> , 2005, 1, 199-208.	2.3	13
1489	Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus. <i>Vascular Health and Risk Management</i> , 2005, 1, 209-15.	2.3	13
1490	Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials. <i>Vascular Health and Risk Management</i> , 2007, 3, 165-71.	2.3	5
1491	A cluster randomised controlled trial of the effect of a treatment algorithm for hypertension in patients with type 2 diabetes. <i>British Journal of General Practice</i> , 2007, 57, 136-43.	1.4	20
1492	Cardiovascular disorders in patients with diabetes mellitus. <i>Experimental and Clinical Cardiology</i> , 2006, 11, 237-8.	1.3	1
1494	Managing hypertension in diabetic patients—focus on trandolapril/verapamil combination. <i>Vascular Health and Risk Management</i> , 2007, 3, 453-65.	2.3	10
1495	PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. <i>Vascular Health and Risk Management</i> , 2007, 3, 355-70.	2.3	27
1496	Multivariate risk assessment and risk score cards in hypertension. <i>Vascular Health and Risk Management</i> , 2007, 3, 313-20.	2.3	4
1497	Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. <i>Experimental and Clinical Cardiology</i> , 2007, 12, 17-28.	1.3	60
1498	Arterial hypertension in diabetes mellitus: from theory to clinical practice. <i>Hippokratia</i> , 2008, 12, 74-80.	0.3	10
1499	Enhancing diabetes care in family practice: a flow sheet. <i>Canadian Family Physician</i> , 2008, 54, 1237-8.	0.4	2
1500	Update on the Canadian Diabetes Association 2008 clinical practice guidelines. <i>Canadian Family Physician</i> , 2009, 55, 39-43.	0.4	39

#	ARTICLE	IF	CITATIONS
1501	Diabetic retinopathy: an update. Indian Journal of Ophthalmology, 2008, 56, 178-88.	1.1	35
1502	Reasons to exercise caution when considering a screening program for type 2 diabetes mellitus. Mayo Clinic Proceedings, 2009, 84, 34-6.	3.0	3
1503	Diabetes care and health status of First Nations individuals with type 2 diabetes in Alberta. Canadian Family Physician, 2009, 55, 386-93.	0.4	31
1504	Diabetic retinopathy is not associated with carbonic anhydrase gene polymorphisms. Molecular Vision, 2009, 15, 1179-84.	1.1	4
1505	Diabetic retinopathy. Clinical Ophthalmology, 2007, 1, 259-65.	1.8	5
1507	Risk factors for diabetic retinopathy: Findings from The Andhra Pradesh Eye Disease Study. Clinical Ophthalmology, 2007, 1, 475-82.	1.8	27
1508	Pharmacologic therapies for diabetic retinopathy and diabetic macular edema. Clinical Ophthalmology, 2007, 1, 383-91.	1.8	21
1509	Risk factors for coronary artery sclerosis in patients with diabetes. Experimental and Clinical Cardiology, 2005, 10, 108-10.	1.3	1
1510	2009 Canadian Hypertension Education Program recommendations: an annual update. Canadian Family Physician, 2009, 55, 697-700.	0.4	5
1511	Hypertension and the family physician. Canadian Family Physician, 2009, 55, 682, 683.	0.4	1
1512	Hypertension management by family physicians: is it time to pat ourselves on the back?. Canadian Family Physician, 2009, 55, 684-5, 686-7.	0.4	4
1513	Drug management for hypertension in type 2 diabetes in family practice. Canadian Family Physician, 2009, 55, 728-34.	0.4	9
1515	Accessibility of home blood pressure monitors for blind and visually impaired people. Journal of Diabetes Science and Technology, 2007, 1, 218-27.	2.2	6
1516	Control of risk factors among people with diagnosed diabetes, by lower extremity disease status. Preventing Chronic Disease, 2009, 6, A114.	3.4	9
1518	Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. American Journal of Managed Care, 2007, 13, 445-52.	1.1	23
1519	Diabetes: treating hypertension. Clinical Evidence, 2009, 2009, .	0.2	0
1520	The influence of gender on the primary care management of diabetes in Tunisia. Pan African Medical Journal, 2009, 3, 2.	0.8	8
1521	Diabetic nephropathy and chronic kidney disease at a busy diabetes clinic: a study of outpatient care and suggestions for improved care pathways at a subspecialty specialist diabetic renal clinic. Ulster Medical Journal, 2010, 79, 57-61.	0.2	1

#	ARTICLE	IF	CITATIONS
1522	Diabetes & coronary heart disease: current perspectives. Indian Journal of Medical Research, 2010, 132, 584-97.	1.0	27
1524	Hypertension and related risk factors in type 2 diabetes mellitus (DM) patients in Gaborone City Council (GCC) clinics, Gaborone, Botswana. African Health Sciences, 2007, 7, 244-5.	0.7	22
1525	Control and management of hypertension at a university health centre in oman. Sultan Qaboos University Medical Journal, 2008, 8, 179-84.	1.0	4
1526	Diabetes mellitus update. , 2006, 10, 29-34.		0
1527	Efficacy of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin: a systematic review and meta-analysis. Open Medicine, 2010, 4, e102-13.	1.5	14
1529	Hypertension in people with type 2 diabetes: Update on pharmacologic management. Canadian Family Physician, 2011, 57, 997-1002, e347-53.	0.4	37
1530	Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine, 2010, 58, 950-6.	1.6	4
1531	Diabetic retinopathy (treatment). Clinical Evidence, 2011, 2011, .	0.2	2
1532	Perceptions related to diet and exercise among Asians and Pacific Islanders with diabetes. Hawaii Medical Journal, 2011, 70, 196-9.	0.4	5
1533	Hypertension control in patients with diabetes. Canadian Family Physician, 2012, 58, 31-3.	0.4	1
1534	Annual adult health checkup: update on the Preventive Care Checklist Form(Â©). Canadian Family Physician, 2012, 58, 43-7.	0.4	8
1535	Diabetes: treating hypertension. Clinical Evidence, 2012, 2012, .	0.2	0
1536	Epidemic studies of diabetic retinopathy in China-a review. International Journal of Ophthalmology, 2011, 4, 670-2.	1.1	3
1537	Control of hypertension in eastern saudi arabia: results of screening campaign. Journal of Family and Community Medicine, 2009, 16, 19-25.	1.1	5
1538	Behavioural interventions for type 2 diabetes: an evidence-based analysis. Ontario Health Technology Assessment Series, 2009, 9, 1-45.	1.8	28
1539	Community-based care for the management of type 2 diabetes: an evidence-based analysis. Ontario Health Technology Assessment Series, 2009, 9, 1-40.	1.8	6
1540	Application of the Ontario Diabetes Economic Model (ODEM) to Determine the Cost-effectiveness and Budget Impact of Selected Type 2 Diabetes Interventions in Ontario. Ontario Health Technology Assessment Series, 2009, 9, 1-21.	1.8	2
1541	Diabetes exacerbates retinal oxidative stress, inflammation, and microvascular degeneration in spontaneously hypertensive rats. Molecular Vision, 2012, 18, 1457-66.	1.1	21

#	ARTICLE	IF	CITATIONS
1542	What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease?. Archives of Medical Science, 2012, 8, 399-402.	0.9	14
1543	Assessment of care for type 2 diabetic patients at the primary care clinics of a referral hospital. Journal of Family and Community Medicine, 2006, 13, 13-8.	1.1	10
1544	Outpatient management of type 2 diabetic patients: a review of evidence-based literature. Journal of Family and Community Medicine, 2006, 13, 3-12.	1.1	8
1545	Lexical concept distribution reflects clinical practice. AMIA ... Annual Symposium proceedings, 2012, 2012, 61-6.	0.2	0
1546	Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies. P and T, 2012, 37, 687-96.	0.9	10
1547	Uncertainty about the systolic blood pressure target in people with diabetes. Canadian Family Physician, 2013, 59, 128-31.	0.4	1
1548	Use of chronic disease management programs for diabetes: in Alberta's primary care networks. Canadian Family Physician, 2013, 59, e86-92.	0.4	17
1549	Cardiac risk is not associated with hypertension treatment intensification. American Journal of Managed Care, 2012, 18, 414-20.	1.1	1
1550	The influence of diabetes on short-term outcome following a prosthetic above-the-knee femoro-popliteal bypass. Cardiovascular Journal of Africa, 2009, 20, 170-2.	0.4	2
1551	Management of Diabetic Nephropathy in the Elderly: Special Considerations. Journal of Nephrology & Therapeutics, 2012, 2, .	0.1	1
1552	Impact of Vitamin E Supplementation on Blood Pressure and Hs-CRP in Type 2 Diabetic Patients doi: 10.5681/hpp.2012.009. Health Promotion Perspectives, 2012, 2, 72-9.	1.9	12
1553	Management of diabetic retinopathy. Malawi Medical Journal, 2013, 25, 116-20.	0.6	14
1554	Diabetes: treating hypertension. Clinical Evidence, 2014, 2014, .	0.2	0
1555	Influence of dyslipidemia in control of arterial hypertension among type-2 diabetics in the western region of the Republic of Macedonia. American Journal of Cardiovascular Disease, 2014, 4, 58-69.	0.5	1
1556	Diabetic hypertensive control and treatment: a descriptive report from the audit diabetes control and management (adcm) registry. Malaysian Family Physician, 2010, 5, 134-9.	0.6	4
1558	Editorial on the original article entitled "Changes in diabetes-related complications in the United States, 1990-2010" published in the New England Journal of Medicine on April 17, 2014. Annals of Translational Medicine, 2014, 2, 118.	1.7	0
1559	A look at the trend in diabetes-related complications in the U.S. over the past two decades: looking ahead. Annals of Translational Medicine, 2014, 2, 121.	1.7	2
1560	Regulation of the hyperosmotic induction of aquaporin 5 and VEGF in retinal pigment epithelial cells: involvement of NFAT5. Molecular Vision, 2015, 21, 360-77.	1.1	33

#	ARTICLE	IF	CITATIONS
1561	Effect of glycated hemoglobin on heart function of the patients with revascularization of coronary artery. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 7181-8.	0.5	1
1562	Trends in incidence of end-stage renal disease among persons with diagnosed diabetes--Puerto Rico, 1996-2010. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 186-9.	15.1	1
1563	The role of Spectral Domain Optical Coherence Tomography in monitoring uncontrolled hypertensive type 2 diabetic patients. <i>Journal of Medicine and Life</i> , 2014, 7 Spec No. 4, 65-7.	1.3	1
1564	Therapeutic Targets for Management of Periodontitis and Diabetes. <i>Current Pharmaceutical Design</i> , 2016, 22, 2216-37.	1.9	13
1565	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. <i>Hippokratia</i> , 2015, 19, 195-9.	0.3	9
1566	Different Risk Indicators of Diabetic Nephropathy in Transforming Growth Factor-beta1 T869C CC/CT Genotype and TT Genotype. <i>Iranian Journal of Public Health</i> , 2016, 45, 761-7.	0.5	2
1567	Intake of dietary salt and drinking water: Implications for the development of age-related macular degeneration. <i>Molecular Vision</i> , 2016, 22, 1437-1454.	1.1	12
1568	Osmotic regulation of expression in RPE cells: The involvement of purinergic receptor signaling. <i>Molecular Vision</i> , 2017, 23, 116-130.	1.1	8
1569	Prevalence of poor glycemic and blood pressure control and pattern of drug use among primary health-care outpatients in Al Ahsa Saudi Arabia. <i>International Journal of Health Sciences</i> , 2017, 11, 38-44.	0.4	1
1570	ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH. <i>European Medical Journal Diabetes</i> , 2017, 5, 84-92.	4.0	10
1571	Evaluation of diabetes care management in primary clinics based on the guidelines of American Diabetes Association. <i>International Journal of Health Sciences</i> , 2018, 12, 40-44.	0.4	6
1572	Diabetes Mellitus and Cardiovascular Disease. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2003, 14, 74-77.	0.7	0
1573	Achieving triple treatment goals in multi-ethnic Asian patients with type 2 diabetes mellitus in primary care. <i>Malaysian Family Physician</i> , 2018, 13, 10-18.	0.6	5
1574	Longitudinal Hypertension Outcomes at Four Student-Run Free Clinic Sites. <i>Family Medicine</i> , 2017, 49, 28-34.	0.5	9
1575	Diabetes retinopathy and related health management in Asians versus whites using BRFSS 2005-2017 data. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2019, 11, 310-317.	0.8	0
1576	Albumin excretion rate among patients with diabetic retinopathy. <i>Caspian Journal of Internal Medicine</i> , 2020, 11, 177-182.	0.2	1
1577	Severity of diabetic retinopathy and its relationship with age at onset of diabetes mellitus in India: A multicentric study. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3255.	1.1	9
1578	Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?. <i>Antioxidants</i> , 2021, 10, 1849.	5.1	3

#	ARTICLE	IF	CITATIONS
1579	Association of Acute Kidney Injury During Diabetic Ketoacidosis With Risk of Microalbuminuria in Children With Type 1 Diabetes. <i>JAMA Pediatrics</i> , 2022, 176, 169.	6.2	16
1580	Cardiovascular risk in patients with and without diabetes presenting with chronic coronary syndrome in 2004–2016. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 579.	1.7	3
1581	Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes. <i>European Endocrinology</i> , 2021, 17, 92.	1.5	1
1582	Profile of sight-threatening diabetic retinopathy and its awareness among patients with diabetes mellitus attending a tertiary care center in Kashmir, India. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3123.	1.1	10
1583	Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. <i>BMC Nephrology</i> , 2022, 23, 9.	1.8	32
1584	The cultural beliefs and practices of diabetes self-management in Javanese diabetic patients: An ethnographic study. <i>Heliyon</i> , 2022, 8, e08873.	3.2	10
1585	Uncontrolled Blood Pressure and Associated Factors Among Persons With Diabetes: A Community Based Study From Kerala, India. <i>Frontiers in Public Health</i> , 2021, 9, 778235.	2.7	3
1586	Understanding the interrelationships of type 2 diabetes and hypertension with brain and cognitive health: A UK Biobank study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 938-947.	4.4	7
1587	Joint modeling of time to diabetic retinopathy and change in fasting blood sugar among type 2 diabetic patients, Northwest Ethiopia. <i>Scientific Reports</i> , 2022, 12, 2236.	3.3	0
1588	Blood Pressure Monitoring as a Digital Health Tool for Improving Diabetes Clinical Outcomes: Retrospective Real-world Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e32923.	4.3	2
1589	Cholesterol lowering with simvastatin in people with diabetes. <i>Current Atherosclerosis Reports</i> , 2004, 6, 85-6.	4.8	0
1590	High prevalence of undiagnosed impaired glucose tolerance in patients with rheumatoid arthritis. <i>SAGE Open Medicine</i> , 2022, 10, 205031212210880.	1.8	1
1591	Update on Management of Non-proliferative Diabetic Retinopathy without Diabetic Macular Edema; Is There a Paradigm Shift?. <i>Journal of Ophthalmic and Vision Research</i> , 2022, 17, 108-117.	1.0	4
1592	Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2397.	4.1	32
1593	Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms. <i>Scientific Reports</i> , 2022, 12, 3525.	3.3	7
1594	The Effect of Diet and Lifestyle on the Course of Diabetic Retinopathy—A Review of the Literature. <i>Nutrients</i> , 2022, 14, 1252.	4.1	24
1595	Diabetic retinopathy for the non-ophthalmologist. <i>Clinical Medicine</i> , 2022, 22, 112-116.	1.9	24
1596	Intensive Blood Pressure Treatment Goals: evidence for cardiovascular protection from observational studies and clinical trials. <i>American Journal of Hypertension</i> , 2022, , .	2.0	0

#	ARTICLE	IF	CITATIONS
1597	Association Between Cardiovascular Disease Risk Factors and Mortality in Adults With Diabetes: A Stratified Analysis by Sex, Race, and Ethnicity. <i>International Journal of Public Health</i> , 2022, 67, 1604472.	2.3	1
1598	Printed educational materials directed at Ontario family physicians do not improve adherence to guideline recommendations for diabetes management: a pragmatic, factorial, cluster randomized controlled trial [ISRCTN72772651]. <i>BMC Family Practice</i> , 2021, 22, 243.	2.9	0
1599	A Promising Combination: PACAP and PARP Inhibitor Have Therapeutic Potential in Models of Diabetic and Hypertensive Retinopathies. <i>Cells</i> , 2021, 10, 3470.	4.1	6
1600	Prevalence of uncontrolled hypertension in people with comorbidities in sub-Saharan Africa: a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e045880.	1.9	8
1602	Improving Diabetes Care: A Fijian Diabetes Service Improvement Study. <i>International Journal of Chronic Diseases</i> , 2022, 2022, 1-9.	1.0	0
1609	<scp>HbA1c</scp> , blood pressure and cholesterol control in adults with diabetes: A report card for Kuwait. <i>Journal of Diabetes Investigation</i> , 2022, , .	2.4	2
1610	Long-term prediction models for vision-threatening diabetic retinopathy using medical features from data warehouse. <i>Scientific Reports</i> , 2022, 12, 8476.	3.3	4